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Abstract 
Rheumatoid arthritis (RA) is a chronic disease characterised by inflammatory 
infiltration of the synovial membrane, with concomitant destruction of adjacent 
cartilage and bone. Elucidation of immunoregulatory networks within the synovium 
offers the potential for therapeutic intervention. Two such pathways were investigated 
in the present study. 
Interleukin-15 (IL-15) is a novel pleiotropic cytokine produced by macrophages and 
fibroblasts, which induces T cell migration and activation and B cell maturation and 
immunoglobulin production. IL-15 was identified in RA synovial fluids and synovial 
membrane cultures and, using immunohistochemistry, its expression was localised in 
the RA synovial membrane to the lining layer and T lymphocyte aggregates. 
Enhanced proliferation and cytokine production to IL-15 was observed in RA synovial 
fluid (SF) T cells in comparison to matched peripheral blood (PB) T lymphocytes, 
which in turn, were more sensitive to IL-15 induced proliferation than PBT cells from 
normal controls. Following IL-15 mediated activation, PBT cells were capable of 
inducing TNFa. production from a macrophage cell line, from syngeneic PB 
monocytes, and from synovial macrophage I synoviocyte co-cultures, through a cell-
contact dependent mechanism, which required no T cell cytokine synthesis. RA SFT 
cells exhibited similar properties, which were IL-15 dependent in vitro. IL-15 up-
regulated CD69 expression on CD45RO+ T cells and neutralisation studies determined 
that such CD69 expression, in combination with LFA-l and ICAM-l, was partly 
responsible for cell-contact mediated macrophage activation by T cells. Finally, in a 
murine model, IL-15 injection induced significant local tissue T cell invasion, 
confirming previous in vitro observations of its chemotactic properties. IL-15 
expression in RA synovial membrane therefore provides a mechanism whereby 
polyc1onal T cell recruitment and activation can lead to macrophage activation and 
TNFa production, without T cell cytokine synthesis. 
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Nitric oxide (NO) is a critical immunomodulatory and microbicidal mediator in several 
animal models of inflammation. Production of NO in RA synovial membrane has 
previously not been characterised. Inducible NO synthase (iNOS) expression was 
localised in RA and OA synovial membrane and NO production was detected in 
synovial membrane cultures from both RA and OA patients, which could be up-
regulated in vitro using bacterial superantigen. NO-donors induced TNFa production 
from macrophage cell lines and from synovial macrophage I synoviocyte co-cultures, 
indicating that NO might modify pro-inflammatory cytokine production in RA. These 
data provided direct evidence for NO synthesis in human synovium. However, NO 
mediates diverse effects in vitro on chondrocyte metabolism and leukocyte activation, 
raising doubts as to its net contribution in RA. The effect of iNOS activity were 
therefore investigated in vivo in iNOS-I- mice, using a model of staphylococcal 
infection, which mediates pathology primarily through superantigen-driven T cell 
activation. The incidence and severity of arthritis and septicaemia was increased in 
iNOS-I- mice compared with iNOS+I- controls. Ex vivo culture established the 
presence of an exaggerated Thl cytokine response in iNOS-I- mice. Moreover, 
superantigen-induced proliferation and Tb 1 cytokine production was enhanced a priori 
in iNOS-I- animals, indicating that NO can regulate T cell cytokine production, with 
protective consequences in vivo in an arthritis model. 
Neutralisation of TNFa production in RA affords significant clinical benefit. 
However, the mechanisms whereby TNFa production is enhanced in RA are unclear. 
The present study provides two novel immunoregulatory pathways which can increase 
TNFa production in human RA synovial membrane. However, the diverse functions 
of NO in host defence and immunoregulation, and consequent doubts as to its net 
effect in articular inflammation, may preclude therapeutic usefulness in human 
arthritis. In contrast, neutralisation of IL-15 offers exciting clinical potential, through 
inhibition of T cell activation and interruption of crucial pro-inflammatory T cell I 
macrophage communication within the RA synovial membrane. 
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Chapter 1 
General Introduction 
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1.1 Rheumatoid Arthritis 
1.1.1 History 
The antiquity of rheumatoid arthritis (RA) is disputed in the absence of convincing 
records documenting its existence in ancient or mediaeval literature. Anecdotal case 
descriptions exist in ancient Hindu and Greek medical writings and in ancient 
remains in North American Indians (reviewed by Sturrock, et al, 1977; Rothschild & 
Woods, 1990), but frequently chronic rheumatic disease is referred to as 'gout' in 
mediaeval manuscripts and in references up to the 19th century. Evidence from 
paleopathology suggests that osteoarthritis was common in ancient and mediaeval 
times (Thould & Thould, 1983), but the small bones of the hands and feet are 
invariably missing from skeletal remains confounding a search for characteristic 
bony erosions of RA. The earliest clear description of RA is found in 1800 in the 
French literature by Landr~-Beauvais who described 'goutte asthenique primitif' 
(reviewed by Snorrason, 1952). Subsequent reports followed before the term 
'rheumatoid arthritis' was used by Garrod in 1859. 
1.1.2 Epidemiology and aetiology 
RA has world-wide distribution. It lacks precise clinical definition and several sets 
of criteria have been developed to facilitate diagnosis. Most epidemiological studies 
have employed the criteria defined by Ropes et al in 1958 or the most recent 
revision of these proposed by the American Rheumatism Association (Amett, et aI, 
1988). The overall prevalence rate for RA in western Europe is about 1 % with a 
female to male ratio of around 3: 1 and peak age of onset in the fifth and sixth 
decades of life. Annual incidence rates vary from 30 to 300 new cases per 100,000 
(Hazes & Silman, 1990; Symmons, et aI, 1994). There are variations in prevalence 
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between ethnic groups, with low rates observed in rural African and Chinese 
populations. 
The precise aetiology of RA remains unclear, but has been variously attributed to 
primary autoimmunity or environmental infectious agents, under the influence of 
several genetic components. 
Genetic contribution RA is a polygenic disease, with overall twin concordance for 
community based RA of -15% (Silman, et al, 1993). The predominant genetic 
influence is at the HLA-DR locus (Stastny, 1978). Around 80% of RA patients 
express DR4 and DR1, which share an epitope mapping to amino acids 70-74 
(QKRAA) of the DR~ chain (Gregerson, et al 1987). Mutation analysis indicates 
that amino acid 71 confers particular susceptibility (Hammer, et al, 1995). The 
mechanism whereby this association influences RA severity is unclear. The 
QKRAA sequence at the HVR may (i) confer high affinity for an arthritogenic 
peptide, (ii) modify thymic education thereby prejudicing the T cell receptor 
repertoire, or (iii) facilitate molecular mimicry (e.g. gpllO of EBV, dnaJ or HSP73 • 
see below). 
Microsatellite polymorphisms at cytokine loci, including TNFa, IL-l~ and IL-l 
receptor antagonist, are being sought in RA patients, based on observations made in 
other human autoimmune diseases, such as insulin dependent diabetes mellitus 
(IDDM; Pociot, et aI, 1993). TNFa polymorph isms so far associated with RA arise 
from linkage with HLA-DR4 (Duff, 1994; Hajeer, et aI, 1996), although a novel 
association has recently been identified which is independent of the HLA, which has 
higher frequency in patients with extra-articular disease (Field, et aI, 1996). Such 
polymorphic variants, if confirmed, may be associated with high output of cytokine, 
such that specific alleles can act as 'modifier genes' on established inflammatory 
processes. 
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Infectious aetiology Many agents have been linked with RA pathogenesis, which 
might contribute to arthritis by persistent infection, by molecular mimicry, in which 
microbial proteins cross-react with host and break tolerance, or by 'immune 
modulation'. The latter is employed by numerous microbes to enhance survival. 
Thus, the generation of virus-derived 'cytokines' or their receptors, evolved for host 
evasion, or the generation of superantigens can directly influence immunological 
pathways. 
Causative agents, however, have proven elusive. Raised antibody titres to Epstein 
Barr virus (EBV) have been reported in RA, which together with observed sequence 
homology of EBV gpllO and the HVR of HLA-DR4-(DR~1 *0401) led to 
suggestions of a causative link (Roudier, et al, 1989). Many RA patients, however, 
have no evidence of previous EBV exposure. Retroviruses offer an alternative area 
of some promise (Kalden & Gay, 1994). High levels of human T cell leukaemia 
virus-l (HTLV-l) infection were detected in Japanese with RA, and HTLV-l causes 
arthritis in mice (Iwakura, et al, 1996). However, a search for HTL V -1 conserved 
sequences in human RA failed to confirm an association with early RA (Di Giovine, 
et al, 1994). That other retroviral sequences exist undetected in the RA population 
remains possible. Other reports have implicated proteus mirabilis, parvovirus, 
chlamydia, mycoplasma and mycobacteria (reviewed by Griffiths, 1995). The 
presence of slow-growing bacterial variants of mycobacteria which evade standard 
detection or culture has also been postulated (McCulloch, et aI, 1993). No single 
agent has been universally detected, although it might be that several microbial 
species, or their DNA or protein products, may be capable of generating related 
clinical syndromes, a subset of which are recognised as 'RA'. 
Candidate antigens Bacteria-related products have been suggested as candidate 
antigens. Heat shock protein (HSP 65) is found in synovial membrane and anti-HSP 
65 specific responses are detected in RA, but also at other inflammatory sites, 
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implying lack of specificity (De Graeff-Meeder, et al, 1990, Gaston, et al, 1990). A 
human hsp 70 (HSP73), similar to E.coli dnaK, has also recently been shown to bind 
motifs in the DR~1 *0401 and 1001 molecules (Auger, et aI, 1996) and specific 
synovial T cells responses have been detected against E.coli dnaJ, which shares 
sequence homology with the shared epitope QKRAA, in early RA and juvenile RA 
patients (Albani, et aI, 1995). Other antigens implicated are often those found 
within articular structures. Both T cell and antibody responses to collagen type IT 
have been detected (Londei, et aI, 1989; Ronnelid, et al, 1994), although such 
responses are not RA specific and may be secondary to cartilage damage. The 
peptide binding motif of the DR4 (DR~1 *0401) may be used to screen candidate 
peptides, e.g. an inflammation responsive glycoprotein (gp39) from human 
chondrocytes has been detected by this means which stimulates T cell responses in 
RA peripheral blood cells, and which, on injection into BALB/c mice, induces a 
relapsing, erosive arthritis (Rijnders, et al, 1996). 
Other factors Several data point to a role for endocrine factors, including the female 
preponderance of RA and reported influence on disease activity of the oral 
contraceptive pill, post partum period (prolactin levels) and nulliparity. Defective 
hypothalamic-pituitary-adrenal responses have been detected in RA patients 
(Chikanza, et aI, 1992). Stress, educational status and diet have also been 
implicated in disease severity. 
1.1.3 Clinical features 
RA encompasses a broad clinical spectrum and may present with systemic 
symptoms of malaise, low-grade fever and weight loss, associated with onset of 
articular disease. The latter usually fit one of three basic patterns. Most commonly, 
RA is onset with minimal jOint involvement, which progresses slowly but 
inexorably over years to involve multiple joints in a severe deforming arthropathy 
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with associated significant functional limitation. Other patients suffer an 
intermittent chronic course, punctuated by acute episodes of arthritis between 
periods of remission. Finally, particularly in elderly patients, RA may be of 
explosive onset with multiple jOint involvement and active synovitis, which may 
partially remit after around three years. Extra-articular disease complicates up to 
40% of RA (reviewed by McInnes & Sturrock, 1995) and is associated with 
significant morbidity and mortality (Pincus & Callahan, 1990). Such disease 
complications should be contained in acceptable theories of aetiopathogenesis, 
which must explain not only intra-articular, but also extended major organ 
involvement in destructive pathology. 
The characteristic clinical manifestations of rheumatoid disease entail the classical 
hallmarks of inflammation - swelling, erythema, heat and pain, presiding over 
progressive host tissue destruction. Radiological and gross pathological 
appearances demonstrate cartilage and underlying bone loss reflecting such 
inflammation. Magnetic resonance imaging detects erosive disease within weeks of 
RA onset (Heron, 1992), indicating that tissue destruction closely parallels symptom 
onset. The normally relatively acellular synovial membrane becomes clinically 
palpable ('synovitis') and often cell-rich inflammatory effusions collect within the 
joint space and capsule. This inflammatory symptomatology in RA provides the 
rationale for investigation of the processes which mediate and regulate the articular 
inflammatory response. 
1.2 Immunopathogenesis of rheumatoid arthritis 
1.2.1 Normal synovial membrane 
The normal synovial membrane contains a lining layer of up to three cells thickness 
consisting of macrophages and fibroblasts (reviewed by Edwards, 1987). 
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Superficial type A synoviocytes are CD68+ and non-specific esterase (NSE) 
positive bone-marrow derived cells of the monocyte/macrophage lineage. Type B 
synoviocytes are of fib rob last origin, derived from local proliferation of adjacent 
underlying stromal cells (Barland, et al, 1962; Revell, et aI, 1987; Revell, 1989). 
They exhibit secretory features and possess active golgi and represent the majority 
of lining layer cells (Athanasou, et aI, 1988). They are approximately marked by 
expression of uridine diphosphoglucose dehydrogenase, VCAM-l, the ~ unit of 
prolyl hydroxylase and by synthesis of hyaluronan, and other extra cellular matrix 
components e.g. that identified by Mab 67 (Edwards, 1987; Lindblad & Hedfors, 
1987; Stevens, et aI, 1990; Edwards & Wilkinson, 1995). Type B cells form a loose 
boundary between lining layer and deeper highly vascular, fibrous connective tissue, 
which contains few cells. Those present are largely of fibroblast morphology, with 
some macrophages, mast cells and adipocytes present and occasional T and B 
lymphocytes identified, usually in perivascular cuffs (Norton & Ziff, 1966; 
Edwards, 1987). Although there is evidence of MHC class 11 expression in lining 
layer and some deeper macrophage-like cells (Lindblad & Hedfors, 1987) and of 
adhesion molecule expression (Morales-Ducret, et al, 1992), there is little to indicate 
the presence of ongoing inflammation in the normal synovium. 
1.2.2 Synovial membrane in RA 
In contrast, in RA marked synovial hyperplasia occurs. The lining layer contains 
increased numbers of type A macrophages as a result of increased extra-vascular 
migration (Edwards & Willoughby, 1982; Dreher, 1982), whereas local proliferation 
accounts for considerable type B fibroblast-like (synoviocyte) expansion (Revell et 
al, 1987; Howat, et aI, 1987). Large numbers of synoviocytes, macrophages and T 
and B lymphocytes are found in the interstitium, as are dendritic cells, mast cells 
and polymorphonuclear cells, particularly neutrophils (Duke, et aI, 1982; Burmester, 
et al, 1983; Kennedy, et al, 1988; Cush & Lipsky, 1988; Thomas, et al, 1994). The 
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latter are predominantly located in synovial fluid, along with T lymphocytes and 
macrophages. No basement membrane separates the membrane and fluid phase of 
synovium, indicating that eggression from the membrane is a function of adhesion 
molecule expression and the presence of chemotactic gradients. Profuse 
angiogenesis is characteristic (reviewed by Colville-Nash & Scott, 1992) and 
endothelial differentiation may generate 'high-endothelial venules' (Freemont, 
1987; Yanni, et aI, 1993; Girard & Springer, 1995), reminiscent of those found in 
lymph nodes. Together with the presence of lymphocytic aggregates, these 
histological appearances resemble an active lymphoid tissue, implying that 
immunological processes are important in RA pathogenesis. 
The production of cytokines and their soluble receptors has been recognised to be of 
critical importance in RA pathogenesis (reviewed by Feldmann, et aI, 1996b). 
Cytokines modify diverse cell functions in vivo, through binding to specific cell 
membrane receptors and considerable interest surrounds the possibility that de-
regulated cytokine production can lead to autoimmune disease. In addition, high 
levels of adhesion marker expression are found on endothelial cells and leukocytes 
in RA synovial membrane and peripheral blood (Pitzalis, et al, 1988; Hale, et al, 
1989; Gearing & Newman, 1993; Cronstein & Weissman, 1993; Johnson, et aI, 
1993; Pitzalis, et aI, 1994). Together with cytokine production, these molecules 
comprise a complex regulatory network which determines the activation, 
suppression and recruitment of inflammatory cells in the RA synovial membrane. 
The mechanisms whereby the above cellular infiltrate contribute to articular damage 
remain poorly understood. Deregulated production of matrix metalloproteinases 
(MMP) and tissue inhibitors of metalloproteinases (TIMPs) (Dayer, et al, 1986; 
Gravellese, et aI, 1991; McCachren, et aI, 1991; Firestein, et aI, 1991), reactive 
oxygen intermediates (Blake, et aI, 1989; Mapp, et al, 1995), and prostaglandins 
(Dayer, et al, 1986) by synovial membrane cells has been described. Cytokines may 
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also exert direct effects through modification of chondrocyte or osteoblast / 
osteoclast biosynthetic activity. Local production of auto antibodies by B 
lymphocytes leads to immune-complex formation, complement fixation, neutrophil 
activation and degranulation and may increase IL-l ~ and TNFa. production 
(Chantry, et aI, 1989; Plater-Zyberk, et al, 1992). Given such complexity, it is 
essential to identify the pre-eminent cell type within the synovial membrane to 
choose therapeutic targets with maximum potential impact. Controversy, however, 
surrounds the nature of the optimum target - the T cell, the macrophage (or its 
products) or the synoviocyte? 
1.2.3 Involvement of T Iympbocytes in RA 
T lymphocytes lie central to the regulation of the normal immune response. The 
majority of synovial T cells are of the CD4 helper/inducer subset (Duke, et aI, 1982; 
Pitzalis, et aI, 1987c; Cush & Lipsky, 1988) and are found in perivascular 
aggregates, which occasionally also contain germinal centres (Duke et aI, 1982). 
CD8+ cells are found in the transitional zone surrounding aggregates, or scattered 
throughout the interstitium. Synovial T cells are predominantly CD45RO+, 
CD45RA-, CD45RBdim, CD27-, indicating advanced differentiation within the 
memory subset (Thomas, et al, 1992; Matthews, et aI, 1993; Horgan, et al, 1994). 
They express activation markers, including high levels of CD69 and MHC class 11, 
particularly HLA-DR, (Pitzalis, et aI, 1987a; Afeltra, et aI, 1993; Fernandez-
Gutierrez, et al, 1995) and several adhesion molecules, including ICAM-l (CD54) 
together with the integrins, VLA-l (CD49a1CD29), VLA-4 (CD49d/CD29) and 
LFA-l (CDllalCD18) (Pitzalis, et al 1988; Potocnik, et al, 1990; Laffon, et aI, 
1991; Thomas, et al, 1992; Pitzalis, et al, 1994). Moreover, CD2, CD3 and CD4 
levels are suppressed. A characteristic, and as yet unexplained, feature of synovial 
T cells is the coincident expression of markers which normally appear in co-
ordinated sequential fashion following antigen or mitogen induced activation. Thus 
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CD69 is coexpressed with HLA-DR, VLA-l or VLA-4, markers which do not 
normally appear until after CD69 levels subside (Iannone, et aI, 1994). 
Furthermore, the IL-2 receptor (IL-2Ra.-chain - CD25) is present on only around 
10% of cells (Pitzalis, et al, 1987a). Since IL-2 is the principle T cell growth factor 
in the normal immune response, alternative mechanisms must therefore operate to 
recruit and activate T cells in the synovial membrane. 
Only a small number (-1 %) of synovial T cells are in cell cycle (Bonvoisin, et al, 
1984; Revell, et aI, 1987; Qu, et aI, 1994). The accumulation of synovial T cells 
therefore, most likely results from the preferential migration of memory T cells into 
the inflammatory synovium (Pitzalis, et aI, 1988; Pitzalis, et aI, 1991; Thomas, et al, 
1992; Iannone, et aI, 1994). A subpopulation of circulating C04+, C045RO+, 
RBdim, C027- memory T cells possess intrinsic migratory properties allowing 
transmigration into endothelial-coated collagen gels (Cush, et alI992). Such cells 
express CD44, CDlla, CD26 and CD49, but not CD62L (Brezinschek, et aI, 1995). 
CD27- memory T cells are usually cutaneous lymphocyte antigen positive (CLA) 
and represent a tissue-homing memory T cell subset, in contrast to C062+ lymph 
node-seeking cells (Baars, et aI, 1995). Activation is not a prerequisite for 
migration, and although C069+ T cells migrate more efficiently, the majority of 
cells with migratory potential are resting (Brezinschek, et al, 1995), Removal of the 
endothelium alters the migratory cell phenotype, and prior activation of the 
endothelial cells with TNFa. induces migration of a further C069+, CD62L + 
population, indicating that the endothelium may regulate T cell recruitment to 
inflammatory sites (Brezinschek et aI, 1995). Enhanced numbers of C045RO+, 
CD45RBdim, CD27- T cell subset were recently identified in peripheral blood of 
RA patients compared to controls, perhaps reflecting long-term systemic antigen 
stimulation (Kohem, et al, 1996), 
29 
In vivo, similar accumulation of CD45RO+ T cells into PPD-induced skin blisters 
has been observed (Pitzalis, et aI, 1991) and subsequent FACS analysis shows the 
early presence of VLA-l + and HLA-DR+ cells which must have resulted from 
preferential recruitment of preactivated cells (Iannone, et aI, 1994). Moreover, the 
interaction of T cells with endothelial cells led to up regulation of CD69 and HLA-
DR expression. Thus, T cells appear to differentiate to a maturation stage at which 
egression from the circulation to tissue is enhanced. The mature synovial phenotype 
can therefore be partially explained by preferential recruitment of differentiated 
memory T cells, with additional activation by endothelial cell contact during 
extravasation. 
The functional significance of cell adhesion molecule expression extends beyond 
cell-cell interactions. Synovial T cells express integrin receptors for extracellular 
matrix (ECM) components, including collagen, vitronectin and fibronectin 
(Rodriguez, et aI, 1992; Pitzalis, et aI, 1994; Kohem, et aI, 1996). Membrane 
interactions with the ECM are capable of further activating T cells within the 
synovial environment (GHat, et ai, 1996). A further consequence is upregulated 
production of matrix-degrading enzymes by T cells, such as heparanase, which 
facilitate movement through inflammatory tissues and thus enhance local migration. 
It has been proposed that the CD45RBdim status of synovial T cells indicates 
longevity within the synovial compartment, although this view has recently been 
challenged (Matthews, et aI, 1993; Iannone, et aI, 1994; Westermann & Pabst, 
1996). In contrast to synovial lining layer cells, synovial T cells exhibit little 
evidence of apoptosis in vivo (Firestein, et aI, 1995; Nakajima, et aI, 1995). 
Analysis of relative levels of bcl-2, bcl-x and Bax gene expression in synovial T 
cells, suggests that survival may be attributable to the production of 'stromal' 
factors, as yet unidentified, produced by synovial fibroblasts, rather than by 
cytokine-mediated rescue (Akbar, et aI, 1996; Salmon, M. - personal 
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communication). Thus, the synovial environment may represent a privileged site for 
memory T cell survival, contributing to the observed phenotype. 
The functional capabilities of synovial T cells have been extensively investigated in 
vitro. T cell clones derived from RA synovial membrane are predominantly IFN-y 
producers (Miltenberg, et aI, 1992; Quayle, et aI, 1993; Cohen, et aI, 1995), 
indicating that RA may be a Thl driven disease as has been suggested for reactive 
arthritis (Schlaak, et aI, 1992; Simon, et al, 1994; reviewed by Sieper & Kingsley, 
1996) and insulin dependent diabetes (reviewed by Liblau, et al, 1995). Many T cell 
clones were also capable of IL-lO production, but few produced IL-4 (Cohen, et al, 
1995). However, polyc1onal synovial T cell populations exhibit deficient 
proliferation and IFN-y or IL-2 production in response to mitogens (Aaron, et al, 
1991, Thomas, et aI, 1992) and demonstrate impaired responses to recall antigens 
(Verwilghen, et al, 1990). Impaired helper I inducer and suppressor function in vitro 
has also been reported (Chattopadhyay, et aI, 1979; McCain, et aI, 1984). In 
contrast, the CD45RO+' RBdim, CD27- subset found within synovium is capable of 
potent B cell help having lost the ability to suppress immunoglobulin production in 
vitro (Thomas, et aI, 1992), suggesting a role in autoantibody production in RA. 
However, taken together with their activated phenotpye, these observations have led 
to the suggestion that synovial T cells are in a state of 'split anergy', (Thomas, et aI, 
1992; Howell, et al, 1992) or of 'frustrated activation' (Pitzalis, et al, 1987a). This 
might be a reflection of their maturation state, the presence of inhibitory factors in 
synovium, such as TGF~, IL-lO, and prostaglandins, or result from interaction with 
synovial antigen presenting cells on entry to the membrane with resultant anergy 
(Salmon & Kitas, 1989; Fava, et aI, 1989; Firestein & Zvaifler, 1990; Schwarz, 
1990; Katsikis, et al, 1994). 
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Evidence from several sources, however, strongly support a central role for T cells 
in RA pathogenesis (Panayi, et aI, 1992; Panayi, 1993). 
1. Therapy directed specifically at T cells leads to reduction in synovial 
inflammation. Thus, physical measures such as thoracic duct drainage, 
peripheral lymphocytapheresis or total lymphoid irradiation induce partial 
amelioration of inflammatory symptoms (Paulus, et aI, 1977; Panayi & Amlot, 
1982; Emery, et aI, 1986; Zvaifler, 1987). Administration of monoc1onal 
antibodies against T cell markers such as CD4 (Homeff, et al, 1991; Wendling, 
et al, 1991; Tak, et al, 1995), CDw52 (Campath) (Weinblatt, et aI, 1995) or CD5 
(Strand, et aI, 1993) have yielded variable responses, with undoubted clinical 
improvement in some patient groups. However, patients submitted to such trials 
often have advanced disease, amenable only to partial remission due to extensive 
secondary mechanical problems, and as such perhaps underestimate the impact 
of T cell targeting. Furthermore, cyclosporin A treatment exhibits demonstrable 
benefit in early (Pasero, et al, 1996) and late RA (Harrison, 1992), indicating 
that T cells can play a significant role, even in established disease. 
2. RA patients infected with human immunodeficiency virus (HIV) have been 
reported to undergo partial disease remission (Bijlsma, et al, 1988). Recently 
however, reports in which HIV+ RA patients have been followed over time 
suggest that remission may not reflect delay in articular destruction (MUller-
Ladner, et aI, 1995). Moreover, several patients have now been described in 
whom little improvement in clinical inflammation followed HIV infection 
(Omstein, et al, 1995). Since the immunological consequences of HIV extend 
beyond effects simply on CD4+ T cells, such data require cautious 
interpretation. 
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3. Several animal models of arthritis have been shown to be T cell dependent. 
Collagen induced arthritis (CIA) in rodents may be induced in naive recipients 
by transfer of primed T cells from CIA mice, or by collagen specific T cell 
clones (Trentham, et aI, 1978; Brahn & Trentham, 1989). Moreover, CIA is 
effectively prevented or ameliorated by T cell depletion if performed during 
immunisation (Ranges, et al, 1988; Williams & Whyte, 1996). Streptococcal 
cell wall arthritis, adjuvant induced arthritis and pristane induced arthritis 
behave similarly (reviewed by Kaklamanis, 1992; Levitt, et al, 1992; Staines & 
Wooley, 1994;). Thus, small numbers of specific T cells can initiate immune 
responses with consequent articular pathology. 
4. Perhaps the strongest evidence for T cell involvement comes from the 
association of RA disease severity with the HLA-DR shared epitope already 
described (Section 1.2; Stastny, 1978). The defined function of class II 
molecules is to present peptide to the T cell receptor. It is therefore attractive to 
hypothesise that continued presentation of an arthritogenic autoantigen occurs 
within the synovial compartment leading to initiation and perpetuation of 
disease. However, it remains possible that the effect of MHC is mediated only 
through shaping of the T cell receptor repertoire during thymic education, or 
through preferential presentation of an extrinsic antigen(s) i.e. pathogen, 
contained on putative causative microbial agents. Nevertheless, each of these 
possibilities implicates the T cell at some stage in RA disease development. 
5. In animal models of autoimmune disease to defined 'self' antigen, such as 
murine experimental encephalomyelitis (e.g. Acha-Orbea, et aI, 1988) analysis 
of the TCR usage demonstrates restricted clonal expansion of V~ genes, 
indicative of the dominant antigen-specific response. However, similar studies 
in RA using southern blot analysis, polymerase chain reaction or monoclonal 
antibody typing of T cell clones, or of IL-2 expanded synovial T cell 
33 
populations, have yielded conflicting results. Whereas some earlier studies 
suggested over-representation of V~14, indicating possible involvement of a 
superantigen (Paliard, et al, 1990; Howell, et aI, 1991), the majority of studies, 
while establishing differential V~ gene usage in synovial compared to blood T 
cells, have failed to provide a consistent pattern in different RA patient cohorts 
(Bowness & Bell, 1992; Struyk, et aI, 1996). In contrast, CDR3 amino acid· 
sequencing by DNA analysis has suggested the presence of conserved amino 
acid sequences within diverse V~ repertoires (e.g. Muruyama, et aI, 1993; 
Struyk, et aI, 1994; reviewed by Struyk et aI, 1996). These data indicate 
conserved sequences in the antigen binding domains of the T cell receptor and 
provide suggestive evidence for antigen-driven expansion of T cells within the 
synovial membrane. 
Few antigen specific T cells need be present within an inflammatory lesion. In 
tuberculoid leprosy, fewer than 2% of T cells within the skin eruption are M. leprae 
responsive (Modlin, et aI, 1988). Similarly, T cell frequency against myelin 
oligodendrocyte glycoprotein in blood of MS patients is only 1:7,299 and in 
cerebrospinal fluid, 1:450 (Sun, et al, 1991) and bacteria-specific T cells in reactive 
arthritis are present at a frequency of -0.1 % (Sieper, et al, 1993). The vast majority 
of T cells within the RA synovial membrane are therefore likely to recognise 
irrelevant antigens. Whether such cells contribute directly to RA pathology, or are 
simply functional 'bystanders', is currently unclear. 
1.2.4 Fibroblasts in RA 
The contribution of the synoviocyte to RA has been subject of controversy. 
Synovial fibroblasts produce cytokines including TGF~, FGF, PDGF, IL-6, TNFa 
and IL-l ~ and are significant sources of MM Ps and of prostaglandins (Remmers, et 
al, 1991; Zvaifler & Firestein, 1994; Edwards, 1995). As such they comprise an 
34 
important component of the inflammatory response in RA, but have been considered 
the inevitable result of chronic inflammatory infiltration. That they represent the 
primary lesion has also been proposed (Zvaifler & Firestein, 1994). Several animal 
models evolve articular erosion in the absence of T cells. Borrelia infection induces 
destructive arthritis in SCIO mice (Schaible et aI, 1990), and the early phase of 
spontaneous arthritis in MRL-MP-lpr/lpr mice is characterised by fibroblastic 
infiltration in the absence of T cells (O'Sullivan, et aI, 1985). Similarly, c-fos 
transgenic mice develop antigen-induced arthritis the articular component of which 
proceeds independent of lymphocyte infiltration (Shiozawa, et al, 1992). Synovial 
fibroblasts exhibit invasive properties in vitro and express adhesion molecules for 
ECM, particularly vitronectin, which would facilitate migration into cartilage with 
ultimate formation of 'erosions' (Zvaifler & Firestein, 1994). 
1.2.5 Macrophages in RA 
Macrophages, derived from the circulating monocytes, constitute some 30-50% of 
the cellular pool in synovial membrane and like T cells, they exhibit features 
suggestive of activation. Ultrastructural examination demonstrates prominent 
filopodia, vacuoles, vesicles and rough endoplasmic reticulum (Athanasou, 1995) 
and histological studies show enhanced expression of complement receptors (C3b), 
Fc receptors and multiple adhesion molecules, including ICAM-l and the (32 
integrins (Theofilopoulos, et aI, 1980; Burmester, et al, 1983; Athanasou & Quinn, 
1991; Johnson, et aI, 1993). HLA-OR up regulation has been widely reported, 
although the mechanism whereby this occurs is unclear in the absence of IFN-y 
(Klareskog, et al, 1981; Burmester, et aI, 1987; Firestein & Zvaifler, 1988). CD14 
and CD68 expression have been used extensively for identification purposes. 
However, the former is lost during maturation in the synovial membrane, and the 
latter may be found in intimal synovial fibroblasts (Wilkinson, et aI, 1992), raising 
doubts as to its specificity outwith the lining layer. Non-specific esterase therefore 
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probably remains the most reliable macrophage marker for histological purposes. 
The principle manifestation of macrophage activation however, is the presence of 
upregulated cytokine gene expression (Firestein, et aI, 1990) and of high 
concentrations of macrophage-derived cytokines detectable within synovial 
membrane and fluid. 
1.2.6 Cytokine production in RA 
Bodel & Hollingsworth first described endogenous pyrogen (now 'IL-l') production 
by synovial cells in 1968. Subsequcntly, it was found that IL-l induced lcukocytc 
infiltration and cartilage breakdown in rabbit synovial joints (Pcttipher, et al, 1986). 
Numerous cytokines have since been localised in the synovial membrane and some 
have become the focus of therapeutic intervention, as it has become established that 
they play a central regulatory role in articular destruction. The pattern of cytokine 
production, however, has lcd to considerable controversy as to which of the cell 
types present in synovial membrane is the key element in pathogenesis (Panayi, et 
al, 1992; Firestein & Zvaifler, 1990). 
The presence of many activated synovial T cells is not reflected in high levels of T 
cell cytokine expression in synovial membrane (Firestein & Zvaifler, 1987; 
Firestein, et al, 1988; Chen, et al' 1993), Although IFN-r, and rarely IL-2, may be 
detected at the mRNA level by peR or in situ hybridisation (Simon, et aI, 1994; 
Buchan, et aI, 1988), immunohistochemical localisation has proven difficult, 
demonstrating expression in small numbers of cells only (Ulfgren, et aI, 1995). 
Neither cytokine has been consistently detected in synovial fluid or in synovial 
tissue cultures by ELISA. Moreover, IL-4 has not been detected by any means. 
These observations have cast doubt on the role of T cells in ongoing synovitis, on 
the basis that T cell effects should be 'cytokine driven'. However, just as the 
frequency of antigen specific T cells in inflammatory sites is limited, so too is the 
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level of T cell cytokine expression. Thus, IFN-y expression in leprosy skin lesions is 
seen in <1% of cells (Cooper, et aI, 1989). Moreover, it has been recently 
recognised that the actual concentration of cytokine adjacent to its cell receptor in 
vivo may be markedly higher than that predicted from in vitro measurements 
(Kaplan, 1996). The level of T cell cytokines thus far detected may therefore be 
sufficient to sustain a small number of arthritogen-specific T cells, but is unlikely to 
explain the extensive T cell activation described. 
In contrast, macrophage derived cytokines have been relatively easily detected. 
These include IL-la, IL-l~, TNFa, IL-6, IL-8 and GM-CSF (Di Giovine, et aI, 
1988; Houssiau, et al, 1988; Arend & Dayer, 1990; Seitz et al, 1991; Field, et al, 
1991; Chu, et al, 1991; Alvaro-Gracia, et al, 1991; Brennan, et al, 1991; Koch, et aI, 
1992; Deleuran, et aI, 1992; Deleuran, et aI, 1994) and encompass a broad range of 
pro-inflammatory activities. Investigations of their role in animal models and in 
vitro suggest that IL-l~ and TNFa may be of prime importance (Arend & Dayer, 
1995; Maini, et aI, 1995b). TNFa is produced by macrophages in the lining layer 
and at the cartilage-pannus junction (Chu, et al, 1992). It is present in up to 50% of 
RA synovial fluids and is detected in vitro after synovial tissue culture. Its 
bioactivities can explain several pathological features observed in RA and include 
up regulation of adhesion molecule expression, activation of osteoclast-mediated 
resorption of bone, suppression of anabolic effects of osteoblasts and chondrocytes, 
promotion of angiogenesis, enhancement of MMP and prostaglandin E2 (PGE2) 
production, stimulation of fibroblast proliferation and activation of T and B 
lymphocytes and of endothelial cells (reviewed by Arend & Dayer, 1995; Feldmann, 
et aI, 1996b). TNFa also upregulates other cytokine production within the synovial 
compartment, since the addition of neutralising anti-TNFa. antibodies to synovial 
tissue cultures inhibits the production of IL-l~, IL-6, IL-8 and GM-CSF (Brennan, 
et aI, 1989, Feldmann, et aI, 1996b). TNFa. production is enhanced in murine CIA 
and adjuvant arthritis, and disease development and progression are suppressed by 
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treatment with anti-TNFa antibodies (Williams, et aI, 1992; Staines & Wooley, 
1994). Moreover, a transgenic mouse which expresses the human TNFa. gene, 
stabilised by replacement of its mRNA 3' untranslated region with that of the p-
globulin gene, develops erosive polyarthritis characterised by marked synovial 
hyperplasia (Keffer, et al, 1991). The most persuasive evidence for a central role for 
TNFa., however, lies in the amelioration of clinical and laboratory parameters of 
disease activity in RA patients treated with 'humanised' monoclonal anti-TNFa. 
antibodies (Elliott, et al, 1994; Rankin, et al, 1995). 
The activities of TNFa overlap considerably with those of IL-l~. Thus, IL-l~ 
upregulates MMP and PGE2 production, enhances cartilage breakdown and 
upregulates osteoclast activity, promotes angiogenesis and induces fibroblast 
proliferation. However in comparison to TNFa, IL-l~ may exert more potent 
effects on chondrocyte and osteoclast activity and induces higher levels of MMP 
production from synoviocytes (reviewed by Arend & Dayer, et aI, 1995). In animal 
models, administration of IL-l~ induces or upregulates inflammatory arthritis, and 
inhibition of IL-lp activity down-regulates inflammatory disease (van den Berg, et 
aI, 1994). However, others have found IL-l receptor antagonist (IL-lra) less 
effective than anti-IL-I~ antibodies, suggesting that IL-l may be of variable 
importance in different models (Wooley, et aI, 1993). Nevertheless, clinical trials 
using IL-Ira in RA have brought about clinical improvement, but remain at a 
preliminary stage (Campion, et al, 1996). 
Addition of anti-IL-l~ antibody or IL-lra to synovial tissue cultures suppresses IL-6 
and GM-CSF production, but does not influence TNFa. production (Feldmann, et al, 
1996b). In combination with the in vivo effects of TNFa. neutralisation, these data 
indicate that TNFa. lies proximal to other monokines, occupying the pivotal point in 
a cytokine 'cascade'. However, recent studies in streptococcal cell wall arthritis, 
zymosan-induced arthritis, antigen-induced arthritis and CIA have suggested that 
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TNFa and IL-l~ may exert distinct biological effects in articular destruction. IL-l~ 
appears more involved in cartilage degradation, whereas TNFa is implicated 
primarily in pro-inflammatory effects in synovium (Van de Loo, et aI, 1995; Van 
Lent, et al, 1995; Joosten, et al, 1996). These data imply that combined neutralising 
therapies may be required to adequately suppress tissue damage and moreover, that 
functional redundancy of cytokines in the synovium is not absolute. 
TGF~, in both latent and active forms (Fava, et aI, 1989; Chu, et al, 1991), and IL-I0 
(Katsikis, et al, 1993) have been detected in synovial membrane and are capable in 
vitro of down-regulating macrophage activation and of opposing the effects of IL-l ~ 
and TNFa. Although TGF~ may induce synovitis when injected into rodent knees 
(Fava, et aI, 1991), its role in the majority of animal models is anti-inflammatory 
(Kuruvilla, et aI, 1991; Brandes, et aI, 1991). Increased levels of IL-lra, and of 
soluble IL-l, IL-2 and TNFa receptors (p55 and p75) are also found in synovial 
membrane and in synovial fluid (Miossec, et aI, 1990; Symons, et aI, 1991; 
Deleuran, et al, 1992; Cope, et aI, 1992; Duff, 1993; Firestein, et aI, 1994). They 
usually inhibit the action of their respective cytokines, although in low 
concentration, soluble TNFaR may stabilise the bioactivity of TNFa (Aderka, et al, 
1992). These molecules provide evidence of an attempt within the synovial 
membrane to down-regulate the inflammatory process. Their net effect in tissue will 
be determined by the precise local balance of cytokine and antagonist The cytokine 
network in RA therefore appears to represent a balance of pro- versus anti-
inflammatory (repair) processes, in which the former dominates over time. 
Chemokines comprise a further class of pro-inflammatory protein represented within 
synovium. Both C-X-C (ex) chemokines, including IL-8, epithelial neutrophil 
activating peptide 78 (ENA 78) and melanoma growth stimulating activity (GROa), 
and C-C (~) chemokines, including macrophage inflammatory protein (MIP)-la, 
MIP-l~, RANTES (regulated upon activation normal T cell expressed and secreted) 
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and monocyte chemoattractant protein (MCP)-1 have been detected in RA synovial 
membrane (Seitz, et aI, 1991; Koch, et aI, 1991; Koch, et al, 1992; Rathanaswami, et 
aI, 1993; Koch, et aI, 1994a; Koch 1994b; Deleuran, et aI, 1994; Hosaka, et aI, 
1994). Synovial fluid therefore contains chemotactic activity which is attributable 
to multiple factors which, in turn, exhibit considerable redundancy (Al-Mughales, et 
al, 1996). Their contribution to leukocyte recruitment occurs in combination with 
the increased expression of adhesion molecules characteristic of the synovial 
environment (Johnson, et aI, 1993; Cronstein & Weissman, 1993; Pitzalis, et aI, 
1994). Specific reorganisation of adhesion molecules, such as ICAM-3 and LFA-1, 
to the tips of uropods follows chemokine exposure, thereby optimising ligand 
interactions at the point of cell-cell contact (Angel del Pozo, et aI, 1996). However, 
the precise role of chemokine activity in RA is unclear, since in vitro transepithelial 
migration studies of lymphocyte recruitment have demonstrated that MIP-1a and 
RANTES do not alter the phenotype or magnitude of peripheral blood lymphocyte 
invasion (Brezinschek, et aI, 1995). It is therefore possible that their primary 
importance lies in regulating migration within the synovial membrane. In this 
respect, the recent demonstration that cytokine-ECM interaction can create high 
local concentrations of bioactive cytokine may be of relevance (GHat, et aI, 1996). 
An additional effect may be to potentiate neovascularisation, as demonstrated for 
IL-8 or ENA 78 (Koch, et al, 1991; Koch, et al, 1994b). 
There is therefore little doubt that synovial macrophages occupy a central position in 
RA pathogenesis through cytokine secretion. Immune complexes, complement 
degradation products, bacterial or viral constituents and cell-cell contact have been 
proposed as stimulatory factors, but none is satisfactorily proven. Thus, although 
the effector role of TNFa in RA is established, much less is known about the events 
initiating and maintaining TNFa production. Nor has a satisfactory explanation 
been provided to link the presence and activity of the majority of T cells with 
macrophages in synovial membrane, beyond the putative presentation of antigen and 
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HLA-DR to a subset of disease-specific lymphocytes. Recently, a novel cytokine, 
designated IL-15, has been identified which is produced by activated macrophages 
and fibroblasts and exerts potent activities on T cells. This functional profile 
indicated that it might be highly relevant in the context of rheumatoid pathogenesis. 
1.3 Interleukin 15 (IL-lS) 
IL-15 (synonym: 'IL-T') was simultaneously identified as a product of the simian 
kidney epithelial cell line, CV-IIEBNA (Grabstein, et al, 1994) and of the HTLV-l-
associated HuT-102 adult T cell leukaemia cell line (Burton, et aI, 1994; Bamford, 
et aI, 1994). Relevant physical characteristics are shown in table 1.1. Although they 
share no primary sequence homology, IL-2 and IL-15 possess similar functional 
activities, as both are members of the short chain four a. helix bundle cytokine 
family. However, whereas 1L-2 synthesis is primarily restricted to activated T cells, 
IL-15 expression, at least at the mRNA level, has been identified in numerous 
normal human tissues, including skeletal muscle, placenta and kidney, and cell 
types, such as activated monocytes and fibroblast cell lines, but not as yet in T cells 
(Grab stein, et aI, 1994; Tagaya, et al, 1996a). However, because IL-15 was first 
identified as aleukaemic T cell product, the possibility remains that T cells 
appropriately activated may also synthesise IL-15. 
1.3.1 IL-lS receptors 
The functional similarities between IL-2 and IL-15 are reflected in shared utilisation 
of the 70175kD IL-2R ~-chain, and the 64kD common y-chain. Thus, the effect of 
IL-15 on activated T cells can be inhibited by antibodies against IL-2~ or y chains 
but not against IL-2Ra. chain. Similar data were obtained on analysis of IL-15 
binding to cells transfected with different IL-2R subunits (Giri, et aI, 1994; 
Grabstein, et aI, 1994; Bamford, et al, 1994). Subsequently, a type 1 membrane 
Table 1.1 Physical characteristics of human interleukin-15 
Properties 
Structure 
Primary sequence homology 
Genomic structure 
Cellular distribution of mRNA 
Receptor a-chain distribution 
T cell receptor signalling 
Mast cell receptor signalling 
Interleukin-15 
four a-helical bundle, 
two disulphide cross-links 
14-15 kO, 114 amino acids 
variable glycosylation 
97% with simian IL-15 
73% with murine IL-15 
<10% with human IL-2 
8 exon 17 intron 
(variable mRNA splicing reported) 
placenta, skeletal muscle, kidney, lung, 
heart, fibroblasts, epithelial cells, monocytcs 
T cells, NK cells, B cells, Monocytes 
JAKlI JAK 3 STAT 31 STAT 5 
JAK2 STAT5 
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protein has been identified in mice which binds IL-15 with high affinity (Giri, et aI, 
1995). Parallel studies in humans have identified a similar receptor, designated IL-
15R a-chain (Anderson, et aI, 1995b; de Jong, et al 1996; Kennedy & Park, 1996). 
The IL-15Ra gene maps to human chromosome 10, adjacent to the IL-2Ra gene, 
with which it shares fragmented sequence homology. It is alternatively spliced to 
yield three active forms, each capable of high affinity binding to IL-15 (Anderson, et 
aI, 1995b). Like IL-2Ra, it does not appear to transduce signals, despite the 
presence of a 37 amino acid intracellular domain. However, notwithstanding these 
similarities, the two a chains appear functionally discrete. IL-15Ra binds IL-15 
with 1000-fold higher affinity than does IL-2Ra to IL-2, with no reported 
crossreactivity (Giri, et al, 1995). Moreover, IL-15Ra forms an unstable complex 
with IL-2R~'Y, in contrast to the tight IL-2Ra~'Y complex which results from the 
stabilising effect of IL-2Ra on ~'Y chain binding (Minami, et al, 1993; de Jong, et al, 
1996). Thus, the up regulation of IL-2Ra expression during T cell activation will 
effectively compete for available IL-2~'Y chain, with consequent down regulation of 
IL-15 mediated signalling, through disaggregation of weak IL-15Ra - ~'Y chain 
interactions. 
The widespread tissue distribution of IL-15Ra further distinguishes it from IL-2Ra. 
Whereas IL-2Ra is primarily expressed on activated T cells, IL-15Ra mRNA has 
been identified in numerous human tissues and cell lines, including activated T cells 
(Anderson, et aI, 1995b). Interestingly, IFN-y stimulated monocytes also express 
IL-15Ra mRNA, indicating the potential for autocrine regulation. However, since 
the distribution of IL-2R~'Y chain is limited, the demonstration of IL-15Ra 
expression alone may not be a satisfactory indicator of IL-15 responsiveness. 
Although IL-15 can transduce signals through ~y chain alone, it does so less 
efficiently than does IL-2 (Grabstein, et al, 1994; Anderson, et al, 1995b; Kumaki, et 
al, 1996). The functional significance of IL-15RIl expression in the absence of ~'Y 
chain is currently unknown. Possibilities include the scavenging of 'free' IL-15 at 
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inflammatory sites, or the presentation of IL-15 to other IL-15 receptor bearing 
cells, thereby increasing the efficiency of ligand-receptor interaction. 
Expression ofIL-2Ra. and IL-15Ra. appear linked. IL-15, like IL-2, upregulates the 
level of IL-2Ra. on human B and T cells, but rapidly down-regulates the expression 
of IL-15Ra.. Thereafter, lymphocyte responsiveness to IL-15 is reduced in 
comparison to IL-2 as measured by JAK3 kinase activation (Kumaki, et al, 1996). 
Thus, macrophage-derived IL-15 can enhance T cell activation during the early 
stages of an immune response, but thereafter down-regulate its own receptor, 
thereby enabling IL-2 to function as the principle T cell growth factor. 
The observation that mast cells proliferate to IL-15 but not to IL-2, led to the 
discovery of a further novel receptor for IL-15, designated IL-15RX (Tagaya, et al, 
1996b). This 60-65 kD protein requires neither IL-2R~ nor y chain for signalling 
and is also found on normal bone marrow mast cells. Whether a cofactor membrane 
protein exists, or indeed whether this receptor enjoys wider cellular distribution is 
not yet known. These data further demonstrate that the functional profiles of IL-2 
and IL-15 are not identical. 
1.3.2 Signal transduction following IL·15 receptor occupancy 
Following IL-15 binding to activated T cells, functional coupling of Janus-
associated kinases (JAK) 1 and JAK3 with the IL-15 receptor occurs (Johnston, et 
aI, 1995a). JAKl and JAK3 in turn activate and tyrosine phosphorylate insulin 
receptor substrate (lRS)-1 and IRS-2, with subsequent tyrosine phosphorylation and 
nuclear translocation of Stat 3 and Stat 5 (signal transducers and activators of 
transcription) (Johnston, et aI, 1995b; Lin, et aI, 1995), Other signalling events 
transduced by IL-15 include phosphorylation of p56lck and p72syk and induction 
of Bcl-2, with resultant protection or rescue from apoptosis (Miyazaki, et aI, 1995; 
- -------------
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Akbar, et aI, 1996). The IL-15RX, in contrast, utilises a JAK2! Stat 5 dependent 
pathway in mast cells which is distinct from that in activated T cells (Tagaya, et al, 
1996b). Whether this pathway also exists in human T cells is unknown. 
1.3.3 Biological activity of IL·15 
1. T lymphocytes • IL-15 activates T cells as judged by several criteria. IL·15 
induces proliferation of PHA activated CD4+ and CD8+ T cells, T cell clones 
and y8 T cells (Grabstein, et al, 1994), with concomitant release of soluble IL-2 
receptors (sIL-2R) (Treiber-Held, et al, 1996). CD69 expression is upregulated 
on CD45RO+, but not CD45RA+, peripheral blood T cells, consistent with the 
distribution of IL-2R~ chain expression on memory T cell subsets (Minami, et 
aI, 1993; Kanegane & Tosato, 1996). IL-15 mediates cytotoxicity, through 
generation of both CD8+ CTL and of lymphokine activated killer (LAK) cells 
(Grabstein, et aI, 1994). IL-15 induces T cell polarization, a recognised 
prerequisite to activation, and migration in collagen gel or filter assays, with 
greater potency than either IL-8 or MIP-la (Wilkinson & Liew, 1995). 
Moreover, it redistributes adhesion molecules, including ICAM-3, -1 and -2, to 
uropods in the presence of ~-integrin ligands, such as fibronectin and VCAM-I 
(Nieto, et aI, 1996). Thus, IL-15 might recruit T cells and thereafter, modify 
homo- or heterotypic cell-cell interactions within inflammatory sites. 
Furthermore, IL-15 has recently been shown to rescue T cells from cytokine 
withdrawal-induced apoptosis, through selective induction of bcl-2 and bcl-xl 
(Akbar, et aI, 1996), indicating that lymphocyte survival within inflammatory 
sites can be enhanced in the presence of IL-15. 
Given its likely early expression in immune responses, the relationship of IL-15 
to T cell subset differentiation, particularly in combination with IL-12, is clearly 
of interest. IL-15 primes naive CD4+ T cells from TCR transgenic mice for 
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subsequent IFN-y, but not IL-4 production (Seder, 1996). Moreover, antigen 
specific responses in T cells from HIV+ patients in the presence of high-dose IL-
15 exhibit increased IFN-y production (Seder, et al, 1995) and preliminary data 
indicate that IL-15 might enhance IFN-y production if IL-12 is relatively 
deficient. However, IL-15 induces IL-5 production from human 
dermatophagoides jarinae II specific T cell clones, implying a positive role in 
Th2 mediated allergic responses (Mori, et al, 1996). Whether IL-15 prejudices 
Thl or Th2 responsiveness in uncommitted ThO cells (Mossman & Coffman, 
1989) therefore remains unclear. Current data indicate that its function as a T 
cell growth factor will likely sustain either Thl or Th2 cells, if already 
committed to that differentiation pathway. 
2. Natural killer cells - IL-15 induces NK cell activation measured either by direct 
cytotoxicity, antibody dependent cellular cytotoxicity (ADC C) or by production 
of cytokines, including IFN-r, TNFa, GM-CSF and MIP-la (Carson, et a11994; 
Carson, et al, 1995; Bluman, et al, 1996; Warren, et al, 1996). These data imply 
that IL-15, rather than IL-2, may be the primary activator of NK cells during 
early immune responses, in combination with IL-12. 
3. B cells - IL-15 costimulates proliferation and immunoglobulin synthesis (IgM, 
IgG, IgA) by human B cells activated with either CD40 ligand or immobilised 
anti-IgM (Armitage, et aI, 1995). A role has also been proposed for IL-15 as a 
growth factor in B cell chronic lymphoproliferative disorders (Trentin, et aI, 
1996). 
4. Mast cells - IL-15 induces mast cell proliferation and activation. The presence 
of the IL-15X receptor in bone marrow mast cells indicates a role in mast cell 
development along with IL-3 (Tagaya et al, 1996b). 
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5. Thymic development - Early reports have implicated IL-15 in T cell 
development. Lymphocytes from IL-2R~ deficient mice do not proliferate to IL-
lS. These animals exhibit abnormal T cell development, with significantly 
reduced thymocyte numbers after 4 weeks (Suzuki, et aI, 1995). Subsequent 
studies comparing the effect of IL-15 and IL-2 on thymocyte development have 
demonstrated that IL-15 may preferentially support differentiation of bipolar IL-
2R~+, CD4-, CD8- progenitor cells towards T y8 or NK cell populations rather 
than to the T ex ~ subset (Leclercq, et aI, 1996). Furthermore, IL-2 reduced 
thymocyte expansion in vitro through binding to IL-2Ra, in contrast to the 
proliferative effect of IL-15 through IL-15Rex expression (Willerford, et aI, 1995; 
Leclercq, et al, 1996). Thus, IL-2 and IL-15 may exhibit differential effects in 
immature T I NK cell development. Recently, IL-15 has also been implicated in 
development of mature CD16+, CD56+ NK cells from CD34+ haematopoietic 
progenitor cells (Mrozek, et al, 1996). 
6. Activity outside the immune system. The widespread tissue distribution of 
mRNA for IL-15 and IL-15Ra indicates that diverse functions may exist beyond 
the immune system. For example, IL-15 exerts anabolic effects, but not 
proliferation, in vitro in skeletal muscle (Quinn, et al, 1995). 
IL-1S thus represents a mechanism whereby local tissue cells can contribute to the 
early 'innate' phase of immunity, providing enhancement of NK cell and 
subsequently T cell responses, prior to optimal IL-2 production. 
1.3.4 Regulation of IL·IS production 
The factors which up regulate IL-15 synthesis are poorly understood. Using 
semiquantitative RT-PCR, up regulation of IL-15 mRNA levels in bone-marrow 
derived murine macrophages was induced by lipopolysaccharide (LPS), BCG, M. 
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tuberculosis or T. gondii, only after prior IFN-y priming. Compared with mRNA for 
IL-12, IL-15 induction was partially resistant to down-regulation by IL-4, IL-13 and 
TGF~. In contrast, IL-IO addition increased levels of IL-15 mRNA in cultures 
(Doherty, et aI, 1996). These data were partially confirmed at the protein level using 
CTLL cell bioassay. Similarly, LPS I IFN-y stimulation, or Human Herpesvirus-6 
infection of peripheral blood monocytes induced IL-15 mRNA expression (Carson, 
et aI, 1995; Bamford, et aI, 1996a; Bamford, et aI, 1996b; Flamand, et al, 1996). 
Thus, recognised macrophage activators appear to increase IL-15 expression, at least 
at the mRNA leveL 
Consistent detection of IL-15 protein synthesis, however, has not followed the 
widespread distribution of its mRNA. Whereas most cytokines are regulated by 
modification of transcription and message stabilisation (reviewed by Paul & Seder, 
1994; Kishimoto, et aI, 1994), significant post-transcriptional regulation has been 
detected for IL-15. The human IL-15 mRNA 5' UTR contains 10 AUO triplets 
which significantly reduce the efficiency of translation (Kozak, 1991; Bamford, et 
al, 1996a). Fusion of the IL-15 mRNA with an HTLV-l R region in the HuT-I02 
cell line deleted the AUO rich 5'UTR sequence, leading to high levels of 
constitutive IL-15 secretion (Burton, et aI, 1994; Bamford, et aI, 1996b). 
Engineered removal of this sequence similarly induces increased levels of IL-15 
protein expression in appropriately transfected COS cells (Bamford, et al, 1996b). 
In a similar system, replacement of the IL-15 signal peptide with that of IL-2, 
induces significantly higher levels of IL-15 production, indicating that this region 
too is involved in down-regulating IL-15 protein production (Tagaya, et al, 1996b). 
Multiple levels of regulation therefore exist to provide an available pool of mRNA, 
but which prevent undesirable IL-15 expression in tissues. 
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1.3.5 IL-15 in pathology 
The corollary to this regulatory organisation is the ready resource of IL-15 mRNA in 
tissues in the event of infection or toxic insult. That such expression could lead to 
autoimmunity forms a basic tenet of this thesis. Evidence for involvement of IL-15 
in human pathology, however, is sparse. A novel transcript of IL-15 has been 
recently identified in human small cell lung cancer cell lines, although its role in 
tumorigenesis is as yet unclear (Meazza, et al, 1996). IL-15 has also been identified 
in alveolar macrophages of sarcoid patients, from whom pulmonary CD4+ T cells 
were found to proliferate to IL-15, implying a role in T cell alveolitis (Agostini, et 
aI, 1996). IL-15 expression has also been detected in alveolar macrophages and 
epithelial cells from induced sputum samples of asthmatic patients (Leung, B.P. & 
Mclnnes I.B. - unpublished observations). Since IL-15 also induces mast cell 
proliferation and supports T cell clone-derived IL-5 production (Tagaya, et aI, 
1996b; Mori, et aI, 1996), these data together indicate that IL-15 might play a role in 
bronchial hyperreactivity. IL-15 expression has been reported in human 
keratinocytes (Sorel, et aI, 1996), It remains unclear whether UVB radiation 
upregulates IL-15 expression (Mohamadzadeh, et aI, 1995), or inhibits its 
production, thereby contributing to UVB-mediated immunosuppression (Blauvelt, et 
aI, 1996). 
RA synovium is characterised by the presence of activated macrophages and 
fibroblasts, and by large numbers of activated T cells. Given its established cellular 
distribution and functional profile, IL-15 represents an attractive candidate cytokine 
for involvement in RA synovitis. Its identification in that context could provide 
considerable insight into the mechanisms whereby T cells are recruited and activated 
in RA. A second exciting possibility is that within the synovial membrane, IL-15 
could direct T cell-mediated regulation of macrophage-derived cytokine production, 
particularly TNFa, thereby driving the pro-inflammatory response. 
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1.4 'Non-cytokine' mediators in RA synovitis 
Non-cytokine mediated pro-inflammatory mechanisms operate in the synovial 
membrane. Of these, the role of free radicals in RA pathogenesis has been of 
particular interest. Reactive oxygen intermediates (ROI) formed through cycles of 
hypoxic-reperfusion can modify multiple processes within the synovial membrane 
by oxidation (Blake, et al, 1989). Proposed molecular targets include IgG, with 
consequent rheumatoid factor formation and lipids, leading to formation of lipid-
radicals. Depolymerisation and fragmentation of hyaluronan after oxidation will 
generate fragments with immunomodulatory potential e.g. chemotactic factors. 
Hyporesponsiveness of synovial T cells might arise secondary to hypoxia and the 
formation of low molecular weight aldehydes (reviewed by Mapp, et al. 1995). 
Definitive confirmation of such hypotheses in vivo is currently lacking, although 
they provide stimulating alternatives to established antigen-driven mechanisms. 
Recently, reactive nitrogen intermediates (RNI), specifically nitric oxide (NO-), 
have been recognised as mediators of fundamental importance in several models of 
infection and inflammation (Moncada & Higgs, 1993; Nathan & Xie, 1994a). These 
observations have raised the possibility that similar mechanisms might operate in 
human inflammatory disease. 
1.5 Nitric Oxide 
In 1987, NO was recognised as the previously elusive endothelium-derived relaxing 
factor (Furchgott & Zawadski, 1980; Ignarro, et aI, 1987; Palmer, et aI, 1987). 
Subsequently, NO emerged as a key regulatory molecule in numerous and diverse 
physiological and patho-physiological processes. 
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1.5.1 NO synthase 
NO is generated by isoforms of the enzyme NO synthase (NOS) which catalyses the 
conversion of L-arginine through hydroxy-arginine to L-citrulline. The terminal 
guanidino nitrogen is oxidised forming a reactive nitrogen-oxygen complex with 
one unpaired electron (NO-), which confers radical properties on NO (Stamler, et aI, 
1992). Three isoforms of NOS have been identified and their enzymology 
extensively studied (reviewed by Moncada & Higgs, 1993; Kiechle & Malinski, 
1993; Bredt & Snyder, 1994; Nathan & Xie, 1994a; Nathan & Xie, 1994b; Marletta, 
1994; Butler, et al, 1995). Endothelial NOS (eNOS) and neuronal NOS (nNOS) are 
constitutively expressed and are capable of rapid onset, short lived generation of low 
concentrations of NO (together termed cNOS). Inducible NOS (iNOS), in contrast, 
is present in cells only after specific up regulation. NOS isoforms share 30-40% 
homology with cytochrome P450 reductase (CPR), with consensus sequences for 
redox-active cofactors including NADPH, flavin adenine dinucleotide (FAD) and 
flavin mononucleotide (FMN). The homology with CPR is reflected at a functional 
level in the ability of NOS to generate ROI in the absence of L-arginine and 
presence of NADPH (Bredt & Snyder, 1994), although the biological relevance of 
this activity is unknown. 
cNDS dimers form from a resting pool of NOS monomers, after binding of L-
arginine, haem and tetrahydrobiopterin (BH4). Calmodulin binds to this complex in 
the presence of elevated calcium, which results usually from agonist activity. This 
facilitates rapid electron transfer through FAD and FMN to haem with consequent 
substrate oxidation. In contrast, expression of inducible NOS (iNOS) requires novel 
protein synthesis and thereafter generates high concentrations of NO over prolonged 
periods. As with cNOS, iNOS forms dimers in the presence of BH4, haem and L-
arginine. However, calmodulin is tightly bound to a basic, hydrophobic site on 
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iNOS, and enzyme activity is independent of ambient calcium concentration (Cho, 
et aI, 1992). 
All three isoforms have been cloned and sequenced (Bredt, et al, 1991; Sessa, et al, 
1992; Xie, et al, 1992). eNOS is 130kD and shares 58% homology with nNOS. An 
N-terminal myristoylation site confers the ability to bind the plasma membrane and 
phosphorylation or cleavage of this site renders eNOS soluble in the cytosol. The 
human gene is located on chromosome 7 and contains AP-l, AP-2, NF-l, acute 
phase reactants and shear stress regulatory consensus sites in its 5' promoter region 
(Marsden, et aI, 1992). eNOS expression has been detected in cells outwith 
endothelium, including platelets, fibroblasts, vascular smooth muscle cells and 
polymorphonuclear cells (Nathan & Xie, 1994a). The larger human nNOS (160kD) 
is located on chromosome 12 (Bredt & Snyder, 1994). It is expressed in different 
neurone types throughout the central nervous system, in the retina and in peripheral 
nerve terminals, e.g. non-adrenergic, non-cholinergic signals in the gastrointestinal 
tract (Bult, et aI, 1990). Alternatively spliced forms of murine cerebellar nNOS 
have been described although their functional significance is unclear. 
iNOS was first cloned from murine macrophages (Xie, et aI, 1992) and subsequently 
from human hepatocytes and chondrocytes (Geller, et al, 1993; Charles, et aI, 1993), 
but not from human macrophages. Human iNOS shares -50% homology with 
cNOS, and 80% with murine iNOS and is located on chromosome 17. Widespread 
tissue distribution of iNOS has been reported with expression observed in human 
keratinocytes, hepatocytes, osteoblasts I osteoclasts, chondrocytes, uterine smooth 
muscle cells, mesangial cells, dermal fibroblasts and respiratory epithelial cells 
(Nathan & Xie, 1994a). Expression in human tumours has also been observed, 
including colorectal adenocarcinoma and glioblastoma (Ellie, et ai, 1996). 
However, considerable controversy surrounds the presence and activity of iNOS in 
human macrophages. Whereas some authors have demonstrated NO production 
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directly, or L-arginine-I NO-dependent activity (Denis, 1992; Hunt & Goldin, 1992; 
Reiling, et aI, 1994; Pietraforte, et aI, 1994; Zembala, et aI, 1994; Mautino, et al, 
1994; De Maria, et aI, 1994; Dugas, et al, 1995; Burkrinsky, et al, 1995), others have 
been unable to detect any evidence of iNOS activity at all (Cameron, et aI, 1990; 
Schneemann, et aI, 1993). The required stimuli for iNOS up regulation in human 
macrophages appear to differ significantly from those in rodents, and where NO 
production has been detected, it is of an order of magnitude lower than that observed 
in rodent macrophages. The functional and evolutionary significance of these data 
are unclear. 
1.5.2 Regulation of NO synthase 
NO may not be stored in 'bioactive' form, thus its concentration in tissue is 
regulated through NOS activity. cNOS generates NO at picomolar concentrations in 
response to local vasoactive mediators, such as bradykinin, thrombin, histamine, 
acetylcholine, 5-hydroxytriptamine, to cytokines e.g. IL-l~, endothelin-3, or to 
physical factors, including shear stress or increased blood flow (reviewed by Lyons, 
1995). Whether cNOS output may be further upregulated is unclear. Preliminary 
evidence for induction of 'nNOS' by IL-l~ and LPS in OA chondrocytes has been 
reported, indicating that the delineation between low and high output NOS on the 
basis of calcium dependency alone may be oversimplified (Amin, et al, 1995). 
The predominant source of NO in inflammatory lesions, however, is iNOS. Factors 
which activate iNOS in vitro include cytokines, microbial products. particularly LPS 
and superantigen toxins, picolinic acid, cAMP-elevating agents and physical factors, 
including UV light or trauma (reviewed by Nathan & Xie, 1994a; Nathan & Xie, 
1994b). Cytokines exert the major regulatory influence in vivo. IFN-y is a potent 
inducer of NO production by rodent macro phages and endothelial cells, in synergy 
with LPS (Ding, et aI, 1988; Liew & Cox, 1991). IL-l~ and TNFa also increase 
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iNOS expression in many cells, either alone or in synergistic combination (Liew, 
1994). Cytokine requirements vary with the species and tissue origin of cells. Thus, 
rodent smooth muscle cells respond either to IL-lp alone, or in synergy with IFN-y 
or TNFa., whereas human vascular smooth muscle cells require a combination of 
LPS, IFN-y and TNFa. for NO production. Similarly, rodent hepatocytes respond to 
LPS alone, whereas human hepatocytes require a combination of LPS, IFN-y, TNFa. 
and IL-2 (Geller, et al, 1992; Liew, 1994, Nathan & Xie, 1994b; reviewed by Lyons, 
1995). 
The multiplicity of activatory factors is matched by a wide range of inhibitory 
agents. TGFp, IL-4, IL-8, IL-lO (indirectly through effects on TNFa. production), 
IL-13, MIP-la., epidermal growth factor (EGF), PDGF, and FGF all oppose iNOS 
activation (Liew, 1994; Nathan & Xie, 1994b; Lyons, 1995). Again species and 
tissue specificity appear cmcial. TGFp inhibits rodent macrophage and endothelial 
iNOS expression, but enhances NO production in Swiss 3T3 fibroblasts (Gilbert & 
Herschman, 1993). Moreover, IL-lO has been shown to increase iNOS activity in 
avian osteoclasts (Sunyer, et al, 1996), as has IL-4 in human macrophages (Mautino, 
et aI, 1994). The temporal sequence of ligand binding appears important, since pre-
exposure of macrophages to LPS suppresses subsequent IFN-y induced NO 
production (Severn, et aI, 1993). Such observations emphasise the difficulties 
attached to extrapolation between species and cell types. Furthermore, it has only 
recently been appreciated that iNOS may be 'constitutively' present in human 
tissues, such as lung, retina, skeletal muscle or CNS, in the absence of specific up 
regulatory factors (Nathan & Xie, 1994a; Park, et al, 1996). This suggests that, in 
addition to a postulated responsive role in inflammation, iNOS may also be involved 
in normal physiological regulation. 
Engagement of class 11 MHC either by alIo-specific monoc1onal antibodies, or by 
bacterial superantigens (SEB, TSST-l), in the presence of syngeneic lymphocytes, 
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increases NO production by macrophages (Hauschildt, et al, 1993; Tao & Stout, 
1993, Isobe & Nakashima, 1993). Similar activation of macrophage NO synthesis 
follows crosslinking of CD69 by antibody (De Maria, et al, 1995). Cell-cell contact 
between T lymphocytes of both Thl and Th2 subsets and macrophages leads to 
iNOS expression mediated in part through CD40/CD40 ligand and LFA-IIICAM-l 
(Tian, et aI, 1995). Thus, homo- or hetero-typic cell contact can induce NO 
synthesis in an inflammatory lesion. The relative contribution of such mechanisms 
in the context of high levels of cytokine production is currently unclear. 
These diverse factors mediate regulation at multiple levels: 
Transcription Two promoter I enhancer sites are found 5' to the murine iNOS gene 
(Xie, et al, 1993; Lowenstein, et al, 1993). Region 1 (-50 to -200 bp) contains LPS 
responsive elements containing AP-l, NF-IL6 and NF-KB binding sites, whereas 
region 2 (-1000 bp upstream) contains an interferon specific response element 
(reviewed by Bredt & Snyder, 1994; Nathan & Xie, 1994a, 1994b). Macrophages 
from IFN-r related transcription factor-l (IRF-l) knockout mice do not produce NO 
in response to IFN-r confirming a role for IRF-l in regulating iNOS expression, 
mediated partly through enhancement of LPS-dependent effects (Kamijo, et aI, 
1994). A hypoxia-responsive enhancer has recently been identified (-209 to -207 
bp; Melil1o, et aI, 1996) indicating that other factors can facilitate iNOS 
transcription outwith cytokine-dependent elements. Transcriptional regulation of 
the human iNOS gene is more complex. Involvement of a NF-KB binding site (-106 
to -115 bp) has been demonstrated using mutant constructs of vascular smooth 
muscle iNOS (Kolyada, et aI, 1996) and recent studies of hepatocyte iNOS 
responsiveness to IL-l~, TNFa and IFN-r revealed three cytokine responsive 
elements -3.8 to -16 kb upstream from the iNOS gene (De Vera, et aI, 1996). This is 
in contrast to the shorter regulatory 5' region (-lkb) of rodent iNOS. Further 
characterisation of the iNOS promoter sites will elucidate inter-species differences 
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currently detected at the protein expression and functional level, particularly in 
comparison of rodent and human macrophage activation. 
Post-transcription iNOS mRNA stability is increased by IFN-y and reduced by 
TGF~ and IL-4 in murine macrophages. TNFa reduced the stability of eNOS 
mRNA in rat smooth muscle cells (Nathan & Xie, 1994a). Modification of mRNA 
levels by many regulatory factors is reported, but it is unclear at present whether 
these effects are directly mediated on mRNA stability or at earlier or later stages. 
Post-translation cNDS is calcium and calmodulin dependent and may be inhibited 
by competitive inhibitors of calmodulin, such as trifluoperazine. iNOS requires 
only physiological concentrations of calcium which are present in resting cells, and 
as such is resistant to calmodulin antagonists (Cho, et aI, 1992). NOS activity may 
also be modified by phosphorylation. eNOS and nNOS share consensus sequences 
for cAMP-dependent protein kinase phosphorylation (Bredt & Snyder, 1994). 
Protein kinase C, cGMP-dependent kinase, calcium I calmodulin-dependent kinase 
have also been implicated in cNOS phosphorylation, raising the possibility of 
regulatory feedback loops, whereby the reaction of NO with target enzymes may 
increase kinase activity, with consequent suppression of NOS activity (Bredt & 
Snyder 1994). However, whether significant phosphorylation occurs in vivo to 
directly modify enzymatic activity, cofactor function or iNOS compartmentalisation 
is unclear. Finally, haem-binding proteins are subject to down regulation by NO. 
Thus, direct inhibition of NOS activity by NO itself has been reported (Assreuy, et 
al, 1993). 
Substrate availability in vitro is determined by the relative presence of L-arginine, 
of argininosuccinate synthetase, which converts L-citrulline to L-arginine, and of 
arginase in macrophages. Similarly, cofactor availability is critical. IFN-y induces 
the enzyme GTP cyclohydroxylase I, which is the rate-limiting enzyme in the 
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biopterin synthesis pathway responsible for the generation of BH4. Although the 
latter is deplete after long term culture of human endothelial cells or fibroblasts, it is 
unclear whether this represents in vitro artefact, or an in vivo example of coordinate 
function by IFN-y. 
External regulation of NOS Glucocorticoids inhibit iNOS-dependent activity. (Di 
Rosa, et aI, 1990). The rate of iNOS transcription is reduced, and although mRNA 
is briefly stabilised, translation is significantly retarded and degradation of iNOS 
protein is enhanced (Kunz, et aI, 1996). NF-lCB p50 or p65 nuclear translocation is 
unaffected, but NF-kB and not AP-l binding in the iNOS promoter region is 
prevented (Kleinert, et aI, 1996). L-N°O-substituted arginines also inhibit NOS 
activity in biological systems. L-Noo methylarginine (L-NMMA) is commonly used 
when no isofonn specificity is necessary. No isoform specific inhibitor has yet been 
identified, although L-N°O nitroarginine (L-NNA) exhibits relative specificity for 
cNOS as does L-Noo amino arginine for iNOS. Aminoguanidine and N-iminoethyl-
L-Iysine are further 'iNOS specific' inhibitors often used in animal models (e.g. 
Connor, et aI, 1995). However, mice in which the eNOS, nNOS and iNOS genes 
respectively have been specifically targeted have now been generated, allowing 
definitive investigation of the specific contribution of individual isoforms to be 
evaluated in different biological systems in vivo (Wei, et aI, 1995; MacMicking, et 
al, 1995; Huang, et al, 1995; Nelson, et al, 1995). 
1.5.3 Molecular targets for NO 
The target interactions of NO which facilitate effector function depend largely on its 
redox and additive chemistry (reviewed by Stamler, 1994). NO has a half-life of 6 
seconds, and can diffuse freely through membranes and within cells. NO reacts with 
oxygen (02), superoxide (02-) and transition metals, to generate nitrosonium ions 
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(NO+), peroxynitrite (OONO-) and metal-NO adducts respectively, each capable of 
further reactivity with thiol groups at nucleophilic centres. NO therefore mediates 
effects primarily through modification of critical iron or thiol groups on protein 
targets. The diversity of effector function reflects the wide prevalence of such 
moieties in regulatory/signalling pathways, enzymes, ion channels and transcription 
factors (Stamler, 1994; Lyons, 1994). In conditions of oxidant stress, cell redox 
conditions may support the direct N-nitrosation of DNA or covalent modification of 
tyrosine groups. DNA may also be targeted by deamination or by induction of 
strand breaks (Nguyen, et al, 1992). 
Reactions with metals Iron containing metals are particularly vulnerable to NO. 
Complex I and complex 11 in the mitochondrial electron transfer chain and aconitase 
in the tricarboxylic acid cycle, are critical targets (Stuehr & Nathan, 1989; Stamler, 
et aI, 1992). Together with inhibition of glyceraldehyde-3-phosphate 
dehydrogenase, through ADP-ribosylation following activation of ADP-ribosyl 
transferase (Dimmeler, et al, 1992), these effects profoundly impair the capacity for 
energy production in the target. Aconitase serves also as an iron response element 
binding protein (IRE-BP) and through binding to IRE-BP, NO has been 
demonstrated to modify ferritin and transferrin expression and thus iron homeostasis 
(Weiss, et al, 1993; Drapier, et aI, 1993). 
The interaction of NO with haem induces functionally significant conformational 
changes, e.g. guanylate cyclase is activated by this means and mediates many 
bioactivities attributable to NO (Nathan & Xie, 1994b; Schmidt & WaIter, 1994). 
Direct nitrosylation of the haem prosthetic group involved in catalysis is usually 
inhibitory. This is evident in CPR-like enzymes, including iNOS itself through 
attenuation of oxygenase activity, and perhaps also in ribonucleotide reductase, with 
subsequent modification of DNA synthesis (Stamler, 1994). In contrast, 
cyclooxygenase 1 and 2 are activated by this mechanism (Salvemini, et al, 1993; 
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Manfield, et al, 1996). Furthermore, interaction with zinc finger containing proteins 
has been reported, which may have functional relevance to the zinc dependent 
activities of matrix metalloproteinases in synovium (Murrell, et al, 1995). 
Thiol group interactions Nitrosonium, peroxynitrite and metal-NO adducts are 
capable of S-nitrosylation with consequent modification of protein function. Target 
proteins undergo (i) conformational change (e.g. tissue plasminogen activator), (ii) 
covalent alteration by the formation of disulphide bonds (e.g. calcium-dependent 
potassium channels), or (Hi) if cysteine residues are present in the catalytic site, may 
be directly inhibited by nitrosylation (e.g. neutrophil NADPH oxidase). The latter 
exemplifies the crucial interaction of NO and ROI production (Clancy, et aI, 1992; 
Stamler, 1994). In circumstances where ROI are primary mediators of tissue 
damage, NO production may be protective by diverting oxygen species away from 
the formation of harmful radicals (Wink, et aI, 1993; Wink, et aI, 1996). In contrast, 
the formation of peroxynitrite has been shown in many systems to be dangerous to 
host tissues and in such circumstances the combination of ROI with NO generation 
is likely to be detrimental (e.g. Mulligan, et al, 1991). The effect of NO in a given 
tissue can therefore vary over time, if the presence of ROI in the tissue alters in 
response to other stimuli. Thus, production of NO may be initially detrimental and 
later protective or vice versa. Similarly, functional outcome of NO effects may alter 
as the redox environment changes over time within a cell, perhaps following 
activation, allowing NO to sequentially exert apparently contradictory responses on 
resting or activated cells. Such possibilities are of particular importance in immune 
responses within chronic inflammatory environments, such as those in the RA 
synovial membrane. 
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1.5.4 Functional consequences of NO production in inflammation 
By virtue of its EDRF activity NO can induce vasodilatation through relaxation of 
vascular smooth muscle leading to erythema and increased local temperature 
(reviewed by Schmidt & Waiter, 1994). Data from murine dextran- and 
carrageenan-induced models of inflammation indicate that NO also induces 
clinically detectable oedema formation, through alteration of endothelial 
permeability (Ialenti, et aI, 1992; Ianaro, et aI, 1994). Thus, two features of the 
classical inflammatory response are regulated by NO. Further roles for NO in 
immunoregulation, responses to infectious disease, alloreactivity and auto immune 
models have been demonstrated. 
(i) lmmunomodulatory properties of NO 
NO inhibits platelet aggregation as a function of its cardioprotective role, through 
production of cGMP (Schmidt & Waiter, 1994). Subsequent studies of ischaemia-
reperfusion in mesenteric vessels and myocardium have indicated that NO also 
reduces neutrophil adhesion through CDll I CD18, ICAM-l and P-selectin 
dependent pathways and by scavenging ROI, which enhance adhesion (Kubes, et al, 
1993; Xin, et aI, 1993). These data indicate that cellular recruitment, and in 
particular the crucial interaction of the leukocyte with endothelium, can be modified 
by NO. 
NO exerts bi-phasic effects on T lymphocyte responsiveness. Initial observations 
described inhibition of in vitro antigen or mitogen driven T cell proliferation, either 
by NO donors or by macrophage derived NO in co-cultures (Fu & Blankenhorn, 
1992; Denharn & Rowland, 1992; Merryman, et al, 1993). Subsequently, it was 
established that low dose NO significantly enhanced peripheral blood lymphocyte 
activation, measured by PHA-induced proliferation, increased glucose uptake, 
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increased NF-lCB binding activity and activation of protein tyrosine kinase p56lck 
(Lander, et aI, 1993). Moreover, in vitro and in vivo, L-arginine enhances 
lymphocyte proliferation, and increases NK cell and lymphokine activated killer 
activity (Barbul, et aI, 1990; Park, et aI, 1991). Recent studies in mice have 
established that NO preferentially inhibits 1111 clonal proliferation to antigen, but 
has no effect on 1112 clones (Liew, et al, 1991; Taylor Robinson, et aI, 1993; Taylor 
Robinson, et aI, 1994; Wei, et aI, 1995). Thus, the local concentration of NO and 
the developmental phenotype influence the modulatory effect of NO on T cells. 
Cellular immune function may be further modified by NO through induction of 
apoptosis (Albina, et al, 1993; Messmer, et al, 1994; Fehsel, et al, 1995). 
Cytokine production is also influenced by NO. Thl clones exhibit reduced IFN-y 
production in the presence of NO, correlating with reduced proliferation, but no 
effect is demonstrable on Th2 cytokine generation (Taylor-Robinson, et aI, 1994; 
Wei, et aI, 1995; Huang, F.P. personal communication). Increased TNFa. production 
from human neutrophils and from PBMN exposed to NO-donors has been detected, 
although the cellular origin of TNFa. in the latter was not specified (Lander, et al, 
1993; Dervort, et aI, 1994). Production of cytokine by purified blood monocytel 
macrophages or macrophage cell lines has been variously reported to be suppressed 
(FUlle, et al, 1991) or enhanced (Deakin, et aI, 1995) in the presence of exogenous 
NO. The mechanism underlying these observations is unknown, but may reflect 
modification of transcription factors, such as NF-lCB (Huang F-P. personal 
communication). 
(ii) Infection 
Early studies detected increased nitrate generation during septicaemia (Green, et aI, 
1981). NO has now been implicated in the response to a large number of organisms, 
including intracellular bacteria, fungi, protozoa, helminths and viruses. NO 
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dependent innate defence has been most studied in macrophages. In most cases 
microbicidal activity is demonstrable in vitro, where it is inhibited by LID-arginine 
analogues, and is enhanced by addition of macrophage activating factors, such as 
IFN-y or LPS. Normally in vivo, T cells and macrophages cooperate to regulate NO 
synthesis through cytokine production. Thus, host responses to Leishmania major 
are dependent on the generation of an effective Thl response, in which IL-12 and 
IFN-y production leads to NO-mediated resistance. Parasite killing activity is 
demonstrable in splenic macrophages in vitro, and treatment of infected mice with 
iNOS inhibitors increases lesion size and parasitic load (Liew, et aI, 1990). 
Moreover, L. major infection in iNOS knockout mice is of increased severity and 
mortality, despite the presence of an enhanced Thl response, indicating that NO is 
critical in host defence to this organism (Wei et aI, 1995). However, NO-mediated 
parasite killing can also proceed in the absence of T cells. Listeria monocytogenes 
infected SCID mice, treated with amino guanidine, exhibit increased mortality and 
enhanced recovery of viable listeria from spleens. IFN-y production by NK cells is 
sufficient to confer resistance (Beckerman, et al, 1993). Thus, in rodents at least, the 
production of NO by activated macrophages provides a principle component of the 
microbicidal armature. 
NO may mediate host toxicity during infection. Elevated nitrate levels are detected 
in animals and humans with septicaemia. NOS inhibitors can reverse the 
hypotension of LPS induced shock in rodents, although the effect is dose and time 
dependent (Kilboum, et al, 1990), and preliminary trials in humans have indicated 
that some clinical features of septicaemia are NO dependent (ValIance & Moncada, 
1991; Petros, et aI, 1994). However, LPS-induced shock in iNOS knockout mice 
has yielded conflicting evidence in favour of either a protective, or a detrimental 
role for NO production (Wei, et aI, 1995; Gross, et aI, 1996), although minor 
differences in genetic strain between 'knockouts' may partially explain apparent 
discrepancies. What is clear is that NO has 'double-edged' effects (Schmidt & 
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Walter, 1994), and in some situations is aggressive to the host. Whether these 
observations can be extended to autoimmune disease in which excess NO 
production occurs is unclear. These data indicate that caution must be shown in the 
potential use of NOS inhibitors in management of autoimmune disease, in which 
equally complex mechanisms exist in subtle equilibrium. 
(iii) Alloreactivity 
NO involvement in graft rejection is suggested by the nitrosylation of proteins 
during cardiac allograft rejection in rats (Lancaster, et al, 1992). iNOS expression is 
found at mRNA and protein levels in rejecting allografts, in both graft and host 
derived cells. Debate surrounds the net effect of NO production in rejection. 
Aminoguanidine treatment prolongs graft survival, reduces the histological grade of 
cellular infiltration and improves cardiac allograft contractility in rats (Worrall, et al, 
1995). However, several studies have determined that iNOS inhibitors are 
deleterious to graft survival through removal of T cell regulatory activity attributable 
to NO (e.g. Langrehr, et aI, 1992). Moreover, BALB/c skin allograft rejection by 
iNOS knockout mice is similar to that by heterozygote controls (Casey 1., personal 
communication). The precise role of NO production in alloreactivity is therefore 
unclear, although the latter data imply that NO production is not obligate in graft 
rejection. 
(iv) Autoimmune models 
The evidence reviewed above clearly implicates NO as an integral component of 
protective host immune responses. That NO is similarly involved in deleterious 
autoimmune responses, either as an aggressive or protective component, has been 
explored in several animal models systems. 
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Murine disease resembling insulin dependent diabetes mellitus (IDDM) occurs 
following inoculation with streptozocin. NO modifies cytokine production within 
the pancreatic ~ islets and inhibition of NO production using NOS inhibitors led to 
delayed onset of disease, with attenuation of the pancreatic inflammatory infiltrate 
(Lukic, et aI, 1991; Kolb & Kolb-Bachofen, 1992). Similarly, in the genetically 
predisposed non obese diabetic (NOD) mouse model, transfer of NOD mouse spleen 
cells induced diabetes in irradiated recipients. The onset of disease was Significantly 
delayed by amino guanidine treatment (Corbett, et aI, 1993). These findings 
implicate NO as an aggressor in IDDM pathogenesis. However, its role in 
experimental allergic encephalomyelitis (EAE) is more complex. NO production is 
upregulated in EAE and iNOS levels have been reported to correlate with disease 
severity (Okuda, et aI, 1995). Whereas, aminoguanidine was reported to inhibit 
clinical signs and progression of EAE in SJL mice and in Lewis rats (Zhao, et al, 
1996), paradoxical aggravation of EAE following administration of LOO-arginine 
analogues has also been detected (Ruuls, et aI, 1996). Suppression or aggravation of 
EAE by NOS inhibitors may depend on the mode of disease induction, or on the 
choice of inhibitor in T cell-induced, or myelin basic protein-induced EAE 
(Zielasek, et aI, 1995). Such discrepancies again emphasise the double-edged 
effector function of NO as an immunosuppressor, or a neurotoxin, dependent on 
subtle alterations of immunogen, inhibitor dosage and regimen. 
NO has been implicated in immune complex mediated disease. In pulmonary 
alveolitis induced by intra-tracheal injection of preformed immune complexes, NOS 
inhibitors reduce the severity of pulmonary haemorrhage and oedema formation. 
Similar inhibition of dermal vasculitis is observed. Moreover, a major component 
of this model is dependent on intact complement function, indicating that NO 
synthesis may interact with complement to mediate pathology (Mulligan, et aI, 
1991). 
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Graft versus host disease (GVHD) in mice resembles the early stages of 
inflammatory bowel disease (IBD), or gut hypersensitivity syndromes, such as 
coeliac disease. (CBAxBALB/c)Fl recipients of CBA spleen cells develop GVHD, 
which is significantly retarded by L-NMMA treatment, with preservation of 
intestinal architecture and reduced density of intra-epitheliallymphocyte infiltration 
(Garside, et al, 1992). However, it is unclear whether this effect operates primarily 
through immunoregulatory modification, or by haemodynamic effects in the 
mesenteric vasculature. NO production has been detected in human IBD, indicating 
that a role in human disease pathogenesis may exist (Middleton, et aI, 1993, 
Broughton-Evans, et aI, 1993). However, altered epithelial permeability found in 
IBD leads to increased exposure to bacteria and bacterial products within the lamina 
propria, with the potential for enhanced local NO production and consequent 
immunomodulation. Whether NO is ultimately protective or detrimental is therefore 
unclear. 
1.5.5 NO in arthritis 
Considerable evidence exists which indicates that NO is an important mediator in 
autoimmune responses. Evidence for a similar role in inflammatory articular 
disease has recently been derived from several animal studies. 
Adjuvant arthritis in rats bears histopathological similarities to RA. iNOS is 
detectable in synovial membrane and elevated levels of urinary and plasma nitrite 
are maximal after 14 days. Continuous administration of NOS inhibitors prevents or 
attenuates the clinical severity of arthritis, normalises weight gain, reduces acute 
phase response and retards erosive articular destruction (Ialenti, et aI, 1993; 
Stefanovic-Racic, et aI, 1994a; Stichtenoth, et aI, 1994; Stefanovic-Racic, et aI, 
1995; Connor, et al, 1995). Treatment during adjuvant priming alone is sufficient to 
confer subsequent reduction in disease severity (Oyanagui, 1994) and anti-
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mycobacterial antigen-specific T cell responses are suppressed in treated rats. These 
observations indicate an immunoregulatory role for NO in this model. Similar data 
were obtained in streptococcal cell wall (SCW) induced arthritis in rats, in which L-
NMMA inhibited the onset and progression of arthritis. Furthermore, treatment of 
established disease led to partial clinical amelioration (McCartney-Francis, et aI, 
1994). Administration of NOS inhibitors to MRL-MP-lpr/lpr mice suppressed the 
development of renal pathology and attenuated clinical and histological evidence of 
arthritis (Weinberg, et al, 1995; Huang, et al 1996). NO synthesis is closely linked 
to IL-12 production in this model, indicating that cytokine modulation by NO may 
complete a positive feedback loop, culminating in end-organ damage (Huang, et al, 
1996). These data together implicate NO generation in articular pathology in 
rodents. 
The role of nitric oxide production in RA, however, is less clear. Nitrite levels are 
elevated in synovial fluid and serum, and urinary nitrate: creatinine ratios are raised 
in patients with active RA, indicating that NO production might be enhanced in 
human articular disease (Farrell, et al, 1992, Kaur & Halliwell, 1994; Grabowski, et 
al, 1996; Ueki, et aI, 1996). The principle source of nitric oxide production is, as 
yet, ill-defined. In vitro studies have identified iNOS expression and NO generation 
in rodent synoviocytes and in human and rodent chondrocytes, osteoblasts and 
osteoc1asts (Stadler, et al, 1992; Charles, et al, 1993; Stefanovic-Racic, et al, 1994b; 
Rediske, et aI, 1994; Ralston, et aI, 1995; Murrell, et aI, 1996). Given their 
previously recognised functional profile, neutrophils, macrophages, mast cells and 
endothelial cells might all contribute to NO generation within synovial membrane 
(Nathan & Xie, 1994a; Nathan & Xie, 1994b; Bames & Liew, 1994; Lyons, 1995; 
Grabowski, et aI, 1996). Moreover, the RA synovial membrane contains abundant 
cytokine activities, such as IL-l~ or TNFa, which have been shown to up regulate 
iNOS in vitro. However, neither iNOS expression nor direct NO production within 
the human synovial membrane have yet been properly characterised. 
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1.6 Objectives 
The immunopathological processes in RA resemble an ongoing immune response. 
Components of humoral and cell mediated arms of the immune system are 
represented, although their relative contributions remain controversial. Regardless 
of whether these processes are primary, or secondary to an unidentified insult, 
evidence from animal and preliminary human studies indicates that manipulation of 
immunoregulatory networks in synovial membrane offers exciting therapeutic 
potential. Two such regulatory pathways are of particular interest to the author. 
(i) T lymphocytes lie central to conventional immunoregulatory paradigms. Their 
apparently sessile appearance in RA is therefore intriguing. 
• By what means are T lymphocytes activated within RA synovial membrane 
in the relative absence of the recognised T cell growth factor, IL-2? 
• What is the functional Significance of the majority of non-arthritogen 
specific T lymphocytes in synovial membrane in RA? 
(ii) Similarly, nitric oxide subserves multiple immunoregulatory functions in animal 
models, but its role in human inflammatory disease remains poorly defined. 
• Where and how is NO produced by the human synovial membrane? 
• What are the functional consequences of NO production within the synovial 
compartment? 
(iii) TNFa. has provided the most promising therapeutic biological target thus far in 
RA. Events mediating its production, however, remain obscure. 
• Can either IL-15 or nitric oxide mediated activities be related to enhanced 
TNFa. production within synovial membrane? 
1.7 Aims 
1. To investigate the presence and functional significance of interleukin-15 
production in RA synovial membrane. 
2. To provide direct evidence for nitric oxide production in RA synovial 
membrane, and to investigate the functional consequences of nitric oxide 
production in articular tissues. 
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Chapter 2 
Materials and methods 
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2. 1 Patients and tissue I fluid samples 
Samples were obtained from patients attending the Centre for Rheumatic Diseases and 
University Department of Orthopaedic Surgery. Glasgow Royal Infinnary (GRl). the 
Rheumatology Department. Gartnavel General Hospital and the Department of 
Orthopaedics. Stobhill General Hospital. Glasgow. Synovial tissues were obtained at 
routine hip or knee arthroplasty. usually from pannus adjacent to cartilage and. in the 
knee. particularly around femoral condyles. Synovial biopsy material was also 
obtained during diagnostic arthroscopy (Dr. M. Field. Glasgow Royal Infinnary) and 
was used for immunohistochemical studies. Buffy coats were provided by the Blood 
Transfusion Service (Law Hospital. Carluke. UK) within 2 hours of donation by 
nonnal volunteer donors. 
RA patients satisfied the American College of Rheumatology diagnostic criteria 
(Amett. et al. 1988). The diagnosiS of OA depended on characteristic clinical and 
radiological presentation (Altman. et al. 1986) with convincing absence of 
inflammatory arthritis (Erythrocyte sedimentation rate [ESR]. C-reactive protein 
[CRP], serum urate - <460 J.1m01/1, no radiological erosions, rheumatoid [RP] and 
anti-nuclear factors [ANA] - negative). Clinical data were collected from the case 
record, including age, gender, disease duration, drug therapy and concurrent disease. 
ESR. CRP (nephelometry) and serum RP and ANA titres (ELISA) were obtained 
from laboratory records (Departments of Immunopathology. Haematology and 
Biochemistry, GRl. Glasgow, UK). 
2.2 Ethical considerations 
Pennission from the Ethical Committee in ORI was applicable to the use of tissues 
from arthroscopy as part of a separate investigation (Role of gene vectors in 
therapeutic delivery of cytokines in inflammatory arthritis; Dr M. Field, ORI). 
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Synovial fluids and tissues were surplus to clinical requirements following routine 
therapeutic or diagnostic procedures and would otherwise have been discarded. 
Blood and synovial fluid samples were collected only when clinically indicated, and 
informed consent was obtained from patients prior to research use of samples so 
obtained. All animal experimentation was performed under project licences provided 
following UK Home Office review and were used only to address questions not 
amenable to in vitro study of human tissue. Experimentation was performed under 
Project Licence 60/1311, procedure 5, Project Licence 6011475, procedure 2, and 
Project Licence 60/01347, procedure 6. 
2.3 Reagents Ibuffers 
The source of reagents either purchased or donated is given in the text and tables. 
Details of preparation of buffers and reagents, where appropriate, are contained in 
Appendix I. 
2 . 4 Cell culture 
All culture media and supplements were obtained from Gibco BRL, Paisley. 
Scotland, UK. Dulbecco's modified Eagle medium was supplemented with 1 mM 
sodium pyruvate, 2 mM L-glutamine, 100 I.U.lml penicillin and 100 ~g/ml 
streptomycin ('complete Dulbecco's MEM'). Supplements were stored in 5 ml 
aliquots (xlOO final concentration) at -20°C and added to medium prior to culture. 
RPMI was supplemented with L-glutamine, penicillin and streptomycin as above 
('complete RPMI'). Murine lymphocyte proliferation medium consisted of complete 
RPMI, 25 mM HEPES, 2.5 ~glml amphoteracin Band 50 ~M 2-mercaptoethanol 
(Sigma Chemical, Poole, UK). Iscove's modified Dulbecco's medium for whole 
blood culture was supplemented with penicillin, streptomycin and L-glutamine as 
above, and stored at -200C in 100 tnl aliquots until use. Foetal calf serum (FCS) was 
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mycoplasma screened by the manufacturer, heat inactivated at 56°C for 30 minutes in 
a circulating waterbath, then stored in 10 ml aliquots at -20°C. Culture was 
performed at 37°C in a humidified incubator with 5% CO2• Cells were counted 
directly using a Neubauer haemocytometer (Weber Scientific International Ltd, UK) 
on a Nikon Labphot microscope or automatically by Coulter Zl cell counter (Luton, 
UK). Viability was assessed microscopically by trypan blue exclusion (0.1 % trypan 
blue [Sigma], 0.1 % acetic acid (BDH), phosphate buffered saline[PBS]). 
2.4. 1 Synovial tissue culture preparation 
Synovial tissue cultures were prepared as previously described (Brennan, et aI, 
1989). Resected tissue was harvested into cold complete Dulbecco's MEM and the 
synovial membrane was dissected free of fibrous connective and adipose tissue, 
before being cut into 2mm fragments. These were incubated in complete Dulbecco's 
MEM with 2.5 mg/ml collagenase (specific activity 193 u/mg, Worthington 
Biochemicals, NI, USA) I 0.1 mglml DNAse (Boerhinger Mannheim, Germany) for 
90 minutes at 37°C with gentle agitation. The digest was passed through a sterile tea 
strainer, washed three times and filtered through Nytex membrane (Cadisch & son, 
London, UK) to remove debris and cellular aggregates. Cells were washed 
throughout by centrifugation at 250g for 7 minutes (Mistral 3000i, MSE, UK) in 15 
ml polypropylene centrifugation tubes (Costar Corporation, MA, USA). A single cell 
suspension was thus obtained which contained a heterogeneous synovial cell 
population. Cell yield was around 5x107 cells / tissue, with range 106 to 5x108 cells. 
Primary cultures were established as follows. 250 Jll of heterogeneous synovial cells 
adjusted to 2x106 cells/m 1 in complete Dulbecco's MEM, 10% PCS, were plated into 
48 well culture plates (Costar). After 1 hour, stimuli were added at different 
concentrations in a total volume of 250 ~l, giving a final density of lxl06 cells/ml in 
500 III with 5% PCS. Cultures were maintained from 24 to 120 hours. Stimuli 
71 
included staphylococcal enterotoxin B (SEB, stock 1 mg/ml, Sigma), lipopoly-
saccharide (LPS, stock 1 mg/ml, Salmonella enteritidis, Sigma), human recombinant 
interferon-r (IFN-r), human recombinant interleukin-l~ (lL-l~) and human 
recombinant tumour necrosis factor a. (TNFa.). Recombinant cytokines, at various 
stock concentrations, were a gift from Dr G.R. Adolf, Bender Wien, Austria. 
Reagents were stored at -20°C as concentrated stock solutions before dilution in 
appropriate medium prior to culture. Nitric oxide synthase activity was inhibited in 
some cultures by addition of NG-monomethyl-L-arginine hydrochloride (L-NMMA, a 
gift from Dr Hodson, Wellcome, Beckenham, UK). L-NMMA (mol. wt. = 225) was 
stored desiccated, at room temperature, and was dissolved immediately prior to use to 
20 mM in appropriate medium, then filtered (Millex-GV 0.22 J.lffi, Millipore, France). 
This solution was added to final culture with further 1:20 dilution to a final 
concentration of 1 mM in vitro. Culture supematants were frozen at -700C until assay 
for cytokine or nitrite production. 
Cytospin preparations were made after tissue digestion to measure the proportional 
cellular yield. Synovial cells were suspended at 5x105 cells/ml in serum free medium 
and spun at 500 rpm for 5 minutes onto silane coated glass slides (500 JlVslide) using 
a Cytospin 3 (Shandon, UK). Silane coated slides were prepared as described 
(section 2.6). Cytopreps were fixed in cold acetone for 15 minutes, air dried and 
stored at -20°C before immunohistochemical characterisation of CD3, CD19 and 
CD68 expression (section 2.6). Synovial cultures were typically 20-40% CD3+, 30-
50% CD68+, <10% CDI9+, consistent with previously published observations 
(Brennan, et aI, 1989). 
2.4.2 Peripheral blood mononuclear cell preparation 
Mononuclear cell populations were obtained by density gradient centrifugation. After 
collection into heparinised sterile universals (10 I.UJml preservative free heparin, Leo 
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Laboratories Ltd, Bucks, UK), venous blood was diluted 1:2 in complete Dulbecco's 
MEM. 7 ml diluted blood was layered over 5 ml Lymphoprep (Nycomed Pharma, 
Oslo, Norway) in a 15ml conical tube and spun at 500g for 30 minutes at 22oC. The 
mononuclear fraction was collected and washed thrice in medium before adjustment to 
the required cell concentration. This population was designated peripheral blood 
mononuclear cells (PBMC). Buffy coats from the Blood Transfusion Service were 
diluted 1:3 in complete Dulbecco's MEM then prepared as for venous blood samples. 
T lymphocyte enrichment was performed by negative selection using successive 
adherence steps to obtain a peripheral blood T lymphocyte fraction (PBTL). 
Mononuclear cell suspensions obtained above were incubated at 2x106 cells/ml in 75 
cm2 tissue culture flasks (Costar) for 1 hour, then non-adherent cells were further 
incubated overnight in complete Dulbecco's MEM, with 10% FCS. Cells remaining 
non-adherent were collected and washed thrice in medium before suspension to the 
desired concentration. Cellular purity was assessed by FACS analysis (FACScan, 
Becton Dickinson) for CD3, CD14 and CD19 marker expression (section 2.5). PB 
monocytes were prepared by selecting adherent cells during the T cell enrichment 
process described above. Cells which adhered after both the I hour and 16 hour 
incubation steps were removed using a cell scraper and maintained in 10% FCS at 
5xl05 cells/ml until required. Prior to use, they were first gently washed in situ to 
remove non-viable monocytes or residual non-adherent lymphocytes, then 
resuspended to the desired concentration. Cell purity was assessed by FACS analysis 
(section 2.5). 
2.4.3 Synovial fluid mononuclear cell isolation 
Synovial fluid obtained by joint aspiration from RA patients was collected with 10 
I.U.lml heparin, then diluted 1:3 in complete Dulbecco's MEM. The mononuclear 
cell fraction was obtained using lymphoprep as before, and T cell enrichment was 
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performed as described above for peripheral blood. The non-adherent fraction was 
designated synovial fluid T lymphocytes (SFfL). The adherent fraction was retained, 
resuspended to 5xlOS cells/ml and plated in 96 well flat bottom plates (Nunclon) for 
cell-contact experiments (section 2.4.8). Cellular purity was assessed using 
cytopreps (section 2.6). 
2.4.4 Proliferation and cytokine production by human cells 
Proliferation assays were performed in triplicate in complete Dulbecco's MEM with 
25 mM HEPES and 10% FCS. 2x1Q5 PBMC, PBTL or SFfL in 100 ~1 were 
incubated in U-bottom 96 well culture plates (Nunclon microwell, Nunc. Denmark) 
for 24. 48, 72 or 96 hours. Stimulatory reagents or medium alone were added in a 
further 100 ~1 at twice the desired final concentration. 30 minutes after seeding of cells 
to culture plates. 1 ).1Ci of 3H-thymidine (Amersham Life Science, UK) in 25 ).11 
complete Dulbecco's MEM was added to each well during the final 6 hours of culture 
before harvesting onto a glass fiber filter (Packard, CT, USA) using a Micromate 196 
Harvester (Packard). 3H-thymidine incorporation was measured using a Matrix 96, 
Direct Beta Counter (Packard). Because background counts varied considerably 
between individuals (range from 100 cpm to 3000 cpm), proliferation was expressed 
as a stimulation index derived as follows: 
SI = (mean counts per minute test culture) I (mean counts per minute medium alone) 
Parallel triplicate cultures in identical conditions were performed in 96 well plates for 
analysis of cytokine production by PBMe, PBTL and SFTL following stimulation. 
Culture supematants were frozen at -700C at different time points indicated in figures 
and assayed for cytokine concentration by ELISA in single batches (section 2.9). 
Reagents included recombinant interleukin-15 (IL-15, donated by Dr D Cosman, 
Immunex Corporation, Seattle, USA), recombinant interleukin-2 (IL-2, R&D 
Systems. Oxon, UK) and phytohaemagglutinin (PHA, Murex Diagnostics Ltd, UK), 
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rabbit polyclonal anti-human IL-15 ('azide free', PeproTech, UK) and rabbit 
polyc1onal anti-human IL-2 ('azide free', Genzyme Diagnostics, MA, USA ). 
2.4.5 Nitric oxide production by monocytes in vitro 
Production of NO by human monocytes was investigated using adherent PBMC, 
prepared as above (section 2.4.2), or monocyte cell lines (U937, THP-l; European 
Collection of Animal Cell Cultures, Salisbury, UK). Cells were incubated in the 
presence or absence of stimuli in 48-well culture plates at various cell concentrations 
(106 to 4x106 /ml) in complete Dulbecco's MEM with 1 to 10% FCS for 24,48, 72 or 
96 hours. Supematants were frozen at -200C until assay for nitrite concentration 
using the Griess reaction (section 2.10.1). Stimuli used were SEB, LPS, IL-I~, 
IFN-y and TNFa as described in section 2.4.1. In some experiments, monocytes 
were first matured by incubation in 10 nM phorbol myristate acetate (PM A, Sigma) 
for 6 - 48 hours in 25 cm2 flasks, prior to addition of reagents. 
In the absence of a recognised human monocyte / macrophage line capable of NO 
production, control experiments were performed using the murine macrophage cell 
line 1774, which is known to produce nitrite after stimulation with 50 I.U.lml IFN-y 
and 10 ng/ml LPS. 1774 cells harvested as described (section 2.4.7) were suspended 
in 100 J.d complete RPMI, 5% PCS, at 2x105 /ml in flat-bottom 96 well plates 
(Nunc1on) and rested for 1 hour. Reagents were added in 100 Jll, then cells were 
incubated for 24 hours before measurement of nitrite concentration in the supernatant 
by Griess reaction (section 2.10.1). Stimuli were SEB, LPS and murine recombinant 
IFN-y (donated by Genentech Inc., CA, USA) at concentrations indicated in the text. 
500 JlM L-NMMA was used as an inhibitory control, to confirm the involvement of 
the L-arginine-dependent NOS pathway (Nathan & Xie, 1994a). 
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2.4.6 Murine spleen cell preparation 
Murine spleens were dissected, weighed, cut into 2 mm fragments in a 10 cm petri 
dish (Sterilin, Middlesex, UK) and gently minced through a tea strainer, using a 10 
ml syringe plunger. This cell suspension was washed three times in complete RPMI, 
passed through Nytex membrane to remove cellular aggregates and debris and 
resuspended to the desired concentration. 
Proliferation assays for spleen (SC) were performed in quadruplicate in U-bottom 96 
well culture plates (Nunclon) at 2x1OS cells/well in 100 ~ proliferation RPM! with 
10% FCS. Stimuli were added in 100 J.11 giving a final culture volume of 200 J.1l. 1 
J.1Ci of 3H-thymidine was added during the final 6 hours of culture and plates were 
harvested as described in section 2.4.4. Cytokine production by se was measured 
by incubating 4x106 cells in Iml of complete RPMI, 10% FCS, for various times in 
48-well culture p]ates, in the presence or absence of stimuli. Supematants were 
frozen at -70°C before cytokine assay in single batches (section 2.9). Stimuli 
included 0.1 to 10 J.1g1ml concanavalin A (Sigma) as positive control. Staphylococcal 
enterotoxin A (SEA), staphylococcal enterotoxin B and Toxic Shock Syndrome Toxin 
(TSST) -1 (all Sigma) and heat-killed staphylococcus aureus LS-l (gift from Dr C. 
Gemmell, Dept. of Bacteriology, University of Glasgow) were used during in vitro 
studies of staphylococcal infection in iNOS deficient mice at concentrations indicated. 
Superantigens were resuspended to 1 mglml in RPM!. 10% PCS, and filter sterilised 
before dilution and use in culture. 
2.4.7 Cell line maintenance 
Human and murine monocyte (THP-l, U937 & 1774) celllines (ECACC) were 
maintained in complete RPMI with 10% PCS between 2x105 and 5x105 cells/ml with 
sub-culture every 2-3 days. CTLL cells (donated by Prof A. Bradley, Dept. Surgery, 
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University of Glasgow) were cultured in complete RPMI, 10% FCS supplemented 
with 10 I.U.lml murine recombinant IL-2 (Genzyme Diagnostics, MA, USA) 
between 1()5 and 5x105 cells/ml, with sub-culture every 2-3 days. For functional 
assays, cells were washed twice before suspension to the desired concentration and 
addition of indicated stimuli. 1774 cells are normally adherent and were harvested by 
cell scraper, then rested for at least 1 hour, after harvesting and washing, prior to 
addition of stimuli. Cell lines were regularly tested for mycoplasma (Mycoplasma 
PCR ELISA kit, Boerhingcr Mannheim, Germany). Cells were stored in 90% FCS; 
10% dimethyl sulfoxide (DMSO) in liquid nitrogen. 
2.4.8 Cell contact protocols 
The ability of T lymphocytes to regulate the pro-inflammatory activity of macrophages 
by direct cell-membrane contact may be investigated by fixing T cells after activation, 
but prior to co-incubation with macrophages (Vey, et al, 1992; Lacraz, et al, 1994). 
PBTL were cultured in 25 cm2 flasks (Costar) for 72 hours in 5% FCS, in the 
presence of medium alone, rIL-15 (100 ng/ml), rIL-2 (lOO ng/ml), rIL-8 (100 ng/ml; 
R&D Systems), rMIP-la (lOO ng/ml; donated by Dr G.l. Graham, CRC Beatson 
Institute, Glasgow, UK) or, as positive control, a combination of 1 J.1g/ml PHA, and 
1 nM phorbol myristate acetate (PMA; Sigma). Cells were washed thrice then fixed 
for 2 hours in filter sterilised (Millex-GV, Mi1lipore, France) 1 % paraformaldehyde in 
phosphate buffered saline (PBS; Sigma) at 40 C with gentle agitation. SFfL were 
prepared in identical conditions but were cultured with or without stimulus for only 24 
hours before fixation. Fixed cells were washed thrice, resuspended to 4x106 cells/ml 
in RPMI, then immediately added in equal volume to 5xl05 cells/ml of either 
unprimed U937 cells, PB monocytes (section 2.4.2) or adherent synovial fluid 
derived macrophage I synoviocyte co-cultures (section 2.4.3) in 10% FCS in flat-
bottomed 96 well plates (Nunc1on). After a further 48 hours, supematants were 
harvested and stored at -700C prior to TNFa estimation by ELISA (section 2.9.2). 
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The in vivo capacity for cell-contact mediated macrophage activation by synovial 
lymphocytes was further investigated by direct fixation of freshly isolated synovial 
mononuclear cells (SFMC). Synovial fluid was prepared through lymphoprep as 
before, then SFMC were cultured for 30 mins in 10% FCS in 25 cm2 flasks (Costar), 
after which the non-adherent cells were fixed in 1 % PFA. 4x106 fixed cells Iml were 
cultured with U937 cells as described above. Supematants were collected after 48 
hours for TNFa estimation. 
Double chamber culture was performed in parallel experiments. PBTL were 
stimulated for 72 hours as described, then added without fixation at 4xl06 cells/m I to 
U937 cells at 5xlOS cells/m!. Identical cultures were established in which PBTL were 
separated from U937 cells by a culture-well insert (Falcon, Becton Dickinson) with a 
porous membrane, which prevented cell-contact but allowed soluble factor mediated 
communication. Supematants were harvested after a further 48 hours and TNFa 
concentrations estimated by ELISA. 
Some experiments were modified to investigate the contribution of surface markers to 
T cell I macrophage communication following IL-15 mediated activation of T cells 
(Isler, et al, 1993). Antibodies against CD69 (Becton Dickinson), LFA-l and ICAM-
1 (both donated by Dr N. Hogg, Imperial Cancer Research, London, UK) were 
diluted to 50 ~g/ml in PBS. Fixed T cells were pelleted by centrifugation at 250g for 
10 minutes, then suspended in 180 ~l medium, to which was added 20 ~l of 
neutralising antibody (final concentration 5 ~glml), or control murine monoclonal 
IgG 1 (DAKO, Denmark) at equivalent concentration. Cells were incubated at 4°C for 
30 minutes, washed twice in cold Dulbecco's MEM and adjusted to 4x106 Iml. These 
cells were added to monocyte preparations as before. These cultures were 
supplemented with 5 ~glml human IgG (Sigma) to reduce non-specific Fc binding by 
cell bound antibody. In some experiments, increased concentrations of neutralising 
antibodies were employed up to a final concentration of 50 ~glm1. 
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2.4.9 Whole Blood Culture 
Phenotypic maturation of peripheral blood lymphocytes to recombinant IL-15 or 
mitogens was investigated using FACS analysis by modification of a whole blood 
culture method (Bocchieri, et aI, 1995). Blood was withdrawn, heparinised (10 
I.U.lml) and immediately diluted 1:5 in complete Iscove's medium. After addition of 
rIL-15 (100 ng/ml), rIL-2 (lOO ng/ml) or PHA (lJlg/ml) to the diluted blood, triplicate 
cultures (500 ,.u each) in 48-well culture plates were established and incubated for 3, 
6, 24, 48 and 72 hours. Unstimulated, diluted blood was withheld to serve as 'time 
0' negative control and analysed within 30 minutes of venesection. FACS analysis of 
these cultures was performed as described below. 
2. 5 FA CS analysis 
2.5. 1 Analysis of Iymphocyte phenotype after whole blood culture 
Double immunofluorescence staining of peripheral blood lymphocytes following 
stimulation with cytokines or mitogens was performed by FACS analysis. 200 JlI of 
blood I Iscove's culture prepared and stimulated as described above were placed in a 
12 x 75 mm polystyrene tube (Falcon 2052, Becton Dickinson, UK). Primary 
antibodies employed were as follows: CD3 (FITC and PE), CD56 (PE), CDl6 (PE), 
CD69 (FITC and PE), CD45RA (FITC), CD45RO (PE), CD19 (FITC) (all Becton 
Dickinson). 10 JlI of primary antibody were added to cells at 4°C for 30 minutes. 
Negative control primary antibodies (IgG 1 FITC, IgG I PE; DAKO) of appropriate 
isotype and conjugate were added to parallel tubes and were similarly processed. 2 ml 
FACSR Brand Lysing Solution was added (1:10 dilution of commercial stock 
contained 5% diethylene glycol, 1.5% formaldehyde; Becton Dickinson), vortexed for 
5 seconds, then cells were incubated for 10 minutes at room temperature in the dark to 
facilitate erythrocyte lysis. Leukocytes were recovered by spinning at 300g for 5 
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minutes, then washed with 1 ml FACSFlow (Becton Dickinson) at 200g for 5 
minutes. Cells were resuspended in 200 J.11 FACSFlow and analysed on a FACScan 
(Becton Dickinson). Gates were set for lymphocytes using forward and side light 
scatter parameters. The percentage of mc or PE positive cells, or of double labelled 
cells, was generated for lymphocytes within this region using Lysis 11 software 
(Becton Dickinson). 
2.5.2 Human cell subset analysis 
Cell preparations from peripheral blood, synovial fluid and tissues were analysed 
using FACS to determine cellular purity. Single cell suspensions were adjusted to 
106 /ml in serum free medium, then 100 J.11 were incubated with 5 J.11 of FITC or PE 
labelled primary antibody in separate tubes (CD3 PE, CD14 FITC, CD19 FITC; 
Becton Dickinson) for 15-30 minutes at 4°C in the dark. Cells were washed in 1 ml 
FACSFLow at 200g for 5 minutes, then analysed as described before. Both 
lymphocyte and monocyte regions, determined by forward and side light scatter 
parameters, were examined to identify cell subsets present. 
2.5.3 Murine spleen cell analysis 
Murine spleen cell suspensions prepared as described (2.4.6) were cultured for 24 
hours with or without SEA (100 ng/ml) or TSST-l (lOO ng/ml). Cells were 
harvested by pipette (Pl000 Gilson, UK), washed once in serum free RPMI, then 
100 J.Ll of 106 cells/ml were incubated with 5 J.Ll of antibody for 20 minutes at RT in the 
dark. Anti-murine CD4 (PE), anti-murine CDS (FITC) and IgG 1 negative control 
antibodies were obtained from PharMingen (USA). After incubation, 1 ml FACSR 
Brand Lysing solution was added for 10 minutes, spun at 300g for 5 minutes, than 
washed once in 1 ml FACSFlow at 200g for 5 minutes. Cells were analysed as 
before in the lymphocyte region gated by forward and side light scatter parameters. 
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2.6 Immunohistochemistry 
Tissue from RA or OA patients undergoing arthroplasty or arthroscopy was collected 
in theatre and processed immediately. Approximately 5 mm fragments of synovial 
membrane were dissected, placed in mounting medium (Cryo-M-Bed, Bright 
Instrument Company Ltd, Cambs, UK) on cork disks and snap frozen in liquid 
nitrogen. Samples were stored at -700C until required. 
Glass microscope slides were soaked overnight in 2% Decon 90 (Decon Labs Ltd, 
UK), then rinsed in tap water for 3 hours before air drying. Slides were dipped in 
2% silane (3-aminopropyltriethoxysilane, Sigma) in acetone for 4 minutes, rinsed in 
running tap water for 6 minutes, then air dried. 4-6 J.l.ffi frozen sections were cut onto 
silane coated slides at -200C using either a Bright 5030 Microtome, or a Leica 
CM1800 cryostat and immediately fixed by immersion in acetone (BDH Lab 
Supplies, Poole, UK) at 4°C for 15 minutes. Sections were air dried for 10 minutes 
and stored at -200C in an air I moisture tight container before use. 
Primary, secondary and negative control antibodies which were used, their source, 
species of origin, isotype and final working dilution are detailed in tables 2.1 to 2.3. 
2.6.1 Alkaline phosphatase staining 
Frozen sections were rehydrated in Tris buffered saline, pH 7.36 (TBS), for 10 
minutes and non-specific, Fe-mediated immunoglobulin binding was blocked with 
25% normal goat serum (NGS) I normal pooled human serum (PHS) (both supplied 
by SAPU, Scotland, UK) in TBS, for 30 minutes at room temperature. All 
incubation steps were performed in a humidified slide container (Shandon). For all 
washes, slides were placed in a slide rack in 250 ml TBS at room temperature with 
gentle agitation for 5 minutes. Primary antibody (Table 2.1), diluted as required in 
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10% NOS I PHS was then incubated in 1O01l1 volume, overnight at 4°C. Sections 
were washed twice for 5 minutes before incubation with secondary biotinylated goat 
anti-immunoglobulin antibody of appropriate species specificity (Table 2.2), diluted in 
10% NOS I PHS, for 1 hour at room temperature. After two further washes, alkaline 
phosphatase conjugated streptavidin, diluted 1:100 (51lg/ml, DAKO), was added for 
1 hour at room temperature. Sections were washed once and bound antibody detected 
by incubation under light microscopic observation for up to 10 minutes with either 
Fast Red solution (Vector Laboratories, UK) per the manufacturers instructions, or 
with fast red salts prepared as follows. Fast red salt (Sigma) was dissolved to 1 
mg/ml in TBS, pH 8.2 containing 1 mg/ml naphthol-AS-MX phosphate (Sigma) and 
5% N.N.-dimethyl form amide (Sigma). Levamisole (Sigma) was added to 0.001 M 
final concentration to inhibit endogenous tissue alkaline phosphatase activity, and the 
solution was filtered prior to use (Millipore). Finally, sections were dipped in 
Harris's haematoxylin (BDH) for 8-12 seconds to provide a nuclear counterstain and 
mounted using pre-warmed aqueous mounting medium (OlycergeFM, DAKO). 
2.6.2 Con-focal microscopy 
To identify the cell subsets expressing inducible nitric oxide synthase (iNOS) within 
the synovial membrane, double immunofluorescence staining was performed with 
visualisation by con-focal microscopy. 4 Ilm synovial sections were cut, fixed and 
blocked as before. Primary rabbit anti-human iNOS antibody (N053, Merck, Table 
2.1) was incubated on sections overnight at 4°C, then with either murine monoclonal 
anti-CD3 or anti-CD68 antibody for 1 hour at room temperature. Sections were 
washed twice, incubated for 1 hour with biotinylated goat anti-rabbit immunoglobulin 
antibody (DAKO), washed again in TBS, and finally incubated for 1 hour with PE-
conjugated streptavidin (DAKO, 5 Ilg/ml) in combination with FITC-conjugated Fab2 
goat anti-mouse immunoglobulin (DAKO). Sections were washed for 15 minutes in 
TBS and mounted in Permafluor (Immunotech SA, France), before storage at -200C 
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until visualisation by con-focal microscopy. Histological fields of interest were 
selected by direct immunofluorescence (Nikon Optiphot-2), then con-focal images 
were acquired (BIORAD MRC1024, Herts, UK). 
2.6.3 Non specific esterase (NSE) double staining with 
anti human iNOS 
NSE may be visualised by incubation with a-naphthyl acetate or butyrate substrate 
and localises predominantly to macrophages with a characteristic cytoplasmic pattern, 
allowing distinction from lymphocyte expression (Meuller, et aI, 1975). 4 J.1m 
sections were stained with rabbit polyc1onal anti-human iNOS antiserum (Merck) as 
described above, but developed with fast blue (Vector, UK), without counterstain, to 
provide subsequent contrast with NSE staining (red-brown). Acid a-naphthyl acetate 
esterase stain (ANAE) was prepared as follows. Hexazotized pararosaniline was 
freshly prepared by mixing equal volumes of 4% sodium nitrite (BDH) with 40 mg/ml 
pararosaniline chloride (Sigma). The reaction mixture consisted of 10 mls 0.067 M 
phosphate buffer, pH 5.0 (9.85 ml 0.067 M KH2P04, pH 5.0 added to 0.15 ml 
0.067 M Na2HP04,2H20 [appendix ID, to which was added 600 J.11 (6%) 
hexazotized pararosaniline and 100 J.11 (1 %) 25 mg/ml a-naphthyl acetate (Sigma) 
dissolved in acetone (BDH) (10 mg dissolved in 400 J,ll). Before use this was 
adjusted to pH 5.8 by addition of a few drops of 2 M sodium hydroxide (BDH). 
Initial experiments identified the formation of non-specific, dark brown precipitates on 
synovial tissues. This was overcome by optimising the incubation time to 20 minutes 
and by centrifuging the reaction solution at lO,OOOg for 1 minute prior to addition to 
tissue. Sections were incubated with 200 J.ll of reaction solution for 20 minutes at 40 C 
in the dark, then washed extensively in running tap water before mounting in 
glycergel without nuclear counterstain. 
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2.6.4 Murine Articular and Footpad Histology 
Hind limbs were removed above the knee and immediately fixed in 10% neutral 
buffered formalin for at least 72 hours. Paws were decalcified in 5% HN03 for a 
further 72 hours, then 6 J.l.m sections were cut using a bone cryostat (by Mr P. Kerr, 
Pathology Department, University of Glasgow). Sections were stained with 
haematoxylin and eosin using the standard method of the Department of Pathology, 
University of Glasgow. Immunohistochemical characterisation of the inflammatory 
infiltrate following rIL-I5-induced chemotaxis was performed using peroxidase 
detection to avoid the strong endogenous alkaline phosphatase activity observed in 
skin, glands, bone and cartilage in murine paw specimens. Sections prepared as 
above were rehydrated through xylene (BDH) and progressively dilute alcohols 
(100%,90% x2, 70% x2, TBS) then treated with 0.3% hydrogen peroxide (DAKO) 
for 10 minutes to block endogenous peroxidase in tissues. Thereafter, tissues were 
stained as described in section 2.6.1, using rabbit polyclonal anti-CD3 antibody 
(DAKO) and horseradish peroxidase-conjugated streptavidin (DAKO), diluted 11100, 
to detect bound antibody. Staining was visualised by developing for 5 minutes in 0.5 
mg/ml diaminobenzidine (Sigma) containing 0.03% hydrogen peroxide, followed by 
haematoxylin nuclear counterstain. 
2.6.5 Control Experiments 
Parallel sections were stained with negative control antibodies to conflrm speciflcity of 
primary antibody binding. Murine monoclonal primary antibodies were controlled 
with isotype matched monoclonal antibodies of irrelevant speciflcity (DAKO) used at 
equivalent concentrations (Table 2.3). Similarly, equivalent concentrations of purified 
rabbit immunoglobulin (DAKO) or 20% higher concentrations of non-immune rabbit 
serum (SAPU) served as controls for primary rabbit polyclonal antibodies and 
antisera respectively (Table 2.3). 
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Tissues were pre-blocked with normal goat serum. Goat secondary antibodies, which 
had been previously solid-phase absorbed against human immunoglobulins, were 
used to reduce background staining. The secondary antibodies utilised did not bind 
tissues in the absence of primary antibodies at the concentrations indicated in the 
above protocol. In double immunofluorescence staining for confocal studies, parallel 
sections were stained with several combinations of primary and secondary antibody to 
exclude the possibility of cross reaction. Thus, primary murine monoclonals were not 
detected by secondary goat anti-rabbit immunoglobulin antibodies, even in the 
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presence of normal rabbit serum, and primary rabbit polyc1onal antisera were not 
detected by secondary goat anti-mouse immunoglobulin antibodies. Streptavidin 
conjugates, either alone, or in the presence of secondary antibodies, did not bind 
tissues directly. 
Neutralisation of primary antibody staining for IL-15 and iNOS was carried out. 
(i) Human rIL-15 served as positive control for M112, which was originally raised 
against simian IL-15 (Grabstein, et al, 1994), and human rIL-2 (R&D Systems) was 
used as a likely candidate for cross-reactivity, given the similar quaternary structure 
and shared receptor specificity with IL-15 (reviewed by Tagaya, et aI, 1996a). A 
dose range (0.5 - 100 ~glml) of each cytokine was used. 
(ii) Various peptides were used to test the specificity of iNOS detection. The 
immunising human iNOS peptide YRASLEMSAL (50 J,lg/ml) and iNOS peptide from 
a similar area of the C-terminus ofrat iNOS YEEPKATRL (50 J.lg/ml) were gifts from 
Dr. R.A. Mumford, Merck Research Laboratories, USA. Recombinant human eNOS 
(50 J.lg/ml) was donated by Dr. I. Charles, Wellcome, UK. Primary antibodies were 
incubated with or without peptide I recombinant protein, either overnight at 4°C, or 
for 2 hours at 37°C, in 10% NGS I PHS in TBS, pH 7.36, before addition to 
sections for subsequent staining as described (section 2.6.1). 
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2.6.6 Quantification of histology 
Quantitative light microscopy was performed on a Laborlux S microscope (Leitz, 
Germany) with an additional 'teaching' binocular eye piece, which allowed two 
observers (Or M. Field and the author) to count cells simultaneously in high power 
fields (x250 magnification). Synovial tissues were divided into three areas (Duke, et 
al, 1982; Cush & Lipsky, 1988): 
• lining layer 
• aggregate area 
• interstitial layer 
In alkaline phosphatase stained RA and OA synovial sections, representative high 
power fields were selected and positive cells were counted in each of the above areas 
as a percentage of the total number of nuclei found in that field. If possible, 200 
nuclei were counted from each field and at least three fields were counted per section, 
with more selected in relatively acellular tissues. Observers were blind to whether 
positive or negative antibody was used and to the clinical diagnosis. Positive cells 
were those in which discrete staining could be localised to a single nucleus. 
Aggregate areas were not found in OA synovial tissues and direct comparison with 
RA in that respect was not possible. Otherwise, OA tissues were used as a disease 
control for RA tissues. Appropriate 'normal' synovial tissue was unfortunately 
unavailable and was not, therefore, included in this study. In double stained sections 
(NSE plus iNOS), the number of single stained cells I field was determined for each 
stain, then double stained cells were counted. The percentage of double stained cells 
for each specific cell subset was calculated as follows: 
number of double stained cells xl 00 
number of double + single stained cells for each marker 
Murine footpad histology after rIL-15 injection (section 2.7.2) was quantified by 
determining the number of infiltrating inflammatory cells in a high power field, and 
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expressing this observation as a percentage of the total number of cells in the same 
field. CD3 positive, peroxidase stained cells in similar sections were scored as a 
percentage of the total number of cells in the same high power fields (x400). 
2.6.7 Photo-micrography 
Photo-micrographs were obtained using an Orthoplan photo-microscope (Leitz, 
Germany) in the Medical Illustration Department, GRI. Colour prints were made on 
EKT AR 25 film (Kodak, UK), and in some experiments, 35mm colour slides were 
made with Ektachrome 64T film (Kodak) and colour prints were subsequently 
developed commercially. 
2.7 Animal Models of Inflammation 
2.7. 1 Staphylococcus aureus arthritis in mice. 
MFl Swiss mice are susceptible to induction of staphylococcal arthritis (Bremmell, et 
al, 1992). The iNOS gene targeted mice recently developed by Wei et al (1995) on a 
129xMFI background, allowed detailed analysis of the effect of NO deficiency in this 
model in the context of normal cNOS activity. Bremmell strain (LS-l) 
Staphylococcus aureus were obtained from Dr C. Gemmell (Dept. of Bacteriology, 
University of Glasgow) and 107 CFU to 108 CFU/mouse were injected intravenously 
via the tail vein in 50 III PBS. Male and female mice aged 3-4 weeks were used 
(provided by Dr X.Q. Wei, Dept. of Immunology, University of Glasgow) caged in 
groups numbering four to six animals, fed standard chow and water ad libitum. Wild 
type 129xMFl (iNOS+/+) and iNOS mutant heterozygote 129xMFl (iNOS+/-) 
served as control groups for comparison with the iNOS mutant homozygote mice 
(iNOS-/-). Mice were observed (blind to treatment / innoculation) for up to 14 days 
for development of arthritis and for clinical signs of septicaemia. 
(i) Arthritis 
Arthritis progression was monitored daily using the following criteria: 
incidence of arthritis 
weight change 
number of limbs involved I mouse 
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footpad I inter alveolar diameter - calliper measurement (Kroeplin, Germany) 
articular index - 3 points I limb, totall2! mouse derived as follows by a 
treatment blinded observer: 
erythema alone (1) 
swelling and erythema (2) 
erythema, swelling, and extension I loss of function (3) 
Mice were observed for up to 14 days before sacrifice, required at that time point by 
Home Office guidelines. 
(U) Septicaemia 
Septicaemia was assessed by the presence of the following: 
stary coat (I) 
hunched posture (I) 
loss of spontaneous movement (1) 
mucocutaneous abscess (1) 
Using these signs, a summative 'septic index' (maximum 4 Imouse) was derived for 
each animal. This index correlated with loss of, or failure to gain, weight from base 
line and with mortality (Chapter 6). Further assessment by articular histology (section 
2.6.4) and measurement of staphylococcal specific responses in spleen cell cultures 
(section 2.4.6) was performed in some experiments as described before. 
Staphylococcal viability was estimated by organ culture as follows. Groups of 3 mice 
were sacrificed 3, 7 and 11 days after Lv. staphylococcal injection. Spleens and 
kidneys were removed aseptically, homogenised, then submitted to serial ten-fold 
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dilutions in sterile PBS. 200 ,.Ll blood was similarly diluted in PBS. Each dilution 
was plated out on 5% blood agar plates (Dept. of Bacteriology, OR!) and cultured 
overnight at 37°C. Plates in which at least 100 distinct colonies were observed were 
counted and the original number of CPU present in blood or tissue was derived from 
the dilution factor. CPU were expressed per ml of blood, or per tissue. 
(iii) Staphylococcal killing assays 
Staphylococcus aureus LS-1 (107 CPU/ml) diluted in gel-Hanks (working solution 
prepared as follows; 80 mls dH20, 10 mls IOx Hanks, 10 mls 1 % gelatin [SigmaD 
were opsonised by mixing with an equal volume of murine plasma prepared from 
iNOS-/- controls for 15 minutes at 37°C. Bacteria were resuspendcd in gel-Hanks to 
107 CFU/ml after cenrifugation at 3000 rpm for 15 minutes. Pooled blood was 
obtained from 4 iNOS-/- mice and from 4 iNOS+/- controls, heparinised (10 
I.U.lml), then 100 ~ was added to 100 III of opsonised bacteria. The mixture was 
incubated for 0, 30, 60 or 90 minutes at 37°C at which point, cells were lysed by 
addition of 3 mls of sterile ice cold water. The resulting solution was diluted ten-fold 
and plated in pairs onto 5% blood agar plates for 18 hours at 370C. The percent 
killing at time x was calculated as follows: 
mean CPU in time x culture x 100 
mean CPU in time 0 culture 
2.7.2 Footpad Lymphocyte Invasion Model. 
The capacity of IL-15 to recruit T lymphocytes in vivo was investigated in a murine 
footpad invasion model. Male DBAl1 mice, aged 8-10 weeks, were injected 
intraperitoneally with 500 mg of Corynebacterium parvum (donated by Prof. P.C. 
Wilkinson, Dept. of Immunology, University of Glasgow) in 100 III PBS and seven 
days later, received 500 ng rIL-15 in PBS, or PBS alone as a control, by 50 III 
injection to the hind footpad. Control mice which had been given no C.Parvum 
received IL-15 or PBS injection as a further control. C. parvum was used because 
89 
earlier studies (Wilkinson & Liew, 1995) showed that primed T cells responded more 
strongly to IL-2 and IL-15 in vitro, in chemotactic assays. Paws were collected 16, 
48 and 72 hours after injection, fixed in 10% neutral buffered formalin, decalcified 
and examined histologically as described in section 2.6.4. Draining lymph nodes 
were collected, cleaned and weighed, and then examined by light microscopy after 
H&E staining. 
To exclude the possibility that any observed inflammatory infiltrate was due to 
contaminating lipopolysaccharide, rIL-15 was tested for the presence of endotoxin by 
limulus amebocyte lysate assay (E-toxate, Sigma, UK) as per the manufacturers 
instructions. 500 ng IL-15 was found to contain less than 0.0015 I.U. endotoxin in 
this assay. 
2.8 RT ·peR for mRNA expression in synovial tissue. 
Fragments of synovial tissue were snap frozen immediately after surgical excision and 
stored at -700C. Synovial fluid cells were pelleted by centrifugation at 450g for 10 
minutes, immediately resuspended in 400 J.lI RNAzolTM (Biogenesis, Bournemouth, 
UK) and were also snap frozen and stored at -70°C. Reverse transcription-
polymerase chain reaction (RT-PCR) was performed as previously described 
(Kawasaki, 1990) and modified by Dr D. XU and Mr B.P. Leung (Dept. of 
Immunology, University of Glasgow), whose technical assistance is gratefully 
acknowledged. 
2.8.1 RNA extraction 
Total mRNA was extracted using RNAzoFM (Biogenesis) as described (Chomczynski 
& Sacchi, 1987). Frozen tissue fragments, or synovial cell pellets, were disrupted in 
800 J.i.l RNAzol using a PlOOO Gilson Pipette. To this was added 80 J.i.l chloroform 
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(Sigma) followed by vortexing for 15 seconds and rest on ice for 5 minutes, before 
centrifugation at 12,OOOg for 15 minutes at 4°C. The aqueous phase was added to an 
equal volume of isopropanol (Sigma), rested at 4°C for 15 minutes, then spun at 
12,OOOg for 20 minutes at 4°C. The pellet was resuspended in 800 III ice-cold 75% 
ethanol, spun at 12,OOOg for 8 minutes, dried under vacuum for 10 minutes, then 
resuspended in 20 III distilled water. RNA concentration was determined by its 
optical density at 260nm and 280nm (Sambrook, et aI, 1989) per the following 
formula: 
- [(62 x Od260) - (36 x Od280)] x dilution of sample = "RNA" Ilglml 
2.8.2 cDNA preparation 
cONA was prepared using the following mixture: 0.5 III 40 I.U.lJ.1l RNasinR RNase 
inhibitor (Promega), 2 III containing 0.5 Ilg random primer (Promega), 4 III 5x RT 
buffer (375 mM KCI, 15 mM MgCI2, 250 mM Tris-HCI, pH 8.3), 2 III containing 
0.25 IlM of each dNTP (Promega), 2 J.1l1O mM OTT (Promega) and 1 III containing 
200 units Moloney murine leukaemia virus reverse transcriptase (Gibco BRL). 2 Ilg 
RNA in 8.5 III was heated to 900C for 5 minutes, cooled on ice then added to the 
above mixture giving a final volume of 20 Ill. After sitting at room temperature for 10 
minutes, the reaction was performed at 37°C for 1 hour. 
2.8.3 Polymerase Chain Reaction (peR) 
PCR was performed as follows. 2 III of the above reverse transcription reaction 
mixture, or around 0.1 Ilg cONA, was mixed with 10 J.1llOx reaction buffer (500 mM 
KCI, 15 mM MgCI2, 0.01 % gelatine, 100 mM Tris-HCI pH 8.3), 2 III containing 
0.2-0.3 IlM of each primer, 4 III containing 40 IlM of each dNTP (Promega), and was 
then made up to 99.5 III with water. This mixture was heated to 95°C for 5 minutes 
then cooled on ice before addition of 0.5 III Taq DNA polymerase (Promega) and was 
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overlaid with 50 III mineral oil (Sigma). A Techne PHC-3 Dri-Block Cycler was 
programmed to give the desired cycle conditions detailed below with respective 
primers used. After the PCR, 20 III of the reaction product was visualised by 
electrophoresis on 1 % (w/v) agarose gel containing 0.5 Ilg/ml ethidium bromide 
(Sigma) with a DNA 1 kb ladder. 
Oligonucleotide primers specific for human iNOS were a gift from Dr I. Charles 
(Wellcome, Beckenham, UK) - 5'-GCCTCGCTCTGGAAAGA-3' and 5'-
TCCATGCAGCAACCTT-3' and were used to amplify a 500 bp fragment. Human 
chondrocyte iNOS cDNA (Or I. Charles) and ~-actin oligonucleotide primers - 5'-
CCACACTGTGCCCATCTACGAGGGGT-3' and 5' -AGGGCAGTGATCTCCTTC 
TGCATCCT-3' (Genosys, Cambridge, UK) were used as internal controls. Reaction 
conditions for iNOS and ~-actin PCR amplification were 95°C (35 secs), 55°C (60 
secs), 72°C (120 secs) for 35 cycles. The double nucleotide sequence of the PCR 
product was derived by Dr X.Q. Wei (Dept. of Immunology, University of Glasgow) 
and found to be identical to that predicted from human chondrocyte iNOS (Charles, et 
al1993; Genbank database No X73029). 
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2.9 Cytokine assays 
2.9.1 IL-15 ELISA 
IL-I5 in synovial fluid and culture supernatants was detected using a sandwich 
enzyme linked immunosorbent assay (ELISA). Immulon 4 micro-ELlS A plates 
(Dynatech, Virginia, USA) were coated with 50 ~l monoclonal anti-IL-I5 antibody 
(MII2, 5 ~g/ml) in bicarbonate coating buffer (O.IM NaHC03), pH 8.2 incubated at 
4°C overnight. Between each of the following steps the plates were washed at least 
four times with PBS /0.05% Tween 20. Non-specific binding was blocked with 200 
~ PBS containing 1 % bovine serum albumin (BSA, Sigma) and 2% heat inactivated 
goat serum (SAPU) for 2 hours at room temperature (blocking buffer). 
Subsequently, 100 ~ test samples or standard recombinant human IL-I5 (three-fold 
dilutions from 100 ng/ml to 50 pg/m!) were diluted in blocking buffer and incubated 
either at room temperature for 4 hours, or at 4°C overnight. Bound IL-I5 was 
detected using 100 ~l rabbit anti-human IL-IS antibody (2 ~g/ml, PeproTech) for 1 
hour at room temperature, followed by 100 ~l alkaline phosphatase-conjugated goat 
anti-rabbit (1:5000, Sigma) for 1 hour, developed with p-nitrophenyl phosphate (1 
mg/m!) in IM Tris, 3 mM MgCl2 buffer and the optical density read at 630 nm 
(reference filter 405 nm) using an MR5000 ELISA reader (Dynatech, UK). The 
lower limit of detection of the assay was 1 nglml (Figure 3.1). 
2.9.2 General ELISA protocol 
Human TNFa and murine TNFa, IFN-y. IL-4 and IL-6 were detected in culture 
supernatants or serum by ELISA, with paired capture and biotinylated detection 
monoclonal antibodies for each cytokine (pharMingen). Immunolon 4 micro-ELlS A 
plates were coated overnight at 4°C with capture monoclonal antibody at 2 J,lglml in 
bicarbonate coating buffer. Wash steps were performed as described above. Plates 
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were blocked with PBS 110% Fes (Gib co BRL) for 2 hours, incubated with test 
samples, or twofold standard dilutions of recombinant cytokine (10 ng/ml- 10 pg/ml) 
in triplicate for 2 hours, and bound cytokine was detected for 1 hour with 1 J.1g/ml 
biotinylated detection monoclonal antibody diluted in blocking buffer. Peroxidase-
conjugated extravidin was added for 45 minutes (1:1000; Sigma), developed with 100 
J.lI TMB Microwell Peroxidase Substrate (Kirkegaard & Perry Laboratories, MA, 
USA) and the plate was read at 630nm as above. The lower limit of detection in each 
assay was as follows:-
hTNFa 
mTNFa 
mIFN-r 
mIL-4 
mIL-6 
2.10 NO measurement 
10 pg/ml 
10 pg/ml 
30 pg/ml 
40 pg/ml 
20 pg/ml 
Nitric oxide (NO) production may be estimated by measuring the concentration of its 
oxidative products, nitrite or nitrate anion (Archer, 1993). 
2.10.1 Griess reaction 
This is a colorimetric assay for nitrite concentration (Green, et al, 1982). Reagents 
were prepared as follows: solution A - 0.1 % a-naphthyl-amine (Sigma) in distilled 
water and solution B-1 % sulfanilamide (Sigma) in 5% phosphoric acid (Sigma). 
Both were stable stored in the dark at 40 C for 2 months. The Griess reagent was 
obtained by mixing equal volumes of solution A and B immediately prior to use. A 
sodium nitrite stock solution (10 J.lglml, Sigma) was diluted twofold to provide a 
standard curve (72.5 nmol/ml- 1 nmol/ml). The assay was performed in triplicate, by 
placing 50 III of either test culture supematant, or standard dilutions of nitrite in 
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identical medium, into a flat bottom 96 well plate, after which 50 J,Ll Griess reagent 
was added to each well. The plate was incubated for 10 minutes at room temperature 
in the dark, and thereafter, the colorimetric reaction was measured at 570nm 
(reference fllter at 630 nm) in an MR5000 ELISA reader (Dynatech) and the test nitrite 
concentration estimated from the standard curve. The lower limit of sensitivity was 2 
nmollml. 
2.10.2 Chemiluminescence assay for nitrite I nitrate 
The presence of high protein concentrations in serum and synovial fluid leads to 
precipitation in the acid pH environment of the Griess reaction. This may interfere 
with colorimetric assessment, therefore, a chemiluminescent assay for nitrite was also 
used (Aoki, 1990; Palmer, et aI, 1987). A reflux reaction was created by 
continuously boiling 75ml glacial acetic acid (BDH) with 25ml 6% sodium iodide 
(BDH) in a 250ml Pyrex reaction flask, through which was passed a low flow of 
nitrogen gas. 50 or 100 J,Ll of either test sample, or standard nitrite solution prepared 
as above, was injected directly into the reaction flask using a Hamilton syringe 
(Sigma). N02 - in the sample is immediately reduced to NO·, which is carried in 
gaseous phase through a condenser and a cold trap, created with a glass U-tube 
surrounded by "dry ice" to remove acetic acid vapour, and on to a chemiluminescence 
NO analyser (Dasibi Environmental Corporation, Japan). NO reacts with ozone 
causing photoemission which may be detected and converted to a digital readout. The 
photomultiplier signal is proportional to the nitrite concentration in the original 
sample, allowing the generation of a standard curve and estimation of nitrite 
concentration in test samples. Sensitivity for this assay was 2 nmollml nitrite. 
Nitrate concentration in biological fluids may be estimated by first reducing nitrate to 
nitrite using the enzyme nitrate reductase (Sigma). To measure 50 samples, reaction 
buffer was prepared as follows: 500 ~15 mg/ml NADPH (Sigma), 500 J,Ll4.15 mg/ml 
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FAD (Sigma), 500 JlI KH2P04, pH 7.5,950 JlI distilled water and finally, 50 JlI 34 
mg/ml nitrate reductase, immediately after which 30 J.1l reaction buffer was added to 
30 JlI sample in a flat bottom 96 well plate. The reaction was incubated at 37°C for 2 
hours, after which nitrite produced was measured by chemiluminescence as described 
above. Standard curves for sodium nitrite and sodium nitrate were included in the 
reductase reaction to provide a control for the efficiency of the reduction. This was 
calculated for the conversion of 100 JlM sodium nitrate to sodium nitrite as shown 
below and was routinely >75%. 
% reduction nitrate = (ppb nitrite I ppb nitrate) x 100 
2.11 Statistical Analysis 
Data were collated and statistical analyses performed using Minitab software for 
Macintosh. Means were compared using either a two-tailed student's Hest or the 
Mann-Whitney test. Paired data were compared using the paired student's Hest, or 
using Wilcoxon's signed sum of ranks test. Tabulated data were submitted to the 
Chi-squared test Significance was accepted at p<0.05. 
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Table 2.1 Primary antibodies used for immunohistochemistry 
Antibody Specificity' Host Species Type Presentation Dilution! Source 
concentration 
UCHTI hCD3 mouse JgGI supematant 11100 DAKO 
HD37 hCDl9 mouse JgGI supematant 11100 DAKO 
KPI hCD68 mouse JgGI supematant 11150 DAKO 
N053 hiNOS C-term peptide rabbit polyclonal neat antiserum 1120,000 Merck Research:t: 
h13 hiNOS C-term peptide rabbit polyclonal neat antiserum 1110,000 Wellcome* 
PA3-030 miNOS C-term peptide rabbit polyclonal affmity 11500 - 10,000 Cambridge Bioscience 
purified (Affmiti) 
N32020 miNOS 21kD protein mouse IgG2a purified ascites 11250 Transduction Labs (Affmiti) 
49M miNOS rabbit polyclonal neat antiserum 11500 - 10,000 Wellcome* 
hiNOS peptide sheep polyclonal neat antiserum 11200 - 10,000 Wellcome* 
MIl2 hIL-15 mouse IgGl supematant 30J.lglml Immunex Corporation+ 
<J[ h =-human; m - murine 
:t: Donated by Dr RA. Mumford, Merck Research Laboratories, USA. 
* Donated by Dr I. Charles, Wellcome Research, Beckenham, UK. 
+ Donated by Dr D. Cosman, Immunex Corporation, Seattle, W A, USA. 
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Table 2.2 Secondary antibodies used in immunohistochemistry 
Host Antibody Specificity Conjugate Concentration Source 
species 
Goat polyclonal mouse immunoglobulins biotin lA Ilg/ml DAKO 
Goat polyclonal rabbit immunoglobulins biotin 3 Ilg/ml DAKO 
Goat Fab2, polyclonal mouse immunoglobulins FITC 30 Ilg/ml DAKO 
Horse polyclonal universal (VectastainR) biotin 1120 stock Vector 
Table 2.3 Negative control antibodies for immunohistochemistry 
Host species Antibody type Specificity Source 
Mouse IgGl Aspergillus niger DAKO 
glucose oxidase ... 
Mouse IgG2a Aspergillus niger 
glucose oxidase ... 
DAKO 
Rabbit Serum Non-immune SAPU 
Sheep Serum Non-immune SAPU 
Sheep Immunoglobulin - Non-immune Sigma 
affinity purified 
... neither constitutively nor inducibly expressed in mammalian cell systems. 
Chapter 3 
A role for interleukin·lS in T cell 
activation in rheumatoid arthritis 
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Introduction 
IL-15 is a novel cytokine with biological functions similar to those of IL-2, but with 
no significant sequence homology (Grabstein, et aI, 1994). It mediates its functions 
through the ~ and y chains of the 1L-2 receptor and its own unique ex chain (Girl, et al, 
1994; Bamford, et al, 1994; Giri, et al, 1995; Anderson, et aI, 1995b). 1L-15 induces 
T cell proliferation, enhances NK cell cytotoxicity and ADCC, up regulates 
production of NK cell derived cytokines, including IFN-y, GM-CSF and TNPa 
(Grabstein, et al, 1994; Carson, et al, 1994). and can co-stimulate proliferation and 
differentiation of B cells (Armitage, et al, 1995). In addition, IL-15 stimulates 
locomotion and chemotaxis of normal T cells measured by an assay of locomotor 
shape-change (head-tail polarization), by checkerboard filter assay and by invasion 
into IL-15 containing collagen gels (Wilkinson & Liew, 1995). IL-15 can be detected 
at mRNA level in several normal human tissues including placenta, skeletal muscle 
and kidney. Production by epithelial and fibroblast cell lines and peripheral blood 
monocytes has been shown, but, unlike IL-2, IL-15 is not reported to be produced by 
activated T cells (Grabstein, et aI, 1994). The role of IL-15 in the context of any 
pathological situation remains to be elucidated. 
Rheumatoid arthritis (RA) is a destructive inflammatory polyarthropathy which 
provides an ideal opportunity to study expression of pro-inflammatory cytokines in 
situ. Chronic RA synovitis is characterised by infiltration of the normally relatively 
acellular synovial membrane by macrophages, T cells and plasma cells, together with 
the presence of activated fibroblast-like synoviocytes (Duke, et al, 1982; Burmester, 
et al, 1983; Cush & Lipsky, 1988). Pro-inflammatory cytokines of macrophage 
derivation, including IL-l, IL-6, IL-8 and TNFa, are readily detected at the protein 
level in RA synovial tissue, and also at the eroding cartilage/pannus junction, 
indicating the importance of macrophages in articular damage (reviewed by Feldmann, 
et aI, 1996b). Nevertheless, a significant T cell infiltrate is present in RA synovial 
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tissue, which exhibits a memory phenotype with markers characteristic of both early 
and late stages of activation (Pitzalis, et aI, 1987; Laffon, et aI, 1991; Thomas, et aI, 
1992; Iannone, et al, 1994). The mechanisms governing recruitment of these T cells 
to the synovial membrane from the circulation remain ill-defined, but probably involve 
co-ordinated adhesion molecule expression and production of appropriate chemotactic 
factors (reviewed by Oppenheimer-Marks & Lipsky, 1995). 
T cells are important in RA pathogenesis (Panayi, et aI, 1992). Therapies directed at 
T cells, such as cyclosporin A and monoclonal antibodies against T cell surface 
antigens produce significant, albeit transient, clinical improvement (Homeff, et aI, 
1991; Wendling, et aI, 1991; Pasero, et al, 1996). Several animal arthritis models can 
be demonstrated to be T cell-dependent (Trentham, et aI, 1978; Staines & Wooley, 
1994). Moreover, the association of RA with the HLA-DR shared epitope strongly 
implicates T cell I antigen recognition in disease aetiology (Gregerson, et aI, 1987). 
Cytokines associated with T cell activation such as IFN-y or IL-2 can be detected at 
the mRNA level (Buchan, et aI, 1988; Simon, et aI, 1994) and at the protein level 
using immunohistochemical analysis (Ulfgren, et aI, 1995). However, only a 
relatively small number of T cells expressing these proteins can be found, and 
furthermore, T cell-derived cytokines are usually undetectable in synovial fluid 
(Firestein & Zvaifler, 1987; Firestein, et aI, 1988). Whether there is sufficient IL-2 
present to account for the extensive evidence ofT cell activation remains uncertain and 
has raised controversy regarding the relative contribution of macrophages and T cells 
to the pathogenesis of RA (Firestein & Zvaifler, 1990; Panayi, et aI, 1992). The 
identification of significant levels of a macrophage-derived cytokine capable of T cell 
chemoattraction, activation and maturation in RA synovial tissue would clearly be of 
considerable interest. 
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3.1 Detection of IL-lS in synovial fluid 
A sandwich ELISA was designed to detect IL-15 in biological solutions, using a 
murine monoclonal anti-simian IL-15 antibody (M112) for capture and an affinity 
purified rabbit polyclonal anti-human IL-15 antibody (PeproTech) for detection. 
Recombinant IL-2, IL-l~ and TNFa were not detected in this ELISA system, nor did 
the level of rheumatoid factor correlate with IL-I5 concentrations detected in synovial 
fluid. The sensitivity for recombinant human IL-15 was 1 nglml (Figure 3.1). 
Synovial fluids were collected from 17 RA patients whose clinical and serological 
characteristics are shown in table 3.1 and from 6 OA patients (mean 69 years ± 11.9, 
range 50-79). The latter were treated with simple analgesic drugs or non-steroidal 
anti-inflammatory drugs. IL-15 was detected in RA synovial fluids at significantly 
higher levels than was observed in OA fluids (p<0.OO3, Mann-Whitney; Figure 3.2). 
Despite a wide variation in disease duration and acute phase response in RA patients, 
local synovial fluid IL-15 levels did not correlate with systemic disease activity 
parameters or with drug therapy (Table, 3.1; Pearson's correlation coefficient). 
3.2 Synovial tissue cultures generate IL.lS 
To determine whether synovial membrane was the source of detectable IL-15. single 
cell suspensions of synovial tissue samples from 7 RA and 4 OA patients were 
cultured for 72 hours in vitro. without exogenous stimulation. IL-15 was detected in 
the supernatants from 417 RA patients. but from only 114 OA patients (Figure 3.3). 
These data indicate that rheumatoid synovial tissue is capable of generating IL-15. 
'0 
o 
Figure 3.1 Standard curve for IL-15 ELISA 
0.14 
0.12 ----------------
0.10 
0.08 
0.06 
- - - - -o 0.1 1 10 100 
Concentration rIL-15 (nglml) 
rIL-15 was diluted ten-fold in PBS /1 % BSA and submitted to assay as 
described in section 2.9.1. Synovial fluids were diluted in PBS then 
assayed as for the standard. The concentration of IL-15 in samples was 
calculated as shown (dotted lines). Sensitivity was typically 1 nglml. 
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Table 3.1 Demography of RA patients from whom synovial fluid samples were 
obtained for IL-15 analysis 
Age Disease RF ESR CRP Drugprofllc 
(years) Duration +/-
(l::ears) 
RAl 89 6 + 4 10 
RA2 36 5 + 36 58 Gold 
RA3 34 4 + 28 57 SASP 
RA4 44 9 + 15 14 SASP 
RA5 44 10 + 16 5 Pred, MTX 
RA6 57 3 + 46 50 SASP 
RA7 60 8 + 51 39 Gold 
RA8 59 33 + 89 161 MTX 
RA9 75 50 + 30 74 SASP 
RAW 49 11 + 46 59 MTX 
RA 11 56 16 + 8 30 Gold 
RA12 65 7 + 71 66 SASP 
RA13 74 20 + 22 44 SASP 
RA14 73 3 + 58 86 Gold 
RA15 54 25 23 66 SASP 
RA16 31 5 + 45 16 Gold 
RA17 57 15 + 80 93 Gold 
Clinical details of RA patients were collected at the time of synovial fluid aspiration. 
Data shown are for samples used in IL-15 ELISA. RF - rheumatoid factor, ESR -
erythrocyte sedimentation rate, CRP - C-reactive protein «10 mg/ml normal 
reference), SASP - sulphasalazine; Pred - prednisolone; MTX - methotrexate; Gold-
intramuscular sodium aurothiomalate. 
Figure 3.2 Detection oflL-15 in RA and OA synovial fluid 
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Synovial fluids from RA or OA patients were collected, and assayed for IL-15 
presence by ELISA. Levels in RA fluids were significantly higher than in OA 
(p=O.OO29, Mann-Whitney). 
Figure 3.3 IL-15 production by synovial membrane cultures 
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Single cell suspensions of synovial tissue from RA and OA patients were cultured 
without exogenous stimulation for 72 hours. IL-15 levels in resultant 
supematants were measured by ELISA (sensitivity indicated - 1 ng/ml). 
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3.3 Immunohistochemical localisation of IL·15 in human synovium 
To further investigate the presence of IL-15 in synovial membrane, parallel cryostat 
sections of RA synovial tissues were stained with murine monoclonal anti-simian IL-
15 (Ml12). Simian IL-15 shares 97% homology with human IL-15 (Grabstein, et aI, 
1994) and similar antibodies localised IL-15 expression in human monocytes 
(Carson, et aI, 1995). Figure 3.4a demonstrates the tissue distribution of M112 
binding in rheumatoid synovium. The pattern of cytoplasmic staining appears to 
represent intracellular rather than membrane-bound cytokine, implying that these cells 
contain, and are likely synthesising, IL-15. Staining was abolished completely by 
pre-incubation with recombinant human IL-15 (50 J.lg/ml), indicating specificity of 
antibody binding (Figure 3.4b). To determine which cells were expressing IL-15. 
parallel sections were stained with monoclonal antibodies against CD68 (tissue 
macrophage) and CD3 (T lymphocyte). IL-15 co-expressed with CD68+ macro-
phages in the lining layer (Figure 3.4c), but not with adjacent CD3+ T cells (Figure 
3.4d). The extent of lining layer staining (mean 54 ± 13.1 % of cells) indicated that 
type B synoviocytes may also express IL-15 (Table 3.2). IL-15 was also detected in 
the T cell rich aggregates. This staining may correlate with intracellular localisation in 
macrophages, which are found in these areas, or may reflect receptor bound IL-15. 
Although T cells have not thus far been shown to produce IL-I5 in vitro (Grabstein, 
et al, 1994), production of IL-15 by CD3+ synovial T cells cannot be excluded by 
these data. In keeping with the lower levels of IL-I5 detected in OA synovial fluid, 
OA synovial sections contained fewer IL-15 expressing cells in both the lining layer 
and interstitial areas (p<O.OOl, Mann-Whitney; Table 3.2) suggesting that up 
regulation of expression of 1L-15 is a feature of RA. 
These data clearly demonstrate the presence of IL-I5 in the RA synovial membrane. 
Subsequent experiments addressed the possible functional significance of this 
observation. 
Figure 3.4 Immunohistochemical localisation of IL-15 in RA synovial membrane 
Table 3.2 Immunohistochemical localisation of IL-15 in synovial membrane 
Diagnosis 
n = number fields 
Rheumatoid 
arthritis (n=30) 
Ostcoarthritis 
(n=21) 
Lining layer 
54 ± 13.1 
(29-80) 
6.5 ± 4.5 
(1-16) 
% positive cells mean ± s.d. 
(range) 
Aggregate areas 
24 ± 12.3 
(5-55) 
Interstitium 
12 ± 7.7 
(3-32) 
2 ± 1.1 
(0.5-4) 
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Synovial tissue sections from RA (9 patients) and OA (5 patients) were stained 
with a monoclonal anti-IL-15 antibody (M112) as described (section 2.6.1). A 
minimum of 500 cells were counted in each section, in at least three fields 
(magnification x 250). Mean values (per field) are presented with standard 
deviation and range in parenthesis. IL-15 expression is greater in RA lining layer 
and interstitium than OA (p<O.ool, Mann-Whitney). Percent of IL-15 positive 
cells is expressed as: 
(positive cells !total number cells) x 100. 
Legend to Figure 3.4 
Immunohistochemical analysis of synovial tissue from a representative RA 
patient. Cryostat sections were fixed and stained with (a) anti-IL-15 (M112), (b) 
anti-IL-15 neutralised by recombinant human IL-15, (c) anti-CD68, or (d) anti-
CD3. Primary antibodies were detected with biotinylated goat anti-mouse IgG, 
then with streptavidin-alkaline phosphatase complex and fast red salts. 
(Magnification x80) 
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3.4 IL·15 footpad injection induces inflammatory cell recruitment in 
DBA/l mice. 
Previous studies have shown that IL-15, like IL-2, is a potent chemoattractant for T 
cell polarization and migration in vitro (Wilkinson & Liew, 1995), raising the 
possibility that IL-15 may recruit T cells into local tissues during inflammatory 
responses. To test this hypothesis in vivo, male DBNl mice, primed 7 days 
previously with C. parvum, received either 500 ng rIL-15 (n=12), or PBS alone 
(n=12), subcutaneously to their hind foot pads. Human IL-15 was used because 
murine IL-15 was unavailable and preliminary experiments had shown that the murine 
T cell line, CTLL-2, proliferated to human 1L-15 (Figure 3.5). 
Figure 3.5 CTLL cell activation by human IL-15 
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Murine T cells proliferate to human rIL-15. CTLL cells (1 X 105 
Iml) were cultured for 24 hours with human rIL-15 (D), or human 
rIL-2 (0) and 3H-thymidine incorporation over the last 6 hours was 
assessed. The response to IL-15 significantly exceeded that to IL-2 
between 50 and 200 pg/ml of cytokine (p<O.OI, Mann-Whitney). 
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Mice which received rIL-15 developed an inflammatory cell infiltrate in the 
hypodermis and muscle layers, in contrast to those which received PBS alone (Figure 
3.6, p<O.OOI, Mann-Whitney; Figures 3.7a & 3.7b). Immunohistochemical staining 
was performed, which showed that up to 56 ± 3.6% (mean ± s.d.; n=4 tissues) of the 
tissue cell population after rIL-15 injection was CD3+ (Figure 3.7c). Few CD3+ cells 
were present in PBS treated limbs «2% total cell number; n=4 tissues). 
Inflammatory cell recruitment was evident within 16 hours and was present up to 72 
hours after cytokine injection (Figure 3.6). No change in paw thickness was detected 
on caliper foot-pad measurements compared with PBS injected limbs. However, the 
size of draining popliteal and inguinal lymph nodes was significantly increased 24 and 
48 hours after rIL-15 injection (Figure 3.8). Histological examination of the lymph 
nodes using H&E, demonstrated marked paracortical expansion, consistent with the 
presence of increased numbers of T lymphocytes (Figure 3.9a & 3.9b). Thus, a 
single injection of rIL-15 induced a local tissue inflammatory infiltrate. 
A single experiment was performed in which 10 unprimed DBNl mice were injected 
in the hind footpad with either PBS or rIL-15. No significant inflammatory infiltrate 
was detected in these mice «10% inflammatory cells I high power field [HPF]), 
whereas C. Parvum primed controls developed histological appearances similar to 
those described above (mean 78 ± 4% inflammatory cells IHPF after 48 hours). 
These data suggest that an enhanced circulating pool of activated T cells was required 
for rIL-l5-mediated recruitment in this model system. 
Figure 3.6 rIL-15-induced inflammatory infiltrate in murine footpads 
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DBN1 mice received either rIL-15 (500 ng; n=12) or PBS (n=12) by footpad 
injection and tissue was examined histologic ally daily thereafter. H&E stained 
sections were scored by a treatment-blinded histologist. Significantly higher 
numbers of infiltrating cells were detected in rIL-15 treated mice (*p<O.OO2, 
Mann-Whitney compared with PBS controls at same time point). Percentage 
infiltrating mononuclear cells was calculated for 3 high power fields (minimum 
1000 cells) in each of 4 paws for each group (saline - filled bar; rIL-15 - clear bar) 
after 16, 48 and 72 hours. Figure shows mean value with s.e.m. 
number inyadin~ mononuclear cells x 100 
total number cells in field 
Figure 3.7 Histology of murine footpad after IL-15 injection in DBNl mIce 
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Legend figure 3.7 next page 
Figure 3.8 Lymphadenopathy after IL-15 footpad injection 
in DBNI mice 
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DBNI mice received rIL-15 (clear bar, 500 ng) or PBS (filled bar) by 
50 J.11 footpad injection. Draining lymph nodes were removed from 4 
mice in each group daily thereafter, dissected free of connective tissue 
and weighed. Data are mean ± s.e.m. for at least 8 lymph nodes at 
each time point. (*p<0.05, Mann-Whitney) 
Legend to figure 3.7 (previous page) 
Histological investigation of murine footpads was performed after 
injection of 500 ng IL-15 or PBS. H&E staining of formalin fixed, 
decalcified footpad 48 hours after (a) saline, or (b) IL-15 injection 
demonstrates inflammatory infiltrate in IL-15, but not in PBS recipient. 
(c) CD3+ cells detected after 48 hours with anti-CD3 I peroxidase 
localisation (2.6.4). A representative field is shown from an IL-15 
injected animal. Few CD3+ cells «5%) were detected in interstitial 
areas of saline treated controls. (Magnification a, b xSO, C x2S0). 
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Figure 3.9 Histology of lymph nodes drai ning IL-15 injected limbs 
Paracortical expansion, suggestive of increased numbers of T cells, was 
observed in popliteal lymph nodes, draining footpads injected 48 hours 
previously with either (a) 500 ng IL-15, or (b) PBS. Lymph nodes were 
fixed in 10% neutral buffered formalin immediately after excision, and 
sections were stained with H&E. (Magnification x40 for each figure) 
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3.5 IL·lS induced peripheral blood T Iymphocyte activation 
T lymphocyte polarization often accompanies entry into G1 phase of cell cycle 
(Wilkinson, 1986). Moreover, IL-15 induces proliferation of PHA-blasts from 
peripheral blood and of transformed T cell lines (Grabstein, et al, 1994). Since PB T 
cells polarize to rIL-15 alone (Wilkinson & Liew, 1995), it was decided to investigate 
whether circulating T cells were capable of cell-division in response to rIL-15. The 
proliferation to rIL-15 of peripheral blood mononuclear cells (PBMC) from 14 RA 
patients was therefore compared with 14 age and sex matched normal controls in 3H-
thymidine incorporation assays. RA patients were all receiving DMARD therapy, but 
no corticosteroids, whereas normal controls were on no regular drug therapy. RA 
derived PBMC, stimulated with 100 nglml of rIL-15, exhibited a significantly higher 
stimulation index than PBMC from normal controls after 72 and 96 hours culture 
(p<O.05, Wilcoxon; Figures 3.lOa & 3.10b). However, 4 RA synovial fluids, 
known to contain IL-15 (by ELISA and by the presence of IL-15-dependent 
chemoattractant activity [AI-Mughales, et aI, 1996]), were found not to be mitogenic 
for PBMC. This is likely to be due to the presence of soluble inhibitors within the 
synovial fluids tested, such as TGF~ (Fava, et al, 1989; Chu, et al, 1991). These data 
show that a circulating T cell population exists in RA which is directly responsive to 
IL-15, but indicate that the behaviour ofT cells in the synovial membrane willlikcly 
reflect multiple cytokine activities. 
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Figure 3.10 Peripheral blood mononuclear cells proliferate to rIL-15 
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(a) Dose response of RA (0, n=14) or control (a, n=14) PBMC to rIL-15 
after 72 hours in triplicate 3H-thymidine incorporation assays. Values 
shown are mean ± s.e.m. Medium control ranged from 500 - 1,500 cpm. 
(*p<O.Ol, Mann-Whitney). Stimulation index calculated as: 
cpm after incubation with IL-15 
cpm medium control 
(b) Time course showing stimulation index of PBMC from RA (0, n=14) or 
age matched controls (A, n=14) after addition of 100 ng/ml rIL-15 in 
triplicate 3H-thymidine incorporation assays. Values shown are mean ± 
s.e.m. ('" p<O.05, "'''' p<O.03, Mann-Whitney) comparing RA patient 
with normal control group. 
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Discussion 
This study clearly demonstrates the presence of IL-15 in the rheumatoid synovial 
membrane. T cell! macrophage interactions in the synovial membrane are integral to 
the progression of synovitis and resulting articular destruction (Feldmann, et aI, 
1996b). The detection of IL-15 in this context provides a mechanism for T cell 
recruitment and activation by a macrophage-derived cytokine in RA. 
High concentrations of IL-15 were detectable in RA synovial fluid, in excess of levels 
previously shown to possess biological activity in vitro (Grabstein, et al, 1994; 
Burton, et aI, 1994; Carson, et al, 1995). The synovial membrane was the likely 
source of this IL-15, since it was present in synovial cultures and could be 
predominantly localised immunohistochemically to the synovial lining layer. The 
possibility remains, however, that this represents detection and release of stored 
cytokine. Further experiments are required, in which the capacity for protein 
synthesis inhibitors to abrogate IL-15 production by synovial membrane in vitro is 
investigated. The recent development of a more sensitive ELISA system for IL-15 
will allow this question to be formally addressed. 
Pro-inflammatory cytokines, such as IL-l, IL-6, TNFa and IL-8, are abundant in 
synovial tissue and are similarly localised to the lining layer, and to cartilage I pannus 
junction and perivascular infiltrates, where they are recognised to be predominantly 
macrophage derived (reviewed by Brennan, et aI, 1991; Feldmann, et aI, 1996b). 
The high proportion of lining layer cells which expressed IL-15, and the co-staining, 
in parallel sections, of IL-15 with CD68+ cells, made it likely that macrophages 
contributed significantly to IL-15 production in RA, consistent with the in vitro 
observation that IL-15 is made by cells of the monocyte series (Grabstein, et al, 1994; 
Carson, et al, 1995). However, IL-15 expression has been reported from the bone 
marrow stromal cell line, IMTLH (Grabstein, et aI, 1994), therefore type B 
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synoviocytes, which are derived from fibroblast-like cells, may also be capable of IL-
lS production. Similarly, IL-15 production by synovial T cells remains possible. IL-
lS was first isolated from HuT-102 cells (Burton, et aI, 1994), indicating that cells of 
the T lymphocytes series might also synthesise IL-15 if appropriately activated. 
In common with IL-2, IL-15 induces T lymphocyte locomotion and proliferation ofT 
lymphoblasts (Grabstein, et al, 1994; Wilkinson & Liew, 1995) raising the possibility 
that it is of importance in recruitment and concomitant activation of T cells at sites of 
chronic inflammation. The RA synovial membrane contains aggregates of polyclonal 
T lymphocytes which concurrently express cell surface markers normally seen 
sequentially through various stages of the activation pathway, such as HLA-DR, 
CD69 and VLA-4 (Pitzalis, et aI, 1987; Burmester, et aI, 1987; Laffon, et al, 1991; 
Iannone, et al, 1994; Femandez-Gutierrez, et aI, 1995). They also possess a mature 
differentiated phenotype (CD45RO+, RBdim, CD27-), probably reflecting preferential 
recruitment of re circulating memory T cells, (Pitzalis, et al, 1988; Pitzalis, et al, 1991; 
Thomas, et al, 1992; Matthews, et al, 1993; Kohem, et al, 1996), which may undergo 
further activation, initiated by endothelial interaction during extravasation, and 
subsequently modified by the cytokine environment within synovial tissue (Iannone, 
et al, 1994). Although IL-2 mRNA can be detected in RA synovial tissue (Simon, et 
al, 1994), and T cells containing IL-2 protein can be found immunohistochemically 
(Ulfgren, et al, 1995), these studies have demonstrated that most CD3+ T cells in RA 
synovium show no evidence of IL-2 expression. Moreover, T cells derived from 
synovial tissues are recognised to exhibit deficient cytokine production in vitro to 
exogenous stimuli or recall antigens (Combe, et aI, 1985; Verwilghen, et aI, 1990; 
Aaron, et al, 1991; Thomas, et aI, 1992) and IL-2Rex expression is limited to -10% of 
cells (Pitzalis, et al, 1987). Therefore, it is unlikely that the observed T cell activation 
can be explained solely by the levels of IL-2 thus far detected, and other cytokine-
dependent mechanisms of T cell recruitment and activation may operate in RA. 1L-IS, 
by virtue of its described functional phenotype, may fulfil such a role. 
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The processes whereby inflammatory cells are recruited to the synovium remain ill-
defined. Synovial endothelial cells express high levels of E-selectin, ICAM-l and 
VCAM-l, which can be up-regulated by IL-l~ and TNFa (Abbot, et aI, 1992; 
Morales-Ducret, et al, 1992; Wilkinson, et al, 1993). Interaction with T cell markers, 
such as VLA-4 and LFA-l, will thereby facilitate endothelial adhesion and 
transmigration (reviewed by Oppenheimer-Marks & Lipsky, 1995). These pathways 
operate in parallel with the activities of synovial chemokines. AI-Mughales, et al 
(1996) have recently demonstrated that RA synovial fluid contains chemoattractant 
activity for T lymphocytes which is biologically active in in vitro assays. Using 
neutralising antibodies they have identified IL-15 as an important contributory 
cytokine in this context (Appendix Ill; Mclnnes, et al, 1996). Recombinant IL-15, 
having no reported chemotactic effects on neutrophils, B cells or monocytes 
(Wilkinson & Liew, 1995), appears T lymphocyte specific. Its locomotor action is 
seen in highly purified T cells (Dixon, R. personal communication; McInnes, et al, 
1996), and in CD4+ and CD8+ T cells subsets, both of which are represented in 
synovial tissue, and it is inhibited by neutralising antibody to the ~y chains of the IL-2 
receptor (Wilkinson & Liew, 1995). Other macrophage-derived lymphocyte 
chemokines, including MIP-l a, MCP-l and IL-8 (Koch, et aI, 1991; Koch, et al, 
1992; Taub, et al, 1993; Deleuran, et al, 1994; AI-Mughales, et aI, 1996) have also 
been implicated in chemoattraction in RA, and IL-15 is therefore unlikely to operate in 
isolation in recruitment of lymphocytes to the synovial compartment. However, 
unlike other T cell chemotactic factors, IL-15 is also associated with lymphocyte 
proliferation, indicating a unique combination of activities which in the synovial 
membrane could have pathological significance by facilitating both recruitment and 
activation ofT cells in RA. 
PBMC proliferated in response to rIL-15 alone, indicating the presence of circulating 
primed T cells capable of cell division in response to a single signal (Janeway & 
Bottomley, 1994). It is of interest that this response was enhanced in RA patients. 
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Since increased numbers of mature CD45RO+, CD27- T cells have been reported in 
RA peripheral blood (Kohem, et ai, 1996), it is attractive to hypothesise that such 
cells represent an expanded memory T cell population in RA, which constitutes a pool 
from which the synovial membrane can recruit, partly through the activity of IL-15. 
Alternatively, the level of IL-15Rcx expression may be increased in some PB T cells in 
RA patients. Currently, lack of available reagents prevents formal investigation of 
this latter possibility. 
The chemoattractant properties of IL-15 have until now been demonstrated only in 
vitro. The murine T cell line, CTLL-2, proliferated to human IL-15 at higher levels 
than to murine IL-2. This unexpected finding may reflect high levels of IL-15Rcx in 
this cell line, or perhaps represent a feature of cytotoxic CD8+ T cell responses in 
vitro to IL-15. Nevertheless, this inter-species cross-reactivity permitted investigation 
of the role of IL-15 in vivo in a model of initiation of inflammation in DBNl mice. 
The demonstration of a cellular infiltrate lasting at least three days after a single 
subcutaneous injection of rlL-15 into murine footpads, suggests that the chemotactic 
activity measured in vitro by AI-Mughales, et al (1996) indeed has biological 
significance. The duration of the observed response, and presence of related 
lymphadenopathy, indicates that other mechanisms aside from IL-1S-induced 
chemotaxis, are operating. The possibility that IL-15 may up-regulate adhesion 
molecule expression either on circulating T cells, or on endothelial cells, needs to be 
explored. IL-lS induces adhesion molecule redistribution on T cells (Nieto, et aI, 
1996), although novel expression of markers was not reported. Nevertheless, it is 
clear that, since up to 56% of infiltrating cells expressed CD3 three days after 
injection, the events initiated by IL-lS can have a prolonged action on T cell 
recruitment 
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These data demonstrate for the first time the presence of IL-15 in a pathological 
setting. It was of interest to determine possible mechanisms whereby IL-15 might 
contribute to RA pathogenesis, beyond T cell recruitment. The relationship of IL-15 
mediated T cell activation with TNFa production by macrophages in synovial 
membrane was therefore investigated. 
Chapter 4 
Interleukin-15 mediates T cell dependent 
regulation of tumour necrosis factor (l 
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Introduction 
IL-15 is a pleiotropic cytokine derived from several cell types, including macrophages 
and fibroblasts (Grabstein, et aI, 1994; 1994; Tagaya, et aI, 1996a), which mediates 
its activity through a heterotrimeric receptor consisting of a unique IL-15Ra chain 
with the ~ and r chains of the IL-2 receptor (Giri, et aI, 1995; Anderson, et aI, 
1995b). IL-15 can induce T cell proliferation, B cell maturation and isotype 
switching, NK cell cytotoxicity and cytokine generation and may protect T cells from 
apoptosis (Grabstein, et aI, 1994; Bamford, et aI, 1994; Armitage, et aI, 1995; 
Carson, et aI, 1995; Akbar, et aI, 1996). IL-15 promotes inflammatory cell 
recruitment in vivo following footpad injection in mice primed with C. Parvum 
(chapter 3), and in chemotactic assays in vitro, induces T cell polarization and 
invasion into collagen gels (Wilkinson & Liew, 1995). Responding migratory T cells 
are mainly of the CD45RO+ phenotype (AI-Mughales, et aI, 1996). IL-15 can be 
identified immunochemically in RA synovial membrane (chapter 3) and RA synovial 
fluid contains potent chemotactic activity attributable, at least in part, to the presence 
of IL-15 (McInnes, et aI, 1996; Al-Mughales, et al, 1996). Moreover, RA peripheral 
blood T cells exhibit enhanced proliferative responses to rlL-15. It therefore seems 
likely that IL-15 plays a critical role in T cell recruitment and activation in RA in the 
relative absence of IL-2. 
The relationship ofIL-15 to other cytokines in the RA synovial membrane is currently 
unclear. Studies in animal models and of synovial tissue in vitro have generated a 
hypothetical hierarchy of cytokine activities in RA (reviewed by Maini, et al, 1995). 
TNFa appears pivotal in regulating synthesis of other pro-inflammatory cytokines, 
particularly IL-l~. which in turn is important in enhancing chondrocyte bioactivity and 
the production of matrix metalloproteinases (MMP) (Dayer, et aI, 1986; Arend & 
Dayer, 1995). Furthermore, in animal arthritis models and in RA patients, 
monoclonal antibodies against TNFa reduce clinical inflammation and laboratory 
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parameters of disease activity (Williarns, et al, 1992; Elliott, et al, 1994; Rankin, et al, 
1995). However, it is unclear which factors up regulate TNFa production in the 
synovium, particularly in the relative absence of IFNy (Firestein & Zvaifler, 1987). 
Non-cytokine dependent mechanisms may therefore be important. Following 
mitogen stimulation in vitro, T lymphocytes can induce macrophage production of 
cytokines and matrix metalloproteinases (MMP) by cell-contact (Vey, et al, 1992; 
Lacraz, et aI, 1994). However, it has not previously been possible to extend these 
observations in the context of RA, because no physiologically relevant T cell 
activation factor has been described prior to the identification of IL-15. 
The current studies were performed to address the possibility that IL-I5 might induce 
TNFa production in RA. They tested the hypothesis that polyclonal synovial T cells, 
activated by IL-15, can exert pro-inflammatory effects through a cell-contact 
dependent mechanism, in the absence of local antigen recognition or cytokine 
secretion. 
124 
4.1 Activation of Synovial T cells by rIL·15 
Previous studies have established that peripheral blood mononuclear cells from RA 
patients produced significantly stronger proliferative responses to IL-15 than those 
from normal age-matched controls (chapter 3; Figure 3.9). It was therefore of interest 
to compare the proliferative response to IL-15 of T cells derived from matched 
peripheral blood (PB) and synovial fluid (SF) samples from 15 RA patients (mean 
age 62.4 years [range 24 - 83]; RF+ 90%). All patients were receiving DMARD 
therapy and none had received intra-articular corticosteroid within three months of 
sampling. Given its similar functional phenotype described thus far, IL-2 was used 
for control purposes. T lymphocyte enriched populations (~90% CD3+, <3% 
CD 14+ by FACS analysis of PH and ~90% CD3+, <8% CD68+ cytoprep analysis of 
SF) from both sources proliferated vigorously to IL-15 and IL-2 in a similar dose-
dependent manner (Figure 4.1 a). However, the response of T cells from the SF was 
significantly higher than that of T cells from PH (p<O.OI, Wilcoxon). By comparison 
and as previously reported (Combe, et aI, 1985; Thomas, et aI, 1992), the 
proliferative response of T cells from SF to the T cell mitogen PHA was markedly 
lower than that of T cells from PH (Figure 4.1b). These results therefore clearly 
establish that RA synovial T cells exhibit up-regulated responses to IL-lS. 
The consequence of activation of synovial T cells by IL-15 has not previously been 
defined. Since TNFa plays a pivotal role in the pathogenesis of RA, the possibility 
that IL-15 might up regulate TNFa synthesis through synovial T cells was 
investigated. T cells derived from PH or SF from 15 RA patients (as above) were 
therefore cultured with IL-15 or IL-2 and the concentrations of TNFa in culture 
supematants determined by ELISA. T cell enriched cultures from SF produced 
significant amounts ofTNFa. in response to IL-15 (p<O.OO5, Wilcoxon). In contrast, 
IL-2 induced only low and variable levels of TNFa. synthesis (Figure 4.2a). The 
induction of TNFa. production from synovial T cells was dose-dependent (Figure 
Figure 4.1 Proliferation of SF and PB lymphocytes to cytokines and mitogens 
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Synovial lymphocytes proliferate to rIL-15 (circles) and rIL-2 
(squares). (a) T cells from PB (filled symbols) or SF (empty symbols) 
from 15 RA patients were stimulated with doses indicated of either 
cytokine for 72 hours. SF responses exceeded those of PB for both 
cytokines (**p<O.OI). (b) In contrast, responses to PHA were 
diminished for SF derived, compared with PB derived, T cells 
(*p<O.05). Data are mean ± s.e.m. 
Figure 4.2 Production of TNFa by PB and SF T cell-enriched cultures 
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(a) 13 RA samples were stimulated with rIL-15 (100 ng/ml) or rIL-2 (lOO 
ng/ml) for 72 hours. IL-15 induced highcr levels of TNFa synthesis 
(p<0.005). (b) Dose response to either cytokinc of 7 RA SF samples in which 
IL-2 responses were measurable. rIL-15 (circle) induced enhanced levels of 
TNFa synthesis from SF lymphocytes compared with rIL-2 (square) 
(**p<0.OO3, *p<O.03, Wilcoxon). Data are mean ± s.e.m. 
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4.2b), thus the reduced response to IL-2 was unlikely to be due to an altered dose-
response. Neither cytokine, however, induced significant TNFcx synthesis by T cells 
derived from PB (Figure 4.2a). In comparison, PHA induced TNFcx synthesis by 
lymphocytes from both SF and PB lymphocytes, but that from PB exceeded that from 
SF (386 ± 110 pg/m1 v 184 ± 39 pg/ml respectively [mean ± s.e.m], p<0.03, 
Wilcoxon). These results therefore demonstrate that synovial T cells can contribute 
directly to TNFcx production in the RA synovial membrane in response to IL-15. 
Moreover, they show that the functional effects of IL-15 and IL-2 on this pathological 
T cell population may be different. 
4.2 IL-15-dependent upregulation of TNFcx production from 
macrophages 
As they are the major source of TNFcx in RA synovitis (Chu, et al, 1991), the effect 
of IL-15 on TNFcx production by macrophages was investigated. Addition of IL-15 
(1 - 100 ng/ml) to cultures of unprimed macrophage cell lines (U937 and THP-l) or 
blood-derived monocytes (n=3) from normal donors failed to induce TNFcx 
production. These data implied that in RA, IL-15 might mediate its effects on 
macrophages primarily via T cells. Therefore, the possibility that IL-15-activated T 
cells could induce TNFa. synthesis by macrophages I monocytes was addressed. 
Optimal PB proliferative responses to IL-15 having been obtained after 72 hours 
culture (Figure 3.10), PB T cells from normal donors were stimulated with 100 ng/ml 
IL-15 or mitogen for 72 hours, then washed thoroughly before co-culture in double-
chamber wells, either in contact with, or separated by a semi-permeable membrane 
from U937 cells. TNFcx production was observed only in cultures in which IL-15-
stimulated T cells and macrophages were in direct contact (Figure 4.3). As expected, 
PHA I PMA-stimulated T cells induced TNFcx production in the presence or absence 
of cell contact (Figure 4.3; section 4.1), These data indicated that a cell-contact event 
Figure 4.3 Double chamber culture of PB T and U937 cells 
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T cell I macrophage cell-contact is required for IL-15-induced TNFa 
production. PHA (I ~glml)1 PMA (I nM) or IL-15 (100 nglml) activated PB T 
cells were cultured in contact with (solid bars), or separated by semi-permcablc 
membrane from (hatched bars), unprimed U937 cells. IL-15-activated T cells 
required cell-contact to induce TNFa production by U937 cells. Data are mean 
± s.e.m. of triplicate cultures, representative of 3 similar experiments. 
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between IL-15-activated T cells and macrophages was capable of inducing TNFa 
production. 
To clarify whether T cell cytokine production was required in addition to cell-contact, 
and to confirm that macrophages were the primary source of TNFa in these mixed 
cultures, T cells were fixed in 1% paraformaldehyde (PFA) before co-culture with 
macrophages. PFA fixation is known to prevent T cell cytokine production but 
preserves cell-membrane integrity providing a simple experimental system for 
investigation of cell-contact mediated effects (Vey, et al, 1992; Lacraz, et al, 1994). T 
cells from PB of normal individuals (n=lO) were therefore cultured for 72 hours with 
medium alone, cytokines or, as positive control PHA I PMA, then fixed in 1 % PFA. 
They were thoroughly washed, then co-cultured with U937 cells for a further 48 
hours (Lacraz, et al, 1994). Preliminary experiments established that pre-stimulation 
with 100 ng/ml IL-15 was optimal for induction of T cell-mediated macrophage 
activation, at a ratio of 8: 1 T cells:U937 (Figure 4.4). PFA fixed-T cells, previously 
stimulated with IL-15, consistently induced production of significant concentrations 
of TNFa by U937 cells (Figure 4.5a). In contrast, similar prior activation of T cells 
with IL-2 was effective in inducing TNFa production only in some donors, and did 
so at lower levels (Figure 4.5a, p<0.003 compared with IL-15-activated PB T cells, 
Wilcoxon). This is unlikely to be due to a dose-response effect, since the 
concentration of IL-2 used (lOO ng/ml) was supra-optimal, and because IL-2 and IL-
15 had identical induction profiles for T cell proliferation (Figure 4.la) and 
polarization (Wilkinson & Liew, 1995). 
To investigate whether other T cell chemotactic factors might possess similar activity 
to IL-15, PB T cells were stimulated with IL-8 or MIP-la at doses known to induce 
polarization and migration (Wilkinson & Liew, 1995), but no TNFa production was 
detected in the above culture system (Figure 4.5a). IL-I5-activated, PFA-fixed T 
cells alone were unable to produce TNFa, even after addition of further PHA 
Figure 4.4 Dose response oflL-15 mediated U937 cell activation 
by peripheral blood T cells 
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with unprimed U937 cells for 48 hours at a ratio of either 4: 1 (solid 
bar) or 8: 1 (hatched bar). TNFa production was highest with 100 
ng/ml IL-15 pre-stimulation, and a final T cell:U937 ratio of 8:1. 
Data are mean ± s.e.m. for one normal donor, representative of four 
similar experiments. 
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Figure 4.5 Activated PH T cells induce TNFa production by U937 
and monocytes 
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IL-15-activated T cells induce TNFa synthesis by macrophages. PFA-
fixed IL-15 (100 ng/ml)-activated PB T cells from normal donors 
induced TNFa production by (a) U937 cells (n=lO), or (b) syngeneic PH 
monocytes (n=3), at significantly higher levels than did IL-2 (100 
ng/ml)-activated T cells (**p<O.OO3). IL-8 (lOO ng/ml) or MIP-la (100 
ng/ml) activated T cells (n=2) were ineffective. Sensitivity of TNFa 
ELlSA was 10 pg/m!. Data are mean ± s.e.m. 
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(1 Jlg/ml), indicating that macrophages were the source of TNFa. in the co-cultures. 
Identical results were obtained when highly purified syngeneic peripheral blood-
derived monocytes (>92% CDI4+, <2% CD3+ by FACS analysis) were used instead 
of U937 cells (Figure 4.5b), demonstrating that these results are unlikely to be due to 
an allogeneic effect between Tcells and macrophages, nor could it be a unique feature 
of an immortalised macrophage cell line. Finally, separation oflL-15-activated, PFA-
flxed T cells from U937 cells in double chamber wells prevented induction of TNFa. 
production confirming that a soluble factor was not involved after fixation. 
4.3 Induction of TNFa. production by cells of synovial origin. 
To determine whether a similar mechanism might operate in vivo in RA, freshly 
isolated synovial fluid mononuclear cells from RA patients (n=8) were fixed with 1% 
PFA without prior stimulation and then added directly to U937 cells. Significant 
TNFa. production was observed after 48 hours in all culture supernatants (Figure 
4.6a), demonstrating that synovial T cells may have been sufficiently activated in vivo 
to induce TNFa. production by macrophages. It was of interest to determine whether 
IL-15 was required to maintain this ability of synovial T cells to induce macrophage 
TNFa. synthesis. Synovial T cells were cultured for 24 hours with medium alone, 
IL-15 or IL-2, then flxed with PFA, before co-culture with U937 cells. TNFa. was 
produced only when synovial T cells were maintained in IL-15 or, to a significantly 
lesser extent, in IL-2 (p<O.Ol, Figure 4.6b). Similar results were obtained using 
syngeneic peripheral blood monocytes (instead of U937 cells) which were obtained 
from each RA patient at the time of joint aspiration (Figure 4.7a). To confirm that 
synovial macrophage TNFa. synthesis could be enhanced by this pathway, PB T cells 
from 4 RA patients were added to syngeneic synovial macrophage / synoviocyte co-
cultures (>75% CD68+, <3% CD3+ by cytoprep analysis). TNFa. synthesis was 
observed only with prior activation of PB T cells by IL-IS (Figure 4.7b). Together, 
these data demonstrate that synovial T cell-mediated upregulation of TNFa production 
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Figure 4.6 Synovial T cells induce TNFa production via cell contact 
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Direct fIxation 
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U937 alone 
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Post-culture 
IL-15 is required to sustain synovial T cell mediated cell-contact 
induction of TNFa synthesis. PF A fixed RA SF T cells induced 
TNFa synthesis by U937 cells, whether (a) fIxed immediately (n=8), 
or (b) after culture for 24 hours (n=lO) in the presence of IL-15 (lOO 
ng/ml). Culture with IL-2 (lOO ng/ml) induced significantly less 
TNFa synthesis (*p<O.01 compared with IL-15). Data are mean ± 
s.e.m. 
Figure 4.7 Cell-contact regulates TNFa production by blood 
monocytes and synovial macrophages 
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Blood-derived and synovial monocyte I macrophages produce TNFa after 
cell-contact activation. (a) PFA-fixed RA SF T cells activated by IL-15 
(100 ng/ml) induced TNFa synthesis by RA blood monocytes from the 
same donor patients (n=3). (b) IL-15-activated T cells induced TNFa 
synthesis by synovial macrophage I synoviocyte co-cultures ("'p<O.Ol). 
PB T cells from RA patients (n=4) were stimulated with medium alone or 
IL-15 (100 ng/ml) for 72 hours, then PFA fixed prior to addition to 
synovial macrophage I synoviocyte co-cultures. Data are mean ± s.e.m. 
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by macrophages through cell-contact can occur in RA, and indicate that IL-15 within 
the synovial membrane enhances this activity. 
4.4 Effect of IL·lS on PB Iymphocyte phenotype 
The ability of single cytokines to induce cell division and to sustain cell-contact 
mediated macrophage activation suggested that the responding cells were of a primed, 
differentiated T cell subset. Thus, experiments were performed to characterise 
alterations in T cell-surface phenotype following activation with IL-15, compared 
with IL-2, on different peripheral blood lymphocyte populations. Whole blood 
cultures were employed to avoid T cell activation during purification. Both IL-15 and 
IL-2 up-regulated CD69 expression on CD3+ lymphocytes, which was detectable in 
whole blood cultures up to 72 hours (p<O.005, Figure 4.8a). Since circulating T 
cells recruited to synovial membrane are predominantly of 'memory' phenotype, the 
effect of IL-15 on CD69 expression in the CD45RO+ subset was next examined. 
CD69 expression was elevated within 24 hours, and enhanced seven-fold in 
CD45RO+ PB T cells by 72 hours after addition of IL-15 in vitro (p<O.02, Figures 
4.8b). In contrast, CD45RA + cells demonstrated only two-fold enhancement of 
CD69 levels (Table 4.1), which was probably accounted for by elevated CD69 
expression on CD8dim, CDI6+, CD56+ NK cells (Figure 4.9), which are recognised 
to reside in the CD45RA population (Prince, et aI, 1992). Modest elevation of CD69 
on a small subset of CD 19+ B cells was observed (Table 4.1). 
Figure 4.8 FACS analysis ofPB lymphocytes following cytokine 
induced activation 
a 
Stimulus 
b 
IL-15 
IL-2· 
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IL-15 
IL-2 
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IL-15~~~~?7~~?7~~77~~~--~ ... 
IL-2 
medium 
72h 
IL-15 upregulates expression of CD69 on PB T cells. (a) CD69 
expression on CD3+ PB T cells stimulated with IL-15 (lOO ng/ml), or IL-2 
(lOO ng/ml) in vitro for 72 hours (n=6, ...... p<O.OO5 compared with medium 
alone). (b) CD69 expression was enhanced in CD45RO+ T cells up to 72 
hours ("'p<0.02, • ... p<0.OO2 compared to medium alone) by addition of IL-
15 (lOO ng/ml) or IL-2 (100 ng/ml) in vitro. No significant difference 
between IL-15 and IL-2 was detected. Data are mean ± s.e.m. 
Figure 4.9 IL-15 upregulates CD69 expression on NK cells 
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Double label FACS analysis was performed after 24 hours whole blood 
culture from normal volunteers. CD69 (FITe) expression was increased in 
CD8dim cells (PE) after culture with (a) rIL-15 (100 ng/ml), but not with (b) 
medium alone. In the same cultures, CDI6+, CD56+ NK cells (PE) were 
entirely CD69+ after addition of (c) IL-15 (100 nglml), but not (d) medium 
alone. Data are representative of four similar experiments. Figures 
represent the percentage of gated cells. 
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Table 4.1 CD69 upregulation by IL-15 and IL-2 in vitro 
medium IL-2 IL-15 
n=5 % CD45RA + /69+ 
Oh <2 <2 <2 
24h 4.8 (0.7) 25 (4)* 25 (4.5)* 
72h 10.4 (4) 25 (4.9)** 24 (4.8)** 
n=6 %CD19+/69+ 
Oh <2 <2 <2 
24h <2 <2 <2 
72 h <2 5.1 (2.3) 5.1 (2.3) 
Whole blood cultures from normal volunteers were maintained up to 72 hours in 
the presence of medium alone, IL-2 (lOO nglml) or IL-I5 (lOO ng/ml). At time 
points indicated, FACS analysis was performed to determine the percentage of 
either CD45RA+ cells, or of CD19+ B lymphocytes, expressing CD69. n = 
number of donor samples cultured "'p<0.05 comparing IL-I5 or IL-2 stimulated 
cultures vs medium alone, ** not significant, Wilcoxon. Data are mean ± s.d. in 
parenthesis. 
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4. S Molecules involved in T lymphocyte ! macrophage cell-contact 
Many surface receptors have been implicated in T cell! macrophage membrane 
contact, including the LFA-I and CD69 (Vey, et aI, 1992; Isler, et aI, 1993). The 
contribution of these markers to the production of TNFa. by monocytes after contact 
with IL-15-activated T cells was therefore investigated. TNFa. production by PB T 
cell! U937 co-cultures (n=4) was significantly reduced by neutralisation of LFA-I 
(p<O.02) or ICAM-I (p<O.03) and almost completely abrogated by addition of anti-
CD69 antibody (p<O.OOl, Figure 4. lOa). Increasing the concentration of neutralising 
antibody (from 5 J..lglml up to 50 J..lg/ml) did not further inhibit TNFa. induction. 
Parallel experiments (n=4) demonstrated similar involvement of CD69 (p<O.OOl), 
LFA-I and ICAM-I (both p<O.Ol) on the production of TNFa. by blood-derived 
monocytes induced by IL-15-activated T cells (Figure 4.10b). Addition of human 
IgG (5 Ilg/ml) to minimise Fc receptor binding on U937 cells and blood monocytes 
by T cell-surface bound antibody did not reverse the observed inhibition of TNFa. 
production by macrophages. Thus, at least CD69 and the LFA-I/ ICAM-I pathway 
were implicated in IL-15-activated T cell-mediated macrophages activation. 
a 
Figure 4.10 Inhibition of T cell! macrophage activation by 
neutralising antibodies 
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Inhibition of cell-contact induced TNFa synthesis by antibodies to cell 
surface markers. PFA-fixed IL-15-activated PB T cells were cultured with 
(a) U937 cells, or (b) PB monocytes. Pre-incubation of the fixed T cells 
with neutralising antibodies to CD69, LFA-I or ICAM-I significantly 
inhibited TNFa synthesis compared to IgG I control antibody treated cells 
(*p<O.OOI, *"'p<0.03, "'**p<O.OI). Human IgG (5 ~g!ml) was present in 
all cultures. Data are mean ± s.e.m. from four separate experiments. 
% inhibition was calculated as follows: 
x 100) 
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Discussion 
Many pro-inflammatory cytokines have been detected in synovial membrane including 
TNFa, IL-l~, IL-6, IL-8 and GM-CSF (Feldmann, et al, 1996b). Intervention using 
monoclonal anti-TNFa. therapy in murine collagen-induced arthritis (Williams, et al, 
1992) and in clinical trials in RA (Elliott, et aI, 1994; Rankin, et al, 1995) leads to 
significant amelioration of joint inflammation. These observations therefore confirm 
the clinical relevance of such cytokine production within the synovial membrane and, 
in combination with previous in vitro reports, establish the central importance of 
TNFa. in the cytokine cascade which regulates synovitis (Maini, et al, 1995). At 
present, however, the factors which up regulate TNFa production in RA remain 
unclear. Data presented here demonstrate that IL-15 is critical in this process. 
IL-15-stimulated proliferation and direct TNFa production in T cells derived from 
synovial fluid was enhanced compared to those from blood, thereby establishing that 
T cell responsiveness to IL-15 was upregulated in vivo. However, T cells represent 
only a minor source of TNFa compared with macrophages in RA synovium (Chu, et 
al, 1991). IL-15-activated PB T cells induced significant TNFa. production from 
either unprimed U937 cells, syngeneic blood-derived monocytes, or RA synovial 
macrophage I synoviocyte cultures, by a cell-contact dependent mechanism. Thus, 
freshly recruited IL-15-activated T cells may contribute to TNFa. synthesis by 
activating macrophages within the synovial membrane. Furthermore, freshly isolated 
SF T cells behaved like IL-15 activated PB T cells, indicating that this pathway could 
operate in vivo in RA. IL-15 was required to maintain this activity in vitro, because 
synovial T cells cultured in the absence of IL-15 for 24 hours lost this ability. This is 
unlikely to be simply the result of apoptosis due to the absence of IL-15, because IL-
2, which can rescue T cells from apoptosis in vitro through IL-2Ry chain binding 
(Akbar, et al, 1996), was incapable of maintaining synovial T cell-contact activity. 
Thus, synovial T cells under the control of IL-15 are clearly able to activate RA blood 
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monocytes to produce TNFa. Since recently recruited CDI4+ monocyte I 
macrophages constitute a major source of TNFa in the synovial membrane (Chu, et 
al, 1991), these data together provide compelling evidence for T cell-contact mediated 
up regulation of TNFa synthesis by macrophages, driven by IL-15 produced in the 
synovial membrane. 
Pro-inflammatory cytokine and metalloproteinase production following cell contact-
mediated activation of macrophages and fibroblasts by T cells and T cell clones 
stimulated with non-physiological mitogens (PHA, PMA, OKTI) has been reported 
(Vey, et aI, 1992; Lacraz, et al, 1994; Li, et al' 1995; Miltenburg, et aI, 1995). Here 
a cytokine has been employed which is widely distributed in the RA synovial 
membrane. The synovial T cell population is predominantly C045RO+, RBdim, 
C027-, implying advanced differentiation (Thomas, et al, 1992; Kohem, et al, 1996). 
They often simultaneously express early (C069), mid (HLA-OR) and late (VLA1) 
markers of activation, perhaps initiated by interactions with endothelium during 
extravasation of mature memory T cells (Burmester, et al, 1987; Pitzalis, et al, 1987; 
Pitzalis, et al, 1988; Potocnik, et al, 1990; Laffon, et al, 1991; Iannone, et al. 1994; 
Femandez-Gutierrez, et aI, 1995), and subsequently modified by the cytokine 
environment within synovial tissue, particularly IL-15. The finding that IL-15-
~duced CD69 expression was primarily restricted to CD45RO+ T cells is compatible 
with these observations, and with a recent report comparing the effect of IL-15 on 
naive and memory T cell CD69 expression (Kanegane, et aI, 1996). Despite 
extensive efforts to determine the synovial T cell repertoire, no consensus has 
emerged for oligoclonal T cell receptor V~ gene expression between RA patient 
cohorts, although some amino-acid conservation of CDR3 regions has been reported, 
raising the possibility that some synovial T cells are antigen driven (reviewed by 
Struyk, et al, 1996). The majority of synovial T cells, however, are polyc1onal. T 
cell contact-mediated macrophage activation, driven by IL-15, is therefore consistent 
with the recognised phenotype and functional profile of synovial T cells. It provides 
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a pathological role, but implies no local antigen recognition and requires no cytokine 
secretion, consistent with the polyclonality of synovial T lymphocytes, and their 
relative absence of cytokine expression. 
The cell-contact pathway for macrophage activation by T cells insynovium is likely to 
utilise multiple cell surface molecules. As expected, the LFA-l! ICAM-1 pathway 
was involved. Following chemokine-induced polarization, T lymphoblasts 
redistribute adhesion molecules, such as ICAM-l or ICAM-3, to the tips of uropods 
and IL-15 has recently been shown to exhibit similar properties (Nieto, et al, 1996; 
Angel del Poze, et aI, 1996). However, since it was not possible to induce 
macrophage activation by T cells maintained with the T cell chemotactic factors, IL-8 
or MIP-la., it seems probable that IL-15 must exert effects beyond ligand 
redistribution on the T cell surface. The data also implicated CD69 in cell-contact. 
Increased CD69 expression occurs in vivo on RA synovial T cells (Laffon, et al, 
1991; Femandez-Gutierrez, et aI, 1995) and has been reported in other autoimmune 
diseases, such as multiple sclerosis and chronic active hepatitis at sites of 
inflammation (Garcia-Monzon, et aI, 1990; Perrella, et aI, 1993). CD69 appears 
following TCR! antigen interaction, although IL-2 alone may up regulate expression 
on NK cells and CD45RO+ lymphocytes (Testi, et al, 1994). Data presented here 
show that IL-15 shares this activity with IL-2 and is therefore likely to account for the 
continued expression of CD69 characteristic of synovial T cells, in the relative 
absence of IL-2 in synovial tissue. Although CD69 has previously been shown to 
mediate mitogen-induced T cell! macrophage contact (lsler, et al, 1993), the current 
observations demonstrate that it might sub serve this function in RA. Both IL-2 and 
IL-15 upregulated CD69 expression equally in PB lymphocytes, but IL-2 was 
significantly less efficient than IL-15 at inducing T cell-dependent macrophage 
activation, either in PB cells, or in synovial cells. This implies that other receptors 
which are involved in cell-contact are preferentially upregulated by IL-15, compared 
to IL-2, and also indicates that the precise combination of surface markers present is 
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likely to be of critical importance. The widespread expression of CD69 on other 
circulating cells, such as platelets (Testi, et aI, 1990), requires that such additional 
levels of regulation be present. 
The bioactivities described thus far for IL-15 have been broadly similar to those of IL-
2 (Grabstein, et aI, 1994; Burton, et aI, 1994; Tagaya, et al, 1996a). The differential 
distribution of IL-2Ra and IL-15Ra, however, implies that this may not always be 
the case (Anderson, et aI, 1995b), although functional evidence to support this 
proposal is currently sparse. Whereas SF T cells proliferated equally to 1L-15 and IL-
2, differential direct TNFa production was observed. In combination with the 
divergent effects of IL-15 and IL-2 in generating PB and SF T cell-induced 
macrophage activation, these findings show, in an immunopathological setting, that 
IL-15 can exhibit effects distinct from IL-2 on the same target cell population. This 
has implications for IL-15 receptor expression within the synovial membrane. It is 
possible that IL-15Ra-chain binding modifies the signal generated by IL-2R~ or 
common '1 chain occupancy, although the a-chain has no apparent direct role in signal 
transduction (Giri, et aI, 1994; Giri, et al, 1995: Anderson, et aI, 1995b). The 
distribution of IL-15R a-chain compared to 1L-2R a-chain in the synovium however, 
is currently unknown and discordant expression in different subsets may partially 
explain these data. Recently, however, a novel receptor for IL-15 has been described 
on mast cells (Tagaya, et al, 1996b), and it remains possible that expression of this or 
related, as yet undescribed, receptors may explain the divergent functional profile for 
IL-15 and IL-2 in the synovial T cell population. 
In the absence of a clearly identified antigen, non-antigen driven processes within the 
RA synovial membrane offer the best targets for therapeutic intervention (Miossec, et 
al, 1996). It is attractive to hypothesise that macrophage or fibroblast derived IL-15 
recruits and further activates circulating memory T cells in the synovial membrane. 
Under the continuing influence of IL-15, newly arrived T cells within the synovial 
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membrane can up regulate TNFa production by macrophages, predominantly through 
cell membrane contact. This may generate a positive feedback loop, whereby IL-15 
produced by activated macrophages maintains T cell-induced synthesis of TNFa, 
which can further activate macrophages to produce IL-15. This proposal predicts that 
anti-T cell therapies which not only inhibit T cell activation, but also deplete T cells 
from the synovial compartment will be most successful. Anti-T cell monoclonal 
antibody therapies in RA have been less successful than direct anti-cytokine 
approaches, perhaps reflecting inadequate T cell depletion within the synovial 
compartment. It is of interest that RA clinical improvement following anti-CD4 
therapy correlates with synovial T cell coating with anti-CD4 (Tak, et al, 1995; Choy, 
et al, 1996). Anti-IL-15 antibody or anti-IL-15Ra antagonists therefore represent 
potential approaches to attenuating RA and perhaps other inflammatory diseases. 
Further efforts are now required to characterise other cell surface molecules involved 
in T cell I macrophage contact and to establish which factors up regulate IL-15 
production, thereby generating further rational targets for novel therapy. 
Chapter 5 
Nitric oxide production within 
human synovial membrane 
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Introduction 
Critical immuno-regulatory and effector activities have been attributed to nitric oxide 
(NO) in several models of infection and inflammation (Nathan & Xie, 1994a; Lyons, 
1995). NO is produced constitutively in small amounts by endothelial NO synthase 
(eNOS), or by neuronal NO synthase (nNDS) and in higher concentrations by 
inducible NO synthase (iNOS) following stimulation by bacterial products, including 
LPS, or by cytokines, including IFN-y, TNFcx and IL-l~ (Bredt & Snyder, 1994; 
Nathan & Xie 1994b). All NOS isoforms may generate NO in inflammatory lesions, 
although in the chronic phase, iNOS is likely to provide the principal contribution. 
Considerable circumstantial evidence indicates that NO production is important in 
autoimmune pathology. Inducible NOS expression and increased NO generation 
have been implicated in murine streptozocin-induced diabetes (Lukic, et aI, 1991; 
Kolb & Kolb-Bachofen 1992) and experimental allergic encephalomyelitis (Zhao, et 
al, 1996). Similarly, articular pathology in MRL-lpr/lpr mice (Weinberg, et al, 1995; 
Huang, et al, 1996) and streptococcal cell wall and adjuvant arthritis models in the rat 
are dependent on NO production. iNOS activity can be detected within the synovial 
membrane by northern blot analysis and NO is produced by synovial explant culture 
(McCartney-Francis, et al, 1993; Ialenti, et al, 1993; Stefanovic-Racic, et al, 1994a). 
Their observed phenotype and cytokine production profile indicates that activated 
synovial macrophages are of central importance in RA pathogenesis (Feldmann, et al, 
1996a). Whereas, in animal models, NO synthesis occurs predominantly in 
macrophages, the capacity for NO synthesis by human macrophages is currently 
controversial. This has raised doubts as to the origin of NO in human diseases in 
which macrophage activation is a central feature, such as RA. NO generation within 
inflammatory foci may differ between rodents and humans, and data from animal 
models therefore require cautious interpretation. However, several other cell types 
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normally found in RA synovium are capable of inducible NO production. Rodent 
synoviocytes (Stefanovic-Racic et al 1994b) and rodent and human neutrophils, 
chondrocytes, osteoblasts and mast cells (Stadler, et al, 1991; Charles, et aI, 1993; 
Stefanovic-Racic, et al, 1993; Bames & Liew, 1994; Ralston, et al, 1995) have been 
clearly shown to generate significant levels of NO in vitro. 
Evidence for NO production within human synovium has, until now, been indirect. 
Preliminary studies indicate that nitrite concentrations are higher in synovial fluid than 
in serum in RA patients (Parrell, et al, 1992). 3-nitrotyrosine is detectable in synovial 
fluid and serum from RA, but not from OA patients or normal donors (Kaur & 
Halliwell, 1994) and elevated urinary nitrate:creatinine ratios are found in active RA 
patients (Grabowski, et aI, 1996). These data, however, do not address either the 
precise tissue or cellular location of NO synthesis. In particular, the relative 
contribution of cartilage and synovial membrane remains unclear since direct NO 
production in vitro has not been reliably demonstrated from human synovial tissue. 
In this context, it was clearly important to establish whether human synovial 
membrane was indeed capable of significant NO production and thereafter, to 
detennine the cellular location of such synthesis, if present 
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s. 1 Assay for nitrite in biological fluids 
NO production was estimated by the concentration of its oxidative products nitrite and 
nitrate ions in culture supematants, serum and synovial fluid. Two methods were 
employed. 
(a) The Griess reaction was performed to detect nitrite in either fresh, or previously 
frozen (_20DC) culture supematants, with typical sensitivity of2 J,tM (Figure 5.1a). 
(b) The Griess reaction develops at acid pH raising the possibility of protein 
precipitation in test samples. Serum or synovial fluid nitrite levels were therefore 
measured by chemiluminescence, after reduction of nitrate to nitrite using nitrate 
reductase. A typical standard curve is shown in Figure 5.1 b, demonstrating 
sensitivity of 2 J,tM. 
S.2 Nitrate I nitrite in rheumatoid synovial fluid and serum 
Matched cell-free synovial fluid and serum samples were collected from 17 patients 
with RA and stored at -70DC prior to assay for nitrite I nitrate concentration using 
chemiluminescence. Figure 5.2a shows that the concentration of nitrite, representing 
total nitrite I nitrate concentration after enzymatic nitrate reduction, was not 
significantly different in paired RA serum or synovial fluid (Wilcoxon). The mean 
concentration of either was not different from total nitrite / nitrate levels measured in 
serum from 17 age and sex matched normal controls (Figure 5.2b; Mann-Whitney). 
Neither the Griess reaction, nor the chemiluminescence assay was sufficiently 
sensitive to detect nitrite concentration alone in serum or synovial fluid samples, 
without prior conversion of nitrate, and it was not therefore possible to confirm or 
refute the data of Farrell et al (1992). Moreover, patient samples were usually 
collected on routine outpatient visits, with no prior dietary modification, and it is 
therefore likely that the effect of dietary nitrate rendered the detection of measurable or 
significant differences improbable (Green, et al, 1982; Knight, et al, 1987). The 
150 
Figure 5.1 Standard curves for nitrite I nitrate estimation 
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(a) Standard curve derived from triplicate sodium nitrite dilutions in 
Dulbecco's MEM estimated by the Griess reaction as described in 
section 2.10.1. Calculation of sample nitrite concentration was as shown 
(dotted lines). 
(b) Standard curves derived from dilutions of sodium nitrite (0) and sodium 
nitrate (D) in Dulbecco's MEM estimated by chemiluminescence as 
described in section 2.10.2. 
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Total nitrate I nitrite levels were assayed using chemiluminescence (section 
2.10.2). 
(a) Paired synovial fluids and serums from 17 RA patients were compared 
for nitrate I nitrite levels. No significant difference between serum and 
synovial samples was observed (paired Hest). 
(b) Nitrate I nitrite levels were compared in serum from RA and age I sex 
matched controls (n=17). No difference between the group means was 
observed (Mann-Whitney). RA synovial fluid group mean is shown for 
comparison. 
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required low nitrate diet was investigated, but proved unpalatable, and was not 
pursued for ethical reasons. Moreover, Grabowski, et al (1996) subsequently 
developed a urinary nitrate:creatinine ratio for clinical follow-up, which clearly 
indicated that nitrate turnover was elevated in active RA, which obviated further 
investigation. 
5.3 Expression of iNOS mRNA in RA synovial membrane 
Inducible NOS expression in human synovium was determined first at the mRNA 
level. RT-PCR was performed using primers specific for human chondrocyte iNOS 
(Charles, et al, 1993). Preliminary experiments using snap-frozen leukocyte pellets 
from freshly isolated synovial fluid from 5 RA patients contained no iNOS mRNA, 
although satisfactory positive control amplification was observed from a plasmid 
containing human iNOS cDNA. RT-PCR was therefore performed, using the same 
primers, on 4 RA synovial membrane samples frozen immediately after surgical 
excision (Figure 5.3). In all 4 tissues, PCR generated the expected 500 bp product, 
consistent with that predicted from human chondrocyte iNOS. This product was 
sequenced by Dr X.Q. Wei (Dept. of Immunology, University of Glasgow) and 
found to be identical to human iNOS (Charles et al 1993), thereby confirming the 
specificity of the reaction. For control,l3-actin was amplified, as was cDNA prepared 
from OA synovial tissue. The latter also contained iNOS mRNA (Figure 5.3). Thus, 
iNOS expression was detectable at the mRNA level in both RA and OA synovial 
tissue. 
Figure 5.3 RT-PCR for iNOS in human synovial membrane 
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RT-PCR was performed to detect human iNOS mRNA expression in 
freshly isolated RA and OA synovial tissue samples. Lanes 1-4 -
representative RA patients, lane 5 - representative OA patient, lane 6 -
positive control (human iNOS cDNA), lane 7 - negative control (dH20 + 
reagents). Subsequent sequencing showed that the peR product was 
identical to human iNOS. ~-actin mRNA was amplified for control. 
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5.3 Nitric oxide production in RA synovial membrane 
The principal objective of this study was to obtain direct evidence for NO production 
by human synovial tissue. Primary heterogeneous cultures were therefore established 
from samples obtained at primary hip or knee arthroplasty. Synovial membranes 
were collected from 13 patients with RA (mean age 62 years [range 28-83], mean 
disease duration 14.7 years [range 5-22], 78% rheumatoid factor positivity) and 
single cell suspensions were cultured at 2x 1Q6 /ml before nitrite measurement using 
the Griess reaction. Spontaneous nitrite generation was measured in 9 of 13 RA 
culture supematants after 72 hours (Table 5.1). The level of nitrite production varied 
considerably (mean ± s.e.m. 9.6 ± 3.6 JlM [range 3.2 - 51]) presumably reflecting 
clinical and cellular heterogeneity. No obvious association with specific DMARD 
therapy, nor correlation with age, disease duration or serum acute phase response 
(ESR, CRP) was observed (Pearson's correlation coefficient). To confirm that 
bacterial contamination of the collagenase preparation was not responsible for 
'spontaneous' NOS expression, 4x106 /ml J774 cells were incubated with 5 mg/ml 
collagenase for 2 hours at 37°C, then cultured for a further 24 hours. Although 1774 
cells are capable of high output of NO, no nitrite production was detected under these 
conditions. These data demonstrate that NO production is a feature of RA synovial 
tissue and indicate that iNOS activity has been initiated in vivo. 
5.4 Induction of NO production in vitro in RA synovial membrane 
In contrast to the situation in rodents, the precise cytokine requirements for activation 
of iNOS in human pro-inflammatory cells remain unclear. The superantigen, 
staphylococcal enterotoxin B (SEB), induces T lymphocyte proliferation and cytokine 
secretion through interaction with the T cell receptor and can also up regulate 
mononuclear cell cytokine expression following MHC class IT binding (Marrack & 
Kappler, 1990; Trede, et aI, 1993). Moreover, SEB stimulates NO production by 
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Table 5.1 Production of nitric oxide by primary human synovial cultures 
Disease Features Nitric oxide production 
Patients Duration 
(yrs) 
DMARD U nstimulated SEBt 
nitrite (J.JM) 
RAl 14 H 9.3 (3.0) 33 (7)* 
RA2 20 M 13 (1.7) 34 (0.5) 
RA3 5 M+H+P 51 (2.7) 131 (6) 
RA4 13 G <2 6 (2.2) 
RA5 9 M 10.5 (1.3) 16.2 (0.5) 
RA6 19 A+P <2 11.7 (3.2)* 
RA7 22 S+P 10.1 (0.3) 32 (5.9) 
RA8 20 <2 <2 
RA9 15 D 10.4 (2) 8.8 (1.0)* 
RA 10 20 5.2 (1.2) 6.7 (2.8)* 
RA 11 10 3.2 (0.5) 44 (8) 
RA12 10 M 4.3 (0.5) 41 (3.9) 
RAt3 15 <2 19 (2.5) 
Production of nitrite (J.tM 1106 cells) by RA synovial cells in vitro. Values are mean 
of triplicate nitrite assay of each of triplicate cultures (s.d.) after 72 hours. SEB 
stimulated RA synovial tissues produce enhanced nitrite levels (p<O.Ol, Wilcoxon). 
tData shown are for optimal concentration of SEB (range 1-10 Jlg Iml) for each 
patient * 1 Jlglml LPS present in culture. 
Disease modifying anti-rheumatic drugs (DMARD): - G - IM sodium aurothiomalate; 
S - sulphasalazine; M - methotrexate; H - hydroxychloroquine; D - penicillamine; A -
azathioprine; P - prednisolone. 
156 
murine macrophages in the presence of T lymphocytes (Isobe & Nakashima, 1992). 
It was first necessary to clarify whether this effect was through direct iNOS 
activation, or through T cell activation and subsequent IFN-y production. 
Preliminary experiments were performed using J774 cells which showed that SEB 
addition alone did not induce NO production (Figure 5.4). However, SEB 
augmented the production of nitrite by IFN-y primed J774 cells in the absence of LPS 
(Figure 5.4). This finding established that SEB can act directly on appropriately 
primed target cells to induce NOS activity, presumably through MHC class 11 
binding. Since several synovial cell species express high levels of MHC class 11 
(Burmester, et al, 1987; Pitzalis, et al, 1987), the effect of SEB on NO production by 
RA primary synovial cultures was therefore investigated. 
SEB induced dose dependent production of nitrite in RA synovial cultures (Figure 
5.5a) which increased up to 72 hours, but not thereafter (Figure 5.5b). All patient 
samples were therefore compared for peak nitrite production at 1 or 10 Ilglml SEB 
after 72 hours. The addition of SEB induced novel or significantly increased nitrite 
production in 12 of 13 RA tissues examined (p<O.OI, Wilcoxon, Table 5.1). LPS 
(1 Ilglml) alone was less effective than SEB in inducing nitrite production (Figure 
5.5a, Table 5.2), indeed, addition of LPS (0.1-10 Ilg/ml) inhibited SEB-mediated 
enhancement in 7 of 7 RA patients studied (Figure 5.5b, Table 5.2; p<0.02). This 
may reflect the synthesis of inhibitory cytokines, such as IL-lO or TGF~. Production 
of nitrite in vitro was completely inhibited by addition of 1 mM L-NMMA. L-NMMA 
did not significantly reduce synovial cell viability by trypan blue exclusion - >80% at 
72 hours in presence or absence of 1mM L-NMMA. These observations demonstrate 
that enhancement of basal NO production through an L-arginine dependent pathway is 
possible within the inflamed human synovial membrane in RA patients. 
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Figure 5.4 SEB induces NO production by IFN-y stimulated 1774 cells 
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The production of NO by 1774 cells in response to SEB was investigated 
either alone (~), or in combination with 40 I.U.lml IFN-y (0). Triplicate 
culture supernatants were frozen after 24 hours and nitrite measured by 
Griess reaction. Representative of three similar experiments. Data are 
mean ± s.e.m. *p<0.OO5 comparing SEB + IFN-y with IFN-yalone. 
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Figure 5.5 Production of NO by RA synovial membrane cultures 
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(a) Dose response for SEB-induced nitrite production, with or without LPS, 
by heterogeneous synovial cells from representative patient RA12 
(**p<O.005 compared with basal levels). LPS addition reduced SEB· 
induced NO production (*p<O.05 compared with SEB alone). 0 SEB 
alone; 0 SEB + LPS 1 Jlglml 
(b) Time course of nitrite production by synovial tissue from RA 11. Parallel 
cultures were established and harvested at the time points indicated, and 
stored prior to simultaneous nitrite assay. Production with SEB was 
significantly greater than basal levels (p<O.OOl, Mann-Whitney) at all 
time points from 24 hours. Data are mean ± s.e.m., representing 4 similar 
experiments. 
o SEB IJlg/ml, 0 SEB IJlg/ml + LPS IJlg/ml, 
• SEB IJlg/ml + L-NMMA ImM, 6. LPS IJlg/ml 
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Table S.2 Effect of LPS on RA synovial membrane NO production 
Patient Unstimulated LPS1 SEBt SEB + LPS'" 
nitrite (@!) 
RA2 13 (1.7) 17 (2.3) 34 (0.5) 25 (l.4) 
RA3 51 (2.7) 87 (2) 131 (6) 111 (3.5) 
RA4 <2 3 (0.7) 6 (2.2) 3.1 (0.8) 
RA5 10.5 (1.3) 8.9 (1.8) 16.2 (0.5) 14.6 (1) 
RA7 10.1 (0.3) 21 (6) 32 (5.9) 28 (2.5) 
RA 11 3.2 (0.5) 6 (0.4) 46 (8) 41 (3.7) 
RA12 4.3 (0.5) 8 (1.4) 41 (3.9) 34 (2.9) 
Production of NO ijJ.M 1106 cells) by RA synovial cells in vitro. Values are mean 
of triplicate nitrite assay of each of triplicate cultures (s.d.) after 72 hours. '1LPS 
(1 J.1g/ml) alone induced significantly less nitrite production than SEB alone 
(p<O.04, Wilcoxon). "'LPS also significantly inhibited SEB enhanced nitrite 
levels (p<0.02, Wilcoxon). tOata shown are for optimal concentration of SEB 
(range 1-10 Jlg Iml) for each patient 
160 
5.5 Cross-reacting antibodies against iNOS in synovial membrane 
Initial efforts to localise iNOS in human synovial tissues employed cross-reacting 
antibodies developed against rodent iNOS, raising the possibility of target non-
specificity or of cross-reactivity with other NOS isoforms, or with P450 reductase 
enzymes (Bredt & Snyder, 1994). The antibodies used and ICC conditions are 
detailed in table 2.1. Both monoclonal and polyclonal anti-murine iNOS antibodies 
exhibited extensive synovial lining layer and blood vessel staining (Figure 5.6a). 
Non-specific nuclear cross-reactivity was observed with the rabbit polyclonal anti-
murine iNOS from Affiniti (Figure 5.6b). Similarly, rabbit (h13) and sheep anti-
human iNOS products (both Wellcome) exhibited widespread lining layer staining. 
However, since none of the staining patterns observed was neutralised by prior 
incubation with 50 Ilglml human recombinant iNOS (riNOS) protein, and because no 
consistent staining pattern emerged, considerable doubt remained as to the specificity 
of the available reagents. 
5.6 Tissue localisation of iNOS in RA synovial membrane 
To resolve such concern, a rabbit antiserum raised specifically against the C-terminal 
heptamer peptide (YRASLEMSAL) of human iNOS was obtained (N053; Nicholson, 
et al, 1996). This sequence is not present on either eNOS or cNOS, nor on rodent 
iNOS. This antiserum detected human iNOS in ELISA at a dilution of 1 :400,000 
(personal communication Dr. H.R. Williams, Merck Research Laboratories, NI, 
USA) and recognised neither human eNOS nor the C-terminal of rodent iNOS by 
ELlSA. Preliminary antibody concentration-range studies were performed which 
established positive staining of human RA synovial tissue down to 1 :40,000 serum 
dilution, although I :20,000 dilution gave optimal tissue localisation and was used 
subsequently. 
a 
b 
Figure 5.6 Anti-rodent iNOS antibodies bind non-specifically in human 
RA synovial membrane 
RA synovial sections were stained with (a) polyclonal anti-murine 
iNOS (Wellcome) and localised with fast red. Extensive lining layer 
staining was detected which could not be neutralised by prior 
incubation with human iNOS (50 )lg/ml). (b) Nuclear cross-reactivity 
was evident following staining with anti-murine iNOS (Affiniti) 
localised with lissamine rhodamine. 
(Magnification x 250). 
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Light microscopy with this antibody demonstrated intra-cytoplasmic staining in cells 
both within, and deep to, the synovial lining layer (Figure 5.7a). The lining layer 
contained significantly greater numbers of iNOS+ cells than interstitial or lymphocytic 
aggregate areas (Table 5.3, p<O.Ol, Mann Whitney). The frequency of positive cells 
for each area varied considerably between different patients, as predicted by the 
heterogeneity of spontaneous nitrite production in primary culture (Table 5.1), and 
within individual tissues. Staining revealed cells in discrete groups, rather than 
spread diffusely through the tissue, as had been a feature of staining with antibodies 
raised against rodent iNOS. Staining for iNOS was abolished by prior addition of the 
immunising human iNOS peptide (N054; Figure 5.7b), but remained unchanged after 
pre-incubation with a peptide from a similar region of rodent iNOS (YEEPKATRL) 
Table S.3 Histological distribution of iNOS in RA synovial membrane. 
n=number fields 
meant s.d. 
(range) 
% cells iNOS positive 
Lining layer 
n=36 
19 ± 13.1 * 
(2-56) 
Interstitium 
n=24 
5 ±5.6 
(0-20) 
Aggregate 
n=31 
7 ±7.8 
(0-37) 
Synovial sections from 10 RA patients stained with anti-human iNOS antiserum 
were assessed by two histologists counting at least 500 cells in at least 3 high 
power fields per section area (magnification x400). Data are mean ± s.d. (range) 
for total number of fields counted. iNOS expression is greater in lining layer 
compared to either aggregate or interstitial areas (* p<O.OOl). Percent of iNOS 
positive cells is expressed as - [(positive cells)/(total number cells in field)] x 100 
Figure 5.7 Immunohistochemical localisation of iNOS in human RA 
synovial membrane 
a 
c 
RA synovial tissue section showing 
lining layer and adjacent interstitium 
stained with rabbit anti-human iNOS 
antiserum (fast red). Ca) anti-iNOS 
serum alone, Cb) anti-iNOS serum 
after pre-incubation with human 
iNOS peptide, (c) anti-iNOS serum 
after pre-incubation with rodent 
iNOS peptide. Staining after pre-
incubation with recombinant human 
eNOS was identical to Cc) . 
(Magnification x300) 
Figure 5.8 iNOS expression in endothelial cells in RA synovial membrane 
RA synovial membrane was stained with anti-human iNOS antiserum and 
localised with fast red. (a & b) Endothelial cells were localised by morphology. 
(c) Prior incubation of section b with recombinant human iNOS neutralised the 
observed staining. In contrast recombinant human eNOS was ineffective in 
neutralising experiments (appearances similar to [b]) 
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or recombinant human eNDS (Figure 5.7c), demonstrating that the pattern of staining 
was specific for human iNOS. iNOS positive smooth muscle and endothelial cells 
were also identified around blood vessels in 8 of 10 RA tissues examined (Figure 
5.8a). As before, this was neutralised by prior incubation with human iNOS peptide, 
but not with human eNDS (Figure 5.8b) indicating that iNOS up regulation is also a 
feature of activated synovial endothelial cells in RA. 
5.7 Cellular localisation of iNOS expression 
The degree of lining layer staining with anti-human iNDS antibody implied that iNOS 
was potentially present in both macrophages and fibroblast-like synoviocytes. It was 
therefore important to establish which of these was the major source of inducible NO 
production in RA. To address this question, double staining for iNOS was 
performed with the macrophage markers, non-specific esterase (NSE) and murine 
monoclonal anti-CD68 by light microscopy and confocal microscopy respectively. 
Double staining with NSE and anti-iNDS (Figure 5.9) revealed that the majority of 
iNOS positive cells either in the lining layer, or the interstitium, were NSE negative 
(mean ± s.e.m, 89 ± 5%) and therefore, unlikely to be macrophages (Table 5.4). 
Only 5% of synovial cells were NSE+ I iNOS+. These data were confirmed using 
confocal microscopy. Figure 5. lOa demonstrates that most iNOS positive cells were 
not double-labelled with anti-CD68, although co-staining of anti-iNOS and CD68 in 
lining layer cells was occasionally observed (Figure 5.lOb), indicating that some 
macrophages were capable of iNOS expression. Together these data showed that the 
majority of NSE+ and CD68+ cells in the lining layer were iNOS negative, indicating 
that most macrophages were not directly involved in NO production (Figure 5.10a, 
Table 5.4). In vitro, T cells do not normally synthesise NO and consistent with this, 
synovial T cells detected with murine anti-CD3 were all iNOS- (Figure 5.lOc). 
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Because murine anti-CD3 monoclonal shares isotype and species origin with anti-
CD68 antibody, this finding serves as an additional specificity control for the positive 
double staining observed with anti-iNOS and anti-CD68. 
Table 5.4 Co-localisation of iNOS with NSE in RA synovial membrane. 
phenotype 
mean±s.d 
(range) 
% positive cells 
NSE+/iNOS-
49±24 
(0-80) 
NSE-/iNOS+ 
45±23 
(16-93) 
NSE+ liNOS+ 
5 ± 3.1 
(0-12.5) 
Sections from 4 RA patients were double stained with anti-human iNOS 
antiserum and non-specific esterase (NSE). At least 250 lining layer and 
adjacent interstitial area cells positive for NSE and I or iNOS were counted per 
section and the number of NSE+, iNOS+, or double positive cells were 
expressed as a % of the total number of cells counted. 
Figure 5.9 Co-localisation of non-specific esterase and iNOS in 
RA synovial membrane 
RA synovial sections were stained with anti-human iNOS antiserum, 
localised with fast blue, then with NSE (brown). No nucl ar 
counterstain was used. The majority of iNOS+ cells were NSE-, 
although occasional double labelled cells were observed (arrow). 
(Magnification x200) 
Figure 5.10 Con-focal microscopic localisation of iNOS in RA synovial membrane 
Confocal images of RA synovial 
frozen tissue sections stained with 
anti-human iNOS (red), in 
combination with Ca) anti-CD68 
(green) showing that most iNOS 
positive cells are CD68 - [x250] (b) 
anti-CD68 showing that CD68 + 
iNOS+ cells are present (double 
stain represented as yellow [x500]) 
or (c) anti-CD3 (green) showing that 
T lymphocytes are iNOS- [x400]. 
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S.8 NO production in OA synovial tissue 
In order to test whether NO synthesis was a specific property of inflammatory 
arthritides, NO production in OA synovial tissues was investigated. RT-PCR had 
earlier demonstrated the presence of iNOS mRNA in an OA synovial membrane 
indicating that increased NO production might be a feature of OA (Figure 5.3). 
Single cell suspensions from 7 OA synovial membranes were therefore cultured for 
72 hours and nitrite generation measured. Spontaneous nitrite production was 
measured in 5 of 7 tissues examined. with mean concentration produced of 19 ± 9 
JlM (Table 5.5 & Figure 5.11). As with RA synovial membrane, addition of SEB (1-
10 J.lglml) lead to novel or significantly increased levels of nitrite production in 7 of 7 
patients in vitro (Table 5.6, p<O.05, Wilcoxon). No significant difference in either 
spontaneous or induced NO production was observed between the group means of 
RA and OA patient samples. The remarkable level of NO generated in the absence of 
exogenous stimuli in patient sample OA8 provoked clinical reassessment from which 
emerged a history of congenital hip disease, with a possible seronegative 
inflammatory arthritis. These data were therefore excluded from statistical analysis. 
The distribution of iNOS in OA synovial membrane was investigated by 
immunohistochemistry, using rabbit anti-human iNOS antiserum (N053) as 
described. iNOS expression was detected mostly in lining layer, with occasional 
interstitial cell staining (Table 5.6). Taken together, these data provide direct evidence 
that iNOS expression and NO production is a feature of OA synovial membrane. 
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Table 5.5 Production of nitric oxide by primary human synovial cultures 
Disease Features Nitric oxide production 
Patients Duration Unstimulated SEBt (yr) 
nitrite (pM) 
OAl 10 15 (0.5) 32 (3.6) 
OA2 7 <2 3.3 (1.0)'" 
OA3 5 <2 3.2 (1.0)'" 
OA4 10 22 (2.5) 57 (8) 
OAS 5 10 (3.3) 24 (3) 
OA6 7 6 (2) 19 (4) 
OA7 8 76 (9) 112 (8) 
OA8 3 128 (26) 98 (8) 
Production of NO (J,JM 1106 cells) by OA synovial cells in vitro. Values are mean 
of triplicate nitrite assay of each of triplicate cultures (s.d.) at 72 hours. SEB 
stimulated OA synovial tissues produce enhanced nitrite levels (p<0.02, 
Wi1coxon). tData shown are for optimal concentration of SEB (range 1-10 ~g 
fml) for each patient. '" 1 ~g/ml LPS present in culture. Patients were all 
receiving non-steroidal anti-inflammatory drugs. 
Figure 5.11 Production of NO by OA synovial membrane culture 
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Dose response for SEB-induced nitrite production, with or without 
LPS, by heterogeneous synovial cells from a representative patient, 
OA06. NO production with SEB was significantly greater than basal 
levels, or with added LPS (*p<O.OOI, Mann-Whitney). Data are mean 
± s.e.m., representing 3 similar experiments. 
o SEB, 0 LPS (11Jg/ml) 
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Table 5.6 Immunohistochemical distribution of iNOS in OA synovial membrane 
n=number fields 
mean ± s.d. 
(range) 
% cells iNOS positive 
Lining layer 
n=28 
11±13 
(0 - 53) 
Interstitium 
n=25 
3 ± 3.5 
(0 - 15) 
Synovial sections from 10 OA patients stained with anti-human iNOS antiserum 
were assessed by two histologists counting at least 500 cells in at least 2 high 
power fields per section area (magnification x4(0). Data are mean ± s.d. (range) 
for total number of fields counted. iNOS expression is greater in lining layer 
compared to interstitial areas (*p<0.006, Mann-Whitney). Percent of iNOS 
positive cells is expressed as - [(positive cells)/(total number cells in field)] x 100 
5.9 Do similar culture conditions induce human monocytes to 
produce NO? 
173 
The ability of human macrophages to produce NO is currently controversial 
(Schneemann, et al, 1993; Dugas, et aI, 1995). Light and con-focal microscopic data 
presented here indicate that human macrophages activated in a chronic inflammatory 
environment can indeed express iNOS, although in the context of RA, they may be of 
secondary importance in quantitative terms. Nevertheless, the enhancement of NO 
production by SEB in both human synovial cultures and 1774 cells raised the 
possibility that this agent might up regulate iNOS expression in human monocytes. 
THP-l cells, U937 cells, or unfractionated PBMC and purified blood monocytes 
(>90% CDI4+, <3% CD3+, <3% CDI9+ by FACS analysis) from 4 normal donors 
and 4 RA patients were cultured between 106 / ml and 4x 106 / ml for 1, 3, 5 and 7 
days with various doses and combinations of SEB (1 - 200 J.1g/ml) and LPS (0.01 - 1 
J.1g1ml) with or without prior maturation for 24 hours with 10 nM PMA. In some 
experiments, reagents were added to culture wells 24 hours after cell seeding to wells 
and in others, the concentration of FCS was reduced to 0.1 %. No combination of 
reagents or in vitro conditions was capable of consistent NO production measured by 
the Griess reaction (sensitivity of 2 J.1M). 
5.10 NO dependent regulation of TNFa production. 
Since TNFa production constitutes an important pro-inflammatory pathway in RA 
pathogenesis, it was of interest to determine whether NO might regulate its production 
in RA synovium. Synovial tissues or fluids were collected and adherent single cell 
suspensions prepared (>75% CD68+, <5% CD3+, <2% CD19+, by cytoprep 
analysis). These were cultured at 2 x106 /ml in the presence of graded concentrations 
of the NO donor, S-nitroso-N-acetylpenicillanline (SNAP), and the levels ofTNFa in 
the culture supematant determined 48 hours later by ELISA. Cells cultured with 
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medium alone produced low concentrations of TNFa.. This was markedly enhanced 
by the presence of SNAP in a dose-dependent manner (Figure 5.12a). In parallel 
experiments, SNAP also increased the production of TNFa. by the macrophage cell 
line U937 which had been primed by prior culture in 1 nM PMA for 24 hours (Figure 
5.12b). The analogue N-acetylpenicillamine (NAP) which does not release NO, 
induced no TNFa synthesis. Neither SNAP, nor NAP, contained detectable LPS, 
using the Limulus amoebocyte assay (<0.0015 I.U./mM stock solution). 
Figure 5.12 Nitric oxide enhances TNFa synthesis in vitro 
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TNFa production (mean ± s.e.m.) to SNAP by (a) adherent cells from 
RA synovial fluid (SFAC) (0, n=4) or RA synovial tissue (0, n=2) or 
(b) PMA matured U937 cells (L\ SNAP, • NAP; representative of 3 
similar experiments). NAP did not induce TNFa production from 
SFAC (n=3). 2 mM SNAP contained <0.0015 I.U. LPS by limulus 
amebocyte lysis assay. Data are mean ± s.e.m. 
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Discussion 
These observations provide direct evidence for NO production by human synovial 
membrane. In contrast to reports in animal experimental systems, in which cartilage 
was the predominant source of NO (Murrell, et aI, 1996), synovial tissue appears 
capable of significant NO generation in human inflammatory arthritis. Evidence from 
in vivo model systems suggests that such NO synthesis is likely to have pathological 
significance. 
The current data constitute a detailed ex vivo study of the cellular origin of NO 
production in RA synovial membrane. As such they significantly extend previous 
reports which provided largely indirect evidence for NO production in RA. Synovial 
fluid nitrite levels are reported to exceed those in serum in RA (Farrell, et aI, 1992; 
Veki, et aI, 1996). This observation was not confirmed in the present study because 
the sensitivity of the chemiluminescence method for nitrite estimation employed here 
was inadequate to detect isolated elevation of nitrite in the presence of normal daily 
nitrate intake (Knight, et aI, 1987). Moreover, Renoux, et al, (1995) recently 
detected higher levels of nitrite in OA synovial fluid than in RA. Dietary influences 
and possible variations in sample acquisition or methodology for nitrite estimation 
therefore cast doubt on the validity of nitrite as an index of NO production in RA. 
However, the fasting urinary nitrate:creatinine ratio, which avoids dietary effects, is 
increased in active RA (Grabowski, et aI, 1996) and elevation of urinary nitrite 
excretion is reduced by prednisolone therapy (Stichtenoth. et al. 1995). 3-
nitrotyrosine levels detected by electron-spin trapping are also elevated in RA synovial 
fluid (Kaur & Halliwell, 1994). These data indicate that articular tissues are a likely 
source of NO. The present study showed clearly. that the synovial membrane itself 
can contribute Significantly to NO production during inflammatory arthritis, in 
combination with cartilage and bone derived cells. 
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Several recent reports have addressed the articular source of NO production. 
Whereas bovine or human chondrocyte cultures produced high levels of NO induced 
by cytokines, including IL-l~ and TNFa, parallel cultures of synovial fibroblasts 
made only minimal levels of NO (Rediske, et aI, 1994; Murrell, et aI, 1996). In 
contrast, comparing NO production by human chondrocytes, osteoblasts and synovial 
fibroblasts, Ralston et al (1996) confirmed chondrocyte production of NO, but 
showed in vitro and using RT-PCR, that NO was produced by passaged synovial 
fibroblasts, after stimulation with IL-I~, TNFa and IFN-y. However, unstimulated 
synovial fibroblasts and synovial fluid-derived leucocytes were iNOS- by RT-PCR. 
Nitrite production by human RA synovial explant cultures and preliminary evidence 
for enhanced NO production by IL-I~, TNFa and LPS has also been reported which 
correlated with levels of CD14 expression (Sakurai et alI995). However, synovial 
fibroblasts in the latter study did not synthesise NO even after activation by cytokine 
combinations. Data presented here clearly establish that primary heterogeneous RA 
synovial cultures spontaneously generate NO. That such production was induced by 
bacterial product contamination during the enzymatic tissue digestion process seems . 
unlikely, since iNOS expression was detectable by RT-PCR and immunohisto-
chemistry in freshly isolated tissue. Moreover, 1774 cells were resistant to NOS 
induction by a similar incubation protocol. These data indicate that NO production is 
upregulated in vivo, and as such constitutes a component of the inflammatory 
response in RA synovial membrane. 
Immunohistochemical localisation of iNOS indicated that synovial fibroblasts 
constitute the predominant source of NO in vivo, with lesser contributions from 
macrophages and endothelial cells. The anti-iNOS antibody employed here also 
detects iNOS in alveolar macrophages in pulmonary tuberculosis patients (Nicholson 
et al1996) and in asthmatic alveolar macrophages (Leung, B.P. & McInnes, LB. 
unpublished observations). Neutralisation studies confirmed that it did not cross-
react with either rodent iNOS or human eN~S. The iNOS staining pattern observed 
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contrasts with that reported using antibody raised against murine iNOS, which 
suggested more extensive iNOS expression, found mainly in CDI4+ synovial 
macrophages (Sakurai, et aI, 1995). This discrepancy may relate to the use of anti-
rodent iNOS antibodies with attendant problems of cross-reactivity or non-specificity 
clearly documented in the current study. 
There is currently considerable controversy as to the capacity of human macrophages 
to produce NO (e.g. Denis, 1991; Schneemann, et al, 1993; Zembala, et al, 1994; 
Dugas, et al, 1995). The in vitro culture conditions optimal for the induction of iNOS 
in murine macrophages are apparently distinct from those required for the induction of 
iNOS in human macrophages. While macrophage cell lines (1774 or RAW) or 
thioglycollate stimulated peritoneal macrophages are used in most rodent systems, 
peripheral blood mononuclear cells are usually employed in human monocyte 
Imacrophage experiments perhaps representing a different maturation stage. 
However, even in reports where the production of NO by human monocyte 
Imacrophages was detectable (Zembala, et al, 1994; Dugas, et al, 1995), the levels are 
an order of magnitude lower than those produced by murine macrophages. This 
implies that cellular delegation of specific functions may differ between species in 
inflammatory lesions. Results from the present study show clearly that, although in 
the minority, some synovial macrophages from RA patients can indeed express high 
levels of iNOS. The latter observation was based not only on the presence of CD68+ 
I iNOS+ cells, since CD68 expression in synoviocytes in the interstitium has been 
reported (Wilkinson, et aI, 1992), but also on the identification of NSE+ I iNOS+ 
cells on light microscopy. The reason why only a limited number of macrophages is 
activated to produce NO in RA is at present unclear. 
There is, however, little doubt that RA synovial macrophages are activated, as 
demonstrated by the production of pro-inflammatory cytokines, such as IL-l, TNFa, 
IL-6 (Feldmann, et al, 1996b). Evidence from clinical intervention studies using 
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monoclonal anti-TNFa. therapy have suggested that such cytokine generation is 
critical in ongoing synovitis (Elliott, et al, 1994; Rankin, et al, 1995). The factors 
responsible for TNFa. upregulation remain unclear. Data reported here show clearly 
that, in contrast to their central position in cytokine production, synovial macrophages 
may express iNOS, but are not likely to be the principle producers of NO. In the 
context of inflammatory arthritis, this property appears to lie within the fibroblast 
compartment. Therefore, a reciprocal role for NO may exist whereby NO produced 
by synovial fibroblasts enhances pro-inflammatory cytokine production by 
macrophages, which in turn may up regulate iNOS expression, thereby generating a 
positive feedback loop. Certainly, TNFa. is a recognised inducer of iNOS expression 
in animal systems (Nathan & Xie, 1994b; Liew, 1994). Further experiments 
examining the effect of NOS inhibitors on spontaneous cytokine production in vitro 
by synovial membrane cultures will help to address this possibility. 
NO is likely to influence other immunoregulatory pathways in RA synovitis. The 
levels of NO spontaneously generated in synovial cultures are sufficient to inhibit T 
cell proliferation (Fu & Blankenhorn, 1992; Merryman, et aI, 1993) and may 
therefore contribute to the 'frustrated activation' phenotype characteristic of synovial 
T lymphocytes (Pitzalis, et aI, 1987). LPS-stimulation-dependent generation of 
angiogenic activity by human macrophages requires an L-arginine-dependent NO-
synthase effector mechanism that may be independent of the generation of TNFa. and 
IL-8 (Leibovich, et al, 1994), indicating that NO may contribute to neovascularisation 
in RA synovial membrane. Moreover, NO can up regulate production of 
metalloproteinases (Murrell, et aI, 1995) and of prostaglandins (Manfield, et aI, 
1996), and has been implicated in IL-l~-mediated inhibition of proteoglycan 
biosynthesis (Hauselmann, et aI, 1994; Jarvinen, et al, 1995; Fukuda, et al, 1995), 
implying a pro-inflammatory effect. However, an acute chondroprotective role has 
recently been proposed for endogenous NO in bovine cartilage (Stefanovic-Racic, et 
al, 1996). Thus, in contrast to the situation in rodent arthritis models, in which NO is 
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usually detrimental (Ialenti, et aI, 1993; McCartney-Francis, et al, 1994), the net 
effect of NO generation in the human situation remains unclear. 
It was not clear whether SEB-induced NO production was mediated through direct 
effects on MHC class 11+ synoviocytes I macrophages, or rather through 'surrogate' 
cytokine production by T lymphocytes activated by V~ region I TCR binding 
(Marrack & Kappler, 1990). The induction of NOS activity by SEB in IFN-r primed 
1774 cells indicated that a direct effect on macrophages was possible in the presence 
of adequate co-stimuli. The presence of the latter would, in any case, reflect 
concomitant T cell activation in vivo and in the context of heterogeneous RA synovial 
cultures, a combination of mechanisms seems likely. Further investigation of highly 
purified subsets of synovial cells will be required to address this question. 
Nevertheless, the ability of SEB to induce NO production in OA tissues. in which 
fewer T lymphocytes were present, perhaps indicates that a direct effect does exist. 
The addition of LPS alone induced low levels only of NO synthesis. and addition 
with SEB did not further increase SEB-induced NO production. but rather led to 
inhibition. This may reflect the generation of inhibitory cytokines, such as IL-IO, 
from CDI4+ synovial macrophages. However, SEB. with or without LPS, was 
unable to induce NO production by peripheral blood monocytes. even after prior 
maturation with IFN-y or PMA. or the presence of SEB-responsive PB lymphocytes. 
These data indicate that the complex signals priming macrophages within an 
inflammatory site are not as easily mimicked in the human, as in the rodent situation. 
The apparently contradictory evidence which exists regarding NO production by 
synovial fibroblasts can be resolved by the current study. Previous discrepancies 
may reflect various stages of fibroblast differentiation in vitro, cell passage used, or 
the culture conditions to confluence employed by different groups (Rediske, et aI, 
1994; Ralston, ct aI, 1996; Murrell, et aI, 1996). By providing immunohistochemical 
evidence for fibroblast iNOS expression, the difficulties attached to interpretation of 
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in vitro data can be avoided. Thus, NO synthesis can be added to the list of 
synoviocyte bioactivities which includes, MMP production, cytokine generation and 
PG synthesis. This provides further evidence indicating a crucial role for fibroblasts 
in RA pathogenesis (reviewed by Zvaifler & Firestein, 1995). 
It is of interest also that both RA and OA patient synovia were capable of NO 
generation. OA synovial tissues contain areas of inflammatory infiltrate, with 
macrophages present, particularly in the lining layer, and low levels of monokines 
detectable, including IL-l~ and TNFa (Gordon, et aI, 1984; Brennan, et aI, 1989; 
Brennan, et al, 1991). High levels of NO production have been detected in OA 
chondrocytes (Amin, et aI, 1995) and indeed, higher levels of nitrite have been 
reported in OA than in RA synovial fluid (Renoux, et aI, 1995). The clinical OA 
syndrome, however, is not considered to be of primarily inflammatory origin. NO 
production is therefore unlikely to be a property of the inflammatory arthritides alone. 
but may reflect a non-specific response to injury or inflammation with potential 
protective or pathological consequences. In particular. given its extensive 
microbicidal activities, the role of NO in synovial defence against infection merits 
consideration. This may have important therapeutic consequences when specific 
iNOS inhibitors come to clinical trial. 
In summary, these results demonstrate directly the production, and further induction, 
of NO by synovial cultures from RA and OA tissue and provide evidence of iNOS 
expression in synovial inflammatory cells. These in vitro and immunohistochemical 
data significantly extend the previous reports of NO production in synovial 
membrane, by clarifying its cellular origin and confirming that the production of NO 
may be inducible in vitro. 
Chapter 6 
Staphylococcus aureus arthritis in mice lacking 
inducible nitric oxide synthase. 
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Introduction 
High concentrations of NO are generated by inducible NOS (iNOS) regulated by pro-
inflammatory cytokines, particularly TNFa, IL-l~ and IFN-y and by bacterial 
components, including lipopolysaccharide (LPS) and staphylococcal enterotoxins 
(Isobe & Nakashima, 1992; Bredt & Snyder, 1994; Nathan & Xie, 1994a). iNOS 
activity constitutes the predominant source of NO in inflammatory lesions. Several 
observations implicate NO in articular inflammation. NOS inhibitors retard or 
abrogate streptococcal cell wall and adjuvant-induced arthritis in rats indicating that, in 
rodents at least, NO synthesis is required for autoimmune joint destruction (Ialenti, et 
al, 1993; MacCartney-Francis, et al, 1994; Stefanovic-Racic, et al' 1994). Elevated 
synovial fluid nitrite levels and urinary nitrite excretion provide indirect evidence for 
NO synthesis in humans in RA (Farrell, et aI, 1992; Grabowski, et aI, 1996). 
Furthermore, data presented in chapter 5 clearly demonstrate NO production by 
fibroblasts and macrophages in the synovial membrane of RA patients (Mclnnes, et 
al, 1996b), which can be further enhanced in vitro by addition of staphylococcal 
enterotoxin B (SEB). 
The net effect in vivo of NO synthesis in human synovial membrane, however, is 
subject to considerable controversy. NO induces matrix metalloproteinase 
production, cyclooxygenase activation and can enhance synovial macrophage derived 
TNFa synthesis (Murrell, et al, 1995; Manfield, et al. 1996). It also promotes 
macrophage driven neovascularisation and has been implicated in IL-I ~ mediated 
inhibition of proteoglycan biosynthesis and thus, cartilage degradation (Lcibovich, et 
al, 1994; Hauselmann, et aI, 1994; Jarvinen, et aI, 1995; Fukuda, et al, 1995). In 
contrast, an acute chondro-protective role for NO has recently been proposed 
(Stefanovic-Racic, et al, 1996) and immunomodulatory effects on T cell activation 
may partially account for the 'frustrated activation' exhibited by T cells in RA 
inflammatory synovium (Pitzalis, et aI, 1987). Thus, in inflammatory arthritis, NO 
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may exhibit bi-potential properties. However, high levels of NO production can also 
be demonstrated in joints of patients with OA (chapter 5; Amin, et al, 1995; Renoux, 
et al, 1995). NO synthesis in the synovial membrane most likely represents a non-
specific response to diverse challenges. In evolutionary terms, the principle role for 
NO in immunity appears to be microbicidal, with immunomodulatory effects designed 
to assist in regulation of anti-microbial cellular and cytokine responses. This raises 
the possibility that NO production may be important in synovial defence against 
infection. This is of particular importance if iNOS inhibitors are to provide effective 
novel anti-inflammatory therapies. 
Septic arthritis commonly results from gram positive bacterial infection, particularly 
by Staphylococcus aureus (Rosenthal, et aI, 1980; Goldenberg & Reed, 1985; 
Goldenberg, 1989; Ostensson & Geborek, 1991). Whereas NO has been clearly 
shown to mediate cytotoxicity against intracellular pathogens, including protozoa, 
viruses and fungi (Nathan & Xie, 1994b), its role in killing extra cellular bacterial is 
poorly defined. Reactive nitrogen intermediates (RN!) have been implicated in 
staphylococcal killing after neutrophil phagocytosis (Malawista, et al, 1992). In a cell 
free system, NO exerted delayed bactericidal activity, but in contrast to the action of 
reactive oxygen intermediates (RO!), exerted no immediate killing effect (Kaplan, et 
al, 1996). 
Septic arthritis can be induced by intravenous inoculation of mice with exo-toxin 
producing Staphylococcus aureus (Bremmell, et aI, 1991; Bremmell, et aI, 1992). 
The resulting articular lesion exhibits synovial hyperplasia, containing neutrophils, 
macrophages and a prominent T lymphocyte infiltrate, with associated erosion of 
underlying cartilage and bone (Bremmell, et aI, 1992; Abdelnour, et al, 1994a). T 
cell activation by bacterial superantigens leads to high levels of cytokine production, 
particularly IFN-y and TNF~ (Abdelnour, et aI, 1994b). The course of 
staphylococcal infection in IFN-y receptor knockout and T cell receptor transgenic 
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mice indicates that such Thl bias is pro-inflammatory (Zhao, et al, 1995a; Zhao & 
Tarkowski, 1995b) and inhibition of T cell activity using anti-CD4 or anti-V~11 
antibodies can significantly improve disease outcome (Abdelnour, et aI, 1994b). 
These data indicate that immunological mechanisms constitute a major component of 
the observed articular pathology. Direct injection of bacterial superantigens, such as 
toxic shock syndrome toxin (TSST)-1 or SEB, leads to T cell mediated shock. In 
these circumstances, NO production is protective to the host (Florquin, et al, 1994). 
In contrast, the staphylococcal cell wall components, peptidoglycan and lipoteichoic 
acid, synergistically induce multiple organ failure in rats by an NO-dependent 
mechanism (De Kimpe, et al, 1995a; De Kimpe, et aI, 1995b). The precise role of 
NO in gram-positive infectious arthritis and septicaemia is therefore currently unclear. 
Wei, et al (1995) recently generated an iNOS gene targeted mouse, which facilitates 
investigation of the contribution of iNOS to inflammatory conditions in the context of 
normal constitutive eNOS and nNDS activity. This provides an ideal model in which 
to study the contribution of NO synthesis in vivo to both acute Staphylococcus aureus 
infection and its T cell-dependent pathological sequelae. By this means the relative 
contribution of microbicidal and immunomodulatory effects of NO in systemic and 
articular inflammation may be investigated. 
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6. 1 Incidence and severity of staphylococcal septicaemia 
Although NO production has been firmly implicated in gram negative endotoxin-
induced shock, its role in gram positive bacterial sepsis is less clear. Septicaemia is 
uncommon in wild-type Swiss mice following Staphylococcus aureus infection 
(Bremmell, et aI, 1992). Initial experiments were thus performed to assess whether 
iNOS deficiency altered this normally resistant phenotype. Preliminary dose-ranging 
studies established that injection of 5x107 CPU staphylococci Imouse led to onset of 
arthritis, but only rarely induced septicaemia in wild-type mice. In three separate 
experiments, iNOS deficient homozygous (iNOS-I-; n=33), heterozygous (iNOS+I-; 
n=28) or wild type (iNOS+I+; n=20) mice therefore received 5x107 CFU/ml of 
Staphylococcus aureus LS-l strain by intravenous injection. 65% of iNOS-I-
compared with 14% of iNOS+I- mice developed clinical evidence of sepsis within 48 
hours, rising to 83% compared with 20% respectively after 4 days (p<0.OO5, Chi 
Square; Figure 6. la). Disease severity in animals developing sepsis was significantly 
greater in iNOS-I- than iNOS+I- mice during the acute phase of disease up to day 6 
(p<O.OOI to p<0.04, Mann-Whitney; Figure 6.1b). These observations were 
reflected in significantly greater weight loss in iNOS-I- mice compared with either 
infected iNOS+I- or iNOS+I+ controls (p<O.OI, Mann-Whitney; Figure 6.2a), or 
with uninfected iNOS-I- littermates (Figure 6.2b). Increased mortality was observed 
in iNOS-I- mice, which reached 30% after 8 days (p<0.OO5 to p<O.03 compared with 
iNOS+I- or iNOS+I+ mice, Log-rank; Figure 6.3). These data demonstrate that 
deficient iNOS expression is associated with increased incidence and severity of 
septiCaemia and implicate NO in vivo in host defence to Staphylococcus aureus 
infection. 
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iNOS-I- mice developed higher incidence of septicaemia of greater 
severity than iNOS+I- or iNOS+I+ littermates. iNOS-I- (0; n=33), 
iNOS+I- (A; n=28) or iNOS+I+ (0; n=20) mice received 5x107 CFU 
staphylococcus aureus i. v. The (a) presence and (b) severity of 
septicaemia were assessed daily by group-blinded observers. Incidence 
was higher from day 2 in iNOS-I- mice than in either control group 
(p<O.OO5, Chi-Square). Severity of septicaemic mice only in either 
group was compared and was greatest in iNOS-I- mice ("'p<O.02, 
**p<O.OOI, ***p<O.04). Data are pooled from three separate 
experiments. 
Figure 6.2 Weight change after staphylococcal infection 
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(a) Mice were weighed daily after Lv. infection with staphylococcus 
aureus and mean ± s.e.m. change in weight was calculated from 
baseline. iNOS-I- mice (0; n=33) lost more weight than iNOS+I-
(A; n=28) or iNOS+I+ (0; n=20) controls ("'p<O.OI, Mann-
Whitney). 
(b) Weight gain in uninfected controls (filled symbols) was identical in 
each group (n=6/group). 
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Figure 6.3 Mortality following staphylococcal infection 
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Mortality after staphylococcLls aureus infection was higher in 
iNOS-I- (0) compared with iNOS+/- (t.; **p<0.03, Log-rank) or 
with iNOS+/+ mice (0; *pdl.02, **p<0.005). Wildtype and 
heterozygote mortality rates were not significantly different. 
population numbers at outset were -/-n=33, +/-n=28 and +1+n=20. 
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It was next important to determine whether clinical septicaemia was reflected in altered 
bacterial distribution and viability in vivo. iNOS-I- and iNOS+I- mice were injected 
Lv. with 5x107 CFU Staphylococcus aureus as before. Ten-fold dilutions of blood 
and tissue homogenates were cultured on blood agar for 18 hours at 37°C to derive 
the number of viable CFU present at successive time intervals, up to day 11. 
Staphylococci were not detected in blood in either group at day 3, but were present in 
iNOS-I- mice at days 7 and 11. In contrast, iNOS+I- mice had few viable blood-
borne bacteria even at day 7 (Figure 6.4a). High numbers of bacteria were present in 
the spleens of both groups after day 3, but persisted to days 7 and 11 only in iNOS-I-
animals (Figure 6.4b). Together these data indicate that although both groups 
similarly localise staphylococci to spleen, their subsequent viability within, and 
dissemination from, the spleen is altered in iNOS-I- animals. That this was relevant 
to end organ infection was demonstrated by the greater number of viable 
staphylococcal CFU detected in kidneys of homozygous animals (Figure 6.4c). 
iNOS deficiency therefore impairs clearance of staphylococci, leading to widespread 
tissue deposition of bacteria and consequent pathology. 
6.2 Incidence and severity of septic arthritis. 
The above data clearly indicate the deleterious consequences of staphylococcal 
infection in iNOS-I- mice. Since NO has been implicated as an important pro-
inflammatory mediator in rodent 'autoimmune' arthritis, it was therefore of interest to 
determine the net effect of iNOS deficiency on the development and severity of septic 
arthritis. iNOS+I- and iNOS+I+ mice developed clinical signs of arthritis within 2 
days of infection, which was evident in 50% of mice after 10 days (Figure 6.5a). No 
significant difference between these groups was observed. Individual animals 
presented a fluctuating course with minor daily variation in clinical severity. In 
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Figure 6.4 Tissue distribution of viable staphylococci after i.v. infection 
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Higher numbers of viable staphylococci were recovered from iNOS-I- mice 
(hatched bars) after Lv. staphylococcus aureus infection compared with 
iNOS+I- mice (solid bars). Tissues (n=3 mice/group) were harvested at time 
points indicated. diluted ten-fold (to n/lO fi ) in sterile PBS. and the number of 
viable CPU was assessed in duplicate cultures in blood agar over 18 hours. 
Figure 6.S Incidence and severity of septic arthritis 
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iNOS-I- (0; n=33) mice developed arthritis more frequently and with 
greater severity than did iNOS+I- (~; n=28) or iNOS+I+ (0; n=20) 
littermates. The (a) incidence and (b) severity of arthritis following 
staphylococcus aureus infection was recorded daily by group-blinded 
observers. iNOS-I- mice exhibited significantly higher incidence of 
arthritis from day 2 (p<0.003) vs iNOS+I+ and from day 3 (p<D.OO3, 
Chi Square) vs iNOS+I- groups. Comparison of severity of arthritic 
mice in each group demonstrated higher mean articular indices in 
iNOS-I- mice (*p<O.OI, "'*p<0.05 vs iNOS+I- or iNOs+/+ groups, 
Mann-Whitney). 
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contrast, iNOS-I- mice displayed disease onset at day 2, which was progressive and 
unremitting in up to 93% of animals by day 10 (p<O.OI; Figure 6.Sa). Thus, arthritis 
was more common in iNOS-I- mice. 
The clinical severity of septic arthritis was compared in arthritic mice using an 
articular index determined daily by a 'cage-blinded' observer. The mean articular 
index was significantly higher in iNOS-I- than in iNOS+I- or iNOS+I+ mice after day 
5 (p<O.OS - p<O.OOS; Figure 6.Sb). The peripheral distribution of arthritis was 
similar between groups, but iNOS-I- mice developed a higher incidence of paraspinal 
abscess formation, with resultant hind limb paralysis and urinary incontinence 
(iNOS-I- 39% v iNOS+I- 10.7%; p<0.05, Chi Square), perhaps reflecting the 
enhanced tissue distribution of viable staphylococci observed previously (Figure 6.4). 
The latter was often a pre-morbid presentation, but in 3 iNOS-I- mice was 
asymptomatic and found only at post mortem. The histological appearances of 
arthritic joints of equivalent clinical severity from S iNOS-I- and S iNOS+I- mice were 
compared, using H&E stained sections (Figures 6.6a - 6.6d). Large numbers of 
polymorphonuclear cells were evident in surrounding tissues. Hypertrophy of the 
synovial membrane was observed in all joints, in which a prominent mononuclear 
infiltrate was present. Invasive pannus eroding cartilage and bony surfaces was 
found in both groups, in which mononuclear cells and synoviocytes were detected, 
but not neutrophils (Figure 6.6c & 6.6d). No obvious difference in the overall 
appearances was observed between iNOS-I- and iNOS+I- jOints. Taken together, 
these data indicate not only that NO protects against the development of septic 
arthritis, but that once established, the arthritic process might be modified by NO 
dependent pathways. 
Figure 6.6 Histology of staphylococcal arthritis in iNOS-I- mice 
Legend figure 6.6 next page 
6.3 Effect of iNOS deficiency on immune responses in 
Staphylococcus aureus infected mice 
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The mechanisms whereby NO synthesis might modify septic arthritis are currently 
unknown. At least two possibilities arise, which are not mutually exclusive. NO 
exerts direct toxic effects on intracellular microbes, primarily through inhibition of 
enzymes essential for mitochondrial function, energy generation and DNA synthesis 
(reviewed by Stamler, 1994). Bacterial viability within the synovial membrane may 
therefore be enhanced in circumstances of relative NO deficiency. Alternatively, since 
immunological processes comprise the major pathological sequelae to staphylococcal 
infection, the immuno-modulatory functions of NO might influence the autoimmune 
component of host tissue destruction. 
Preliminary experiments established that staphylococci were capable of inducing 
significant levels of NO production in vitro in spleen cell cultures. Spleen cell 
suspensions obtained from mice 12 days after staphylococcal infection were 
maintained up to 5 days in the presence of heat killed Staphylococcus aureus. 
iNOS+/+ derived cultures produced high levels of nitrite within 3 days, which were 
maintained up to 5 days, whereas iNOS-/- cultures produced low levels of NO only, 
Legend to Figure 6.6 
Joints from mice infected 5 days previously with Staphylococcus aureus, were 
fixed in formalin, decalcified then stained with H&E. The histological 
appearances in (a) iNOS-/- and (b) iNOS+/- joints were similar. High power 
views in (c) iNOS-/- or (d) iNOS+/- mice demonstrated the presence of 
invasive synovial pannus, leading to erosion of bone and cartilage. Light-
microscopic appearances were similar in both groups. 
(Magnification a & b x40, c & d x250). 
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even after 5 days (p<O.OOI; Figure 6.7). Low levels of NO production in iNOS-I-
cultures have been detected previously and may result from partial induction of cNOS 
activity (Wei, et aI, 1995; Amin, et aI, 1995). iNOS+I- spleen cells exhibited 
intermediate NO production, which was significantly higher than in iNOS-I- cultures 
(p<O.02; Figure 6.7), perhaps indicating a gene dose effect as has been suggested 
elsewhere (MacMicking et al, 1995; Wei, et al, 1995). Spleen cell cultures derived 
from uninfected control mice produced no detectable nitrite after addition of heat-
killed staphylococci, indicating that prior in vivo priming was necessary for optimal 
NO production. 
The production of pro-inflammatory cytokines during the course of infection was next 
investigated. TNFa has previously been implicated in pathogenesis of gram positive 
shock (Miethke, et al, 1992). Serum TNFa levels were significantly higher at day 3 
(p<O.05) and day 7 (p<O.OI) in iNOS-I- compared with iNOS+I- mice (Figure 6.8a). 
Although serum TNFa levels were similar in both groups by day 11, spleen cells 
from iNOS-I- donors cultured with heat-killed staphylococci in vitro at this time point 
generated significantly higher levels of TNFa (p<O.OI, Figure 6.9) than those from 
similarly stimulated spleen cells from iNOS+I- or iNOS+I+ mice. As expected, the 
elevated levels of serum TNFa correlated with the period of maximal clinical sepsis 
and weight loss (Figures 6.1 b & 6.2a). Serum IFN-y and IL-6 levels were also 
measured at similar time points. Whereas no IFN-y was detected, high levels of IL-6 
were present. In contrast to the above however, no significant difference was 
observed between iNOS-I- and iNOS+I- groups at any time point (Figure 6.8b). In 
vitro, NO differentially modulates LPS and IFN-y induced IL-6 and TNFa release 
from 1774 macrophages (Deakin, et al, 1995). These data indicate that the production 
of pro-inflammatory cytokines might similarly be differentially regulated in vivo. 
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Figure 6.7 Nitrite production by spleen cell cultures stimulated 
with heat-killed staphylococci 
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NO production was significantly reduced in iNOS-I- cultures 
stimulated by staphylococcal cell wall. Pooled spleen cell cultures 
were established from iNOS-I- (0), iNOS+I- (A), or iNOS+I+ (D) 
mice (n=4 mice Igroup) to which were added lx107 CPU Iml of heat-
killed Staphylococcus aureus. Supcrnatants were harvested at the time 
points indicated and the nitrite concentration measured by the gricss 
reaction (2.10.1). Data are mean ± s.d. of duplicate assay of triplicate 
cultures. *p<O.02 - heterozygote vs homozygote; .... p<O.OOI - wild 
type vs homozygote; .... p<O.O 1 wild type vs heterozygote. 
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Figure 6.8 Serum cytokine levels after staphylococcal infection 
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iNOS-I- mice (hatched bars) exhibited significantly higher serum TNFa 
levels than iNOS+I- mice (solid bars) after 3 and 7 days ("'p<O.05. 
"''''p<O.009. Mann-Whitney). No significant difference in serum IL-6 
levels was detected. Serum from individual mice was collected at time 
points indicated (n=3 I time point) and frozen until triplicate assay for 
cytokine concentration by ELISA (section 2.9.2). Data are mean ± 
s.e.m. 
Figure 6.9 Production of TN i~a by spleen cell cultures from 
Staphylococcus a.lreus infected mice 
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TNFa production from iNOS-I- (0) pooled splenic cultures exceeded 
that from iNOS+I- (~) or iNO)+I+ (0) controls (p<O.OO5, Mann-
Whitney). Spleens (n=4 mice hroup) were removed 12 days after i.v. 
staphylococcal infection and Cl. J tured in the presence or absence of 
heat-killed Staphylococcus aUTf IS LS-l at the concentrations shown 
for 24 hours. TNFa productiOI. was measured by ELISA. Data are 
mean ± s.e.m. of duplicate assa) of triplicate culture. representative of 
two separate experiments. Sim;lar relative production was observed 
after 48 and 72 hours culture. 
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High concentrations of NO-donors in vitro inhibit the proliferation and cytokine 
secretion of Thl cell clones to antigen (Taylor-Robinson, et aI, 1994; Huang, F.P. 
personal communication) and enhanced antigen-specific Thl responses in iNOS-I-
mice have been reported following Leishmania major or Listeria monocytogenes 
infection (Wei, et al, 1995; MacMicking, et al, 1995). Thus, the possibility that 
deregulated ThlITh2 balance might underlie the adverse outcome in iNOS-I- mice 
following staphylococcal infection was investigated. The proliferative response and 
production of IFN-y and IL-4 was compared in pooled spleen cell suspensions 
obtained from mice 12 days post-infection. Cultures were maintained in the presence 
or absence of heat-killed Staphylococcus aureus (104 to 107 CPU/well) for up to 5 
days and cytokine production was estimated by ELISA. Peak 3H-thymidine uptake 
occurred after 72 hours, but no significant difference in proliferation was observed 
between the dose responses of iNOS-I- and iNOS+I- derived cultures up to 5 days. 
In contrast, spontaneous IFN-y production was significantly higher in iNOS-I-
cultures (p<O.OO5, Mann-Whitney; Figure 6.10) at each time point. Addition of heat-
killed staphylococci led to significant up-regulation of IFN-y synthesis in iNOS+I-
and iNOS+I+ cultures, to levels similar to those spontaneously produced by iNOS-I-
spleen cells (Figure 6.11). This shows that the diminished spontaneous IFN-y 
production observed was not due to inherent inability to produce IFN-y in 
heterozygote or wild type mice. However, no further up-regulation of IFN-y 
synthesis in iNOS-I- cultures was observed. indicating that maximal induction of 
IFN-y production had been achieved in vivo (Figure 6.11). These data suggest that 
IFN-y synthesis was differentially upregulated in vivo in infected iNOS-I- and 
iNOS+I- mice. No IL-4 was produced by any group, even after staphylococcal 
stimulation. Together, these observations are consistent with the presence of a 
dominant Thl response which is enhanced in iNOS-I- mice. 
Figure 6.10 Spontaneous prodJction of IFN-y by spleen cell 
cultures post-stap!lylococcal infection 
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iNOS-I- (0) spleen cell cultures produced significantly highcr levels 
of IFN-y than iNOS+I- Cb.) or iNOS+/+ (0) controls. Poolcd spleen 
cell cultures, prepared from aniE1als (n=4 mice /group) sacrificed 12 
days after i.v. staphylococcal infection. were maintained for up to 5 
days in vitro and IFN-y produc\!d was assayed by ELISA (2.9.2). 
Data are mean ± s.e.m. of dl:plicate assay of triplicate culture 
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Figure 6.11 Effect of heat-killed staphylococci on IFN-y production 
by spleen cell cultures 
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Spleen cell cultures from iNOS-I- (0) or iNOS+I- (A) mice infected 12 
days previously with Staphylococcus aureus I were maintained with 
concentrations shown of heat-killed staphylococci for 5 days. 
Significant enhancement of IFN-y production was observed in iNOS+I-
cultures (*p<O.OI vs iNOS+I- baseline without staphylococci). Peak: 
production was not significantly different between groups (Mann-
Whitney). IFN-y produced was measured by ELISA. Data are mean ± 
s.e.m. of duplicate assay of triplkatc culture. 
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6.4 Superantigen responses in mice lacking iNOS 
v~ 11 transgenic mice develop severe septic arthritis with associated mortality when 
infected with Staphylococcus aureus LS-l, which secretes TSST-l (Abdelnour, et al, 
1994b). Together with studies demonstrating the toxic consequences of direct 
injection of bacterial toxins, such as SEB (Florquin, et al, 1994), these data indicate a 
critical role for superantigen production in disease outcome following staphylococcal 
infection. Studies were therefore undertaken to determine whether lack of iNOS 
altered spleen cell proliferation and cytokine production to different superantigens in 
the absence of intact bacteria. 
Spleen cells from uninfected iNOS-I- or iNOS+I- mice were cultured with increasing 
concentrations of TSST-l or SEA. Significantly enhanced proliferation was observed 
to TSST-l and SEA in iNOS-I- cultures after 48 and 96 hours (p<O.OI to p<O.05; 
Figures 6.12 & 6.13). IFN-y production in these cultures was similarly increased 
compared to that in iNOS+I- derived spleen cell cultures (p<O.OOI to p<O.OI; Figures 
6.14 & 6.15). Low levels of IL-4 were detected in cultures at 96 hours, but in 
contrast to the situation with IFN-y, no significant difference was found between 
iNOS-I- and iNOS+I- groups (Figures 6.14 & 6.15). FACS analysis was performed 
after 48 hours, which demonstrated the presence of similar CD4+ and CD8+ 
populations in both iNOS+I- (19.67 ± 2.5% CD4+, 7 ± 0.7% CD8+) and iNOS-I-
(21 ± 2% CD4+, 7.5 ± 0.5% CD8+) spleen cell cultures (mean ± s.d. of three 
individual experiments), suggesting that the enhanced IFN-y production was not due 
to different T cell subset proportions in vitro. Nitrite production was sought in all 
cultures using the Griess reaction, but none was detected (sensitivity <2 JlM), similar 
to previous observations using heat-killed bacteria in spleen cultures from uninfected 
mice (section 6.3). 
Figure 6.12 Spleen cell culture proliferation to TSST-l 
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Pooled spleen cell cultures from uninfected mice were maintained for 
(a) 48 or (b) 96 hours after addition of increasing concentrations of 
TSST-l. 3H-thymidine incorporation was measured during the final 6 
hours of culture. Data are mean ± s.e.m. of quadruplicate cultures, 
representative of two similar experiments. iNOS-I- (0) cultures 
proliferated significantly more than those derived from iNOS+I- (~) 
mice (*p<O.05, **p<O.Ol, Mann-Whitney). 
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Figure 6.13 Splcen cell culture proliferation to SEA 
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Pooled spleen cell cultures from uninfccted mice were maintained 
for (a) 48 or (b) 96 hours after addition of increasing concentrations 
of SEA. 3H-thymidine incorporation was measured during the final 
6 hours of culture. Data are mean ± s.e.m. of quadruplicate cultures, 
representative of two similar experiments. iNOS-I- (0) cultures 
proliferated significantly more than those derived from iNOS+I- (6) 
mice (*p<O.02. **p<O.05. Mann-Whitney). 
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Figure 6.14 IFN-y and IL-4 production by spleen cell cultures to 
Toxic shock synd;'ome toxin-l 
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Pooled splenic cultures from uninfcctcd iNOS-I- (0) or iNOS+I- (A) mice 
were stimulated Wilh TSST-l at the concentrations shown for (a,c) 48 
hours or (b,d) 96 hours and the production of IFN-y (a, b) and IL-4 (c,d) 
was measured by ELISA. iNOS-I- cultures generated significantly higher 
IFN-y concentrations at both time points than iNOS+I- cultures ("'p<O.OO I, 
"''''p<O.OI, Mann-Whitncy). IL-4 synthesis was similar in both groups. 
Data are mean ± s.c.m. of quadruplicate cultures. 
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Figure 6.15 IFN-y and IL-4 production by splcnic cultures to 
Staphylococcal enterotoxin A. 
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Pooled spleen cell culldrcs from uninfcctcd iNOS-I- (0) or iNOS+I- (A) 
mice were stif1l'llatcd with SEA at the conccntrations shown for (a,e) 48 
hours or (b,d) 96 hours and the production of IFN-y (a,b) and IL-4 (c,d) was 
measured by fUSA. iI'~OS-I- cultures generated significantly higher IFN-y 
concentrations at both timc points than iNOS+I- cultures (*p<O.Ol, 
**p<O.OO5, Mann-Whitncy). IL-4 synthesis was similar in both groups. 
Data are mean ± s.c.m. of quadruplicate cultures. 
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Thus, iNOS-I- spleen cells exhibit significantly enhanced proliferation and IFN-y 
production in response to superantigens. These data indicate that following 
Staphylococcus aureus LS-l infection in vivo, TSST-l production can induce an 
exaggerated ThI response, which could in turn lead to increased pathology. 
6.5 Effect of iNOS deficiency on bacterial viability 
The above data strongly suggest that immunomodulatory defects in the iNOS-I- mice 
contribute to poor outcome following staphylococcal infection Investigations were 
performed to address the possibility that direct bacterial killing was also impaired in 
these mice. Staphylococcus aureus LS-l were opsonised, then cultured in whole 
blood from uninfected iNOS-I- and iNOS+I- mice for up to 90 minutes, in two 
separate experiments. Bacterial killing was similar in both groups (Figure 6.16) 
suggesting that iNOS expression was not critical for blood-borne neutrophil mediated 
bactericidal effects. These observations were in accord with previous reports which 
showed that immediate killing by neutrophils was ROI dependent, relative to RNI 
(Kaplan, et aI, 1996). Moreover, the delay associated with iNOS expression implies 
that it is unlikely to occupy a critical position in immediate bacterial killing activity. 
Figure 6.16 Staphylococcal killing by murine blood cultures in vitro 
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No difference in viability was observed in staphylococci incubated with 
whole blood cultures from iNOS-I- (hatched bar) or iNOS+/- (solid bar) 
mice. 100 III of 107 CPU/ml freshly opsonised live Staphylococcus 
aureus were added to 100 III heparinised blood, pooled from 4 mice 
from each group, for the times indicated. Cells were then lysed with ice 
cold water and the number of viable bacterial CPU remaining was 
estimated by culture on blood agar for 18 hours after ten-fold dilutions 
in PBS. Data are mean of duplicate cultures, representative of two 
similar experiments. 
209 
210 
Discussion 
Bacterial septic arthritis leads to severe articular destruction with significant associated 
morbidity and mortality (Goldenberg, 1989). The incidence is higher in patients with 
underlying inflammatory arthritis than in the general population, and is likely to 
increase further with wider therapeutic use of immunosuppressive drugs, total joint 
arthroplasty and the emergence of antibiotic resistant bacterial species (Goldenberg, 
1989; Ostensson & Geborek, 1991). Mechanisms underlying joint destruction are 
not properly understood, but appear to depend on both host· and bacteria-derived 
products. The rapid onset, time course and histopathological appearances of murine 
staphylococcal infection closely resemble those seen in human septic arthritis. It is 
therefore an ideal model in which to study the net effects of the microbicidal and 
immunomodulatory functions of NO in articular inflammation. Data presented here 
clearly demonstrate increased incidence and severity of septicaemia and arthritis in 
mice lacking the capacity for high output of NO. Thus, in contrast to the situation in 
'autoimmune' inflammatory models in rodents, in which the generation of NO is 
associated with aggravation of pathology, NO production in the context of 
staphylococcal septicaemia and subsequent T cell mediated articular pathology appears 
to play a protective role. 
By virtue of its diverse roles in maintenance of vascular tone, major organ perfusion, 
leukocyte adhesion, and platelet aggregation, NO has been implicated in gram 
negative bacterial shock, in which LPS mediates induction of high levels of iNOS 
expression (Kilboum, et aI, 1990; Wei, et aI, 1995; reviewed by Lyons, 1995; 
Gross, et aI, 1996). Whether NO similarly modifies gram positive bacterial 
pathology, in the absence of LPS, has remained controversial. The staphylococcal 
cell wall component, lipoteichoic acid (LTA), induces delayed circulatory failure in 
rats by an NO-dependent mechanism (De Kimpe, et aI, 1995a), and in synergy with 
peptidoglycan (PG), LTA promotes multiple organ failure in anaesthetised rats 
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through induction of high levels of TNFa, IFN-y and NO production (De Kimpe, et 
al, 1995b). However, discrepancies in the effects of NO production in anaesthetised 
compared to alert mice in gram negative sepsis have been reported (MacMicking, et 
aI, 1995) and it is possible that such experiments do not accurately reflect the 
physiological circumstances which accompany infection. In contrast, SEB-induced T 
cell mediated shock in mice induces high levels of NO production, which are 
protective through down regulation of TNFa and IFN-y production, with consequent 
reduction of mortality (Florquin, et aI, 1994). However, the NOS inhibitor employed 
in these studies was not isoform specific, raising the possibility of complicating 
cardiovascular effects. Moreover, staphylococcal infection in vivo will reflect the 
combined effect of cell-wall component and superantigen-driven responses, such that 
data derived from use of individual components, including LTA or SEB, require 
cautious interpretation. 
The iNOS-I- septic arthritis model described here avoids such criticisms, since eNOS 
dependent cardiovascular and neuronal functions are intact, and the TSST-l secreting, 
Staphylococcus aurells strain, LS-l was employed. The incidence and severity of 
septicaemia in iNOS-1- mice was significantly higher than that observed in iNOS+I- or 
iNOS+I+ controls. This was reflected in increased weight loss, mortality and 
bacterial dissemination to tissues, and by elevation of serum TNFa levels, which 
correlated with the period of maximal clinical sepsis. Increased IFN-y production in 
iNOS-I- mice compared with controls was observed, consistent with the suggestion 
that Thl cytokine production mediates late septicaemic complications of 
staphylococcal infection (Zhao & Tarkowski, 1995a). These data clearly indicate that 
NO is a critical mediator in gram positive shock and establish a net protective effect 
for high output of NO following staphylococcal infection. 
Low levels of NO production in response to staphylococcal challenge were detected in 
iNOS-I- spleen cells in vitro, suggesting that NO synthesis was not completely 
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abrogated in these mice. It is attractive to hypothesise that the precise level of NO 
production within inflammatory lesions may therefore be crucial to outcome. Low 
concentrations of NO enhance cytokine production and proliferation by Thl clones in 
vitro, in contrast to the inhibitory effect of NO at higher concentrations (Taylor-
Robinson, et aI, 1994; Huang, F.P. personal communication). Low levels of NO 
production in iNOS-I- mice may therefore have been sufficient to enhance harmful 
immune responses, but were apparently inadequate to confer protection upon the 
host. In contrast to iNOS+I- controls, iNOS-I- mice thus fail to extract the advantage 
of staphylococcal clearance and immunological down regulation afforded by high 
levels of NO production. 
T cells lie central to pathogenesis of staphylococcal infection. They are detected in 
synovial membrane within 48 hours of infection and anti-CD4-mediated T cell 
depletion ameliorates subsequent septic arthritis (Abdelnour, et al, 1994a). Non-
exotoxin producing mutant staphylococci exhibit impaired pathogenicity (Bremmell & 
Tarkowski, 1995) and clonal expansion by superantigens is required for arthritis 
development (Abdelnour, et al, 1994b), such that TSST-l producing staphylococcal 
arthritis is attenuated by prior deletion of V~11 TCR expressing T lymphocytes. 
Moreover, V~3 TCR transgenic mice show increased mortality associated with 
enhanced IFN-y production after infection with SEA-producing Staphylococcus 
aureus (Zhao, et aI, 1995b) These data indicate an important role for superantigen 
secretion, mediate.d primarily through their effect on T cell activation and Thl 
cytokine production. The present data demonstrate that NO is involved in regulating 
these processes. Naive iNOS-I- spleen cells proliferated more and produced IFN-yat 
higher levels than did iNOS+I- controls, in response to either TSST-l or SEA 
stimulation. IL-4 production, in contrast, was of low level and was identical in the 
two groups. These data suggest that NO normally restricts Thl responses induced by 
superantigens, analogous to the NO-dependent suppression of antigen specific Th 1 
responses in murine leishmanial infection in vivo (Wei, et al, 1995) and of Thl clones 
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in vitro (Taylor-Robinson, et al, 1994; Huang, F.P. personal communication). Since 
IFN-y is an important iNOS activator, this provides an important negative feedback 
loop in vivo. 
It therefore seems likely that the inability to generate high levels of NO following 
staphylococcal infection in iNOS-I- mice led to an exaggerated superantigen-driven 
Thl response. The mechanism whereby NO mediates such effects is unclear. Direct 
regulation of cytokine production may be exerted by NO at the transcriptional level, 
through alteration of NF-lCB binding, or by mRNA stabilisation (Matthews, et al, 
1996; Huang, F.P. unpublished observations). However. given its previously 
reported role in induction of apoptosis (Albina, et al. 1993; Messmer, ct al. 1993; 
Fehsel, et al, 1995). it is also possible that NO enhances the apoptosis which is the 
normal consequence of superantigen-mediated activation for the majority of T cells 
(Kawabe & Ocbi, 1991). Other regulatory pathways which have been established in 
staphylococcal superantigen-driven shock include increased endogenous 
glucocorticoid production and synthesis of anti-inflammatory cytokines, such as IL-
10 and G-CSF (Florquin & Goldman. 1996). The interaction of NO with these 
pathways is currently unclear. 
Staphylococcal arthritis was observed with increased frequency and severity in 
iNOS-I- mice. However, the role of Thlrrh2 imbalance in determining the outcome 
of septic arthritis is less well defined, reflecting doubt as to the precise role of IFN-y 
in the pathogenesis of murine arthritis. Whereas IFN-y up-regulates MHC class 11 
expression and pro-inflammatory monokine production, including IL-lp and TNFa 
(Farrar & Schreiber. 1993; Verhoef & Mattsson. 1995). it can also inhibit fibroblast 
proliferation. collagen, prostaglandin and MMP secretion and can oppose IL-l p 
mediated bone resorption and cartilage degradation (Freundlich et al, 1986; Gowen, ct 
al, 1986; Seitz, et al. 1994). Direct intra-articular injection of IFN-y exacerbates 
collagen-induced arthritis (CIA), and increased levels of IFN-y mRNA are detectable 
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in the synovial membrane following staphylococcal infection, suggesting that high 
levels of local IFN-y production are arthritogenic (Mauritz, et aI, 1988; Zhao, et aI, 
1996). However, systemic administration of IFN-y inhibits CIA (Nakajima, et al, 
1990; Williams, et aI, 1993), and IFN-y receptor (IFNyR) knockout mice develop 
milder septic arthritis than do IFNyR +1+ controls following staphylococcal infection 
(Zhao, et al, 1995b). Recent studies in Xid mice also determined that high levels of 
IFN-y production were arthroprotective in septic arthritis (Zhao, et aI, 1995c). In 
vitro data in this study indicate that iNOS-I- mice generated higher levels of IFN-y 
than iNOS+I- controls, but developed more frequent and severe arthritis. It is 
therefore possible that the protective effects of IFN-y observed in other models at 
articular inflammatory sites are NO dependent. Further studies designed to quantify 
the level of IFN-y expression in iNOS-I- and iNOS+I- synovia during infection are 
now required to confirm that local IFN-y expression is enhanced. Moreover, since 
the light microscopic histological appearances were similar in the two groups, it wi11 
also be important to characterise the cell subsets present, given the recognised ability 
of NO to modify cell adhesion and migration (Kubcs, et aI, 1993; Xin, et aI, 1993). 
NO has also been implicated in direct killing of gram positive bacteria and it seems 
likely that this will contribute to the clinical consequences of staphylococcal infection 
in iNOS-I- mice. Cytokineplasts from human neutrophiIs kill staphylococci by an 
NO-dependent mechanism (Malawista, et aI, 1992) but these pathways appear 
secondary to ROI in importance for immediate killing. In cell free systems, NO 
enhances staphylococcal killing over longer periods, suggesting that it might play a 
role if ROI production were compromised (Kaplan, et aI, 1996). Consistent with 
this, neutrophils from iNOS-I- and iNOS+I- mice exhibited similar killing activity in 
vitro in a short term bactericidal assay. However, the increased dissemination of 
viable staphylococci to blood and kidneys in iNOS-I- mice after initial localisation to 
the spleen, provided circumstantial evidence that bacteria preferentially survived in the 
iNOS-I- splenic environment. It is thus possible that NO-dependent killing will be 
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observed only in longer term assays using spleen-derived macrophages. Recently, 
human neutrophil phagocytosis of fluorescein-Iabelled fixed staphylococci was 
shown to be augmented by addition of L-arginine and abrogated by NOS inhibitors 
(Moffat, et aI, 1996). Further studies using more sensitive bactericidal assays are 
therefore required to address the specific role of NO in bacterial phagocytosis and 
subsequent killing in iNOS-I- compared with iNOS+I- derived polymorphonuclear 
cells and macrophages. The interaction with ROJ in these circumstances also 
deserves further investigation. Several recent reports have identified a key protective 
role for NO by diverting ROJ from causing intracellular damage (Wink, et aI, 1993; 
Wink, et al, 1996) and transient inhibition of the effects of ROJ on staphylococcal 
killing has been observed after addition of NO-donors (Kaplan, et aI, 1996). Another 
possibility is that NO mediated effects are mediated not through immediate viability, 
but rather by modifying bacterial adhesion and tissue localisation. Expression of 
cellular adhesion factors, such as collagen adhesin, are important virulence factors 
which offer enticing targets for nitrosylation, functional modification and thus, host 
defence (Patti, et al, 1994). 
Several clinical and therapeutic implications arise. These data provide the first 
evidence for a protective role for NO in rodent articular pathology in vivo. The use of 
specific iNOS inhibitors in treatment of human inflammatory arthritis has been 
proposed on the basis of their inhibitory effects in animal inflammatory models. The 
incidence of septic arthritis is already increased in such patients and removal of a 
major natural anti-bacterial mediator may further increase this risk. Since NO exerts 
influence in vitro on diverse pro- and anti-inflammatory pathways which are present 
in vivo in the synovial membrane, it seems unlikely that such an approach will afford 
significant clinical improvement Indeed, the potentially harmful removal of a major 
component of non-specific synovial defence against infection may outweigh any 
putative benefits. Human synovial membrane is capable of NO production in 
response to bacterial superantigen and these observations should provoke a search for 
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direct evidence for NO synthesis in human septic arthritis. NO production in that 
context may constitute an important pathway whereby bacterial killing is optimised 
and T cell activation is opposed. Together with reported amelioration of septic 
arthritis after CD4 and Vp11 T cell depletion (Abdelnour, et al, 1994b), this raises the 
challenging proposal that therapeutic T cell suppression might be desirable in treating 
such patients. 
Superantigens have been implicated in induction of autoimmunity by mechanisms 
which include activation of quiescent auto-reactive T cells, partial activation of auto-
reactive B cells through class IT recognition, or induction of aberrant cognate help for 
B cells by T cells by superantigen-mediated crosslinking (Friedman, et al, 1991; 
Goodacre, et al, 1994). Through suppression of superantigen responses, NO may 
reduce the tendency for auto-reactivity following staphylococcal infection. whereas 
impaired NO production may result in the opposite effect. Moreover, inadequate NO 
production at an initial inflammatory site might precipitate enhanced Th1 cytokine 
production, with increased levels of tissue MHC class 11 expression. Aberrant class 
II expression has been implicated previously in thyroid and pancreatic autoimmunity 
(BottazzD, et al, 1983). Further investigations are required to address such novel 
disease mechanisms. 
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Chapter' 
General Discussion 
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Neither the factors which account for onset of RA, nor those which mediate 
chronicity have been defined. Moreover, it should not be assumed that these two 
processes are identical. Nevertheless, the synovial immune response offers an 
attractive therapeutic target, although it is currently unclear which pathways offer 
the most potential clinical benefit. Controversy surrounding the nature of the 
critical regulatory cells within synovium, therefore lies central to rational choice in 
further development of biological therapies (Firestein & Zvaifler, 1990; Panayi, et 
aI, 1992; Kingsley, et aI, 1996). In normal circumstances, the interaction of T 
lymphocytes and macrophages is critical to generate cytokines from both cells, 
which together regulate the nature and outcome of the immune response. Since 
outcome encompasses a spectrum from complete resolution to chronicity, this 
relationship is likely to be critical in RA. Perhaps the most puzzling feature of RA 
synovial immuno-biology, therefore, has been the presence of a large population of 
T cells of activated phenotype, in the context of relatively low levels of T cell 
activation cytokines, either those capable of autocrine stimulation of T cells, e.g. IL-
2, or those providing evidence for T cell effector function, e.g. IFN-y In contrast, 
widespread evidence exists of macrophage activation and of monokine synthesis. 
The identification of IL-15, a cytokine of macrophage or fibroblast derivation, 
which is capable of T cell recruitment and activation in the synovial membrane, 
therefore provides a novel pathway, whereby co-ordinate T cell and macrophage 
function can occur in RA. 
IL-15 expression was detected in RA synovial lining layer and within T lymphocyte 
aggregates. Parallel staining in the former indicated that mostly CD68+ cells were 
IL-15 positive. Extensive staining in T cell rich areas was observed, raising the 
possibility that synovial T cells might contribute to their own activation through 
autocrine production of IL-15, although this appearance might also represent 
membrane bound cytokine, or macrophages which are also present in these areas. 
IL-15 expression has now been confirmed immunohistochemically in RA synovial 
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membrane, including biopsy material from early RA patients (Tak, P.P, personal 
communication). IL-15 was also detected to a significantly lesser extent in reactive 
arthritis synovial membrane (Thurkow, et al, 1996). Interestingly, double staining 
with T cell markers in the latter investigation confirmed that synovial T cells 
expressed IL-15. Future in situ hybridisation studies will be required to properly 
characterise the cellular location of IL-I5 synthesis in synovial membrane. 
Several mechanisms have been proposed to explain synovial T cell activation in the 
relative absence of IL-2. Synovial T cells are of mature CD45RO+, RBdim, CD29+, 
CD27- phenotype and simultaneously express activation and adhesion markers, 
characteristic of various stages of the 'normal' T cell activation pathway. This 
phenotype almost certainly reflects preferential recruitment of specific T cell subsets 
from peripheral blood, which possess intrinsic migratory potential (Pitzalis, et aI, 
1991; Iannone, et aI, 1994; Kohem, et aI, 1996). Activation is not, however, a 
prerequisite for such migration and other factors presumably operate to induce the 
observed phenotype. These include activation by adhesion molecule-ligand 
interactions following endothelial cell contact during extravasation and, since ~ 1 and 
~2 integrin receptors also bind to components of the extra-cellular matrix, further 
interactions in the synovial membrane itself (e.g. Damle & Aruffo, 1991; Gilat, et al, 
1996). In this context, IL-15 provides an important additional pathway whereby T 
cell activation can be initiated and maintained. IL-15 readily induces proliferation 
of PHA-T cell blasts (Grabstein, et al, 1994; Tagaya, et al, 1996a) and of a subset of 
circulating RA PB T cells. The latter likely represent previously primed CD45RO+ 
T cells, since these cells preferentially express CD69, an early marker of T cell 
activation, within 24 hours of IL-15 addition in vitro. Moreover, T cells from the 
RA synovial compartment exhibit enhanced responsiveness to IL-15, assessed either 
by prOliferation or by cytokine production, compared with PB T cells. 
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The clinical effects of T cell modulation in RA are generally favourable, indicating 
some regulatory role. This may represent inhibition of specific arthritogenic clones, 
or perhaps reflect general inhibition of polyclonal T cells. Clinical efficacy of anti-
CD4 therapy is related to the extent of synovial T cell binding by therapeutic 
antibody, indicating that the majority of synovial T cells are indeed contributing to 
pathogenesis (Choi, et al, 1996). However, this effector pathway does not seem to 
include cytokine production by the majority of T cells within the synovial 
membrane. IFN-y and IL-5 production have been detected following IL-15 
stimulation of T cells (Seder. et aI, 1995; Seder, 1996; Mori, et aI, 1996), and 
modest TNFa. production was detected following IL-15 stimulation of synovial T 
cells in vitro (Chapter 4). Nevertheless, it appears that in vivo, the presence of IL-15 
alone is not sufficient to induce significant IFN-y or IL-2 production by synovial T 
cells. It was therefore of interest to investigate novel mechanisms where by IL-15 
activated T cells might contribute to inflammation in RA. 
Studies in animal models and in clinical trials in RA using neutralising monoclonal 
antibodies against TNFa. have indicated that the latter cytokine occupies a central 
position in the regulatory cytokine network in synovial membrane (Williams, et aI, 
1992; Maini, et aI, 1995). TNFa synt~esis is therefore a biologically relevant 
indicator of macrophage activation in vitro. T cells and macrophages lie in 
juxtaposition in lymphocyte aggregates, in which IL-15 expression was observed, 
raising the possibility that cell-contact mediated communication could occur. 
Previous studies have established that T cells or T cell clones, after activation by 
mitogen, can induce cytokine and MMP production by macrophages and fibroblasts 
through cell contact (Vey, et aI, 1992; Isler, et aI, 1993; Lacraz, ct aI, 1994). The 
present study demonstrated that IL-15-mediated activation conferred similar 
properties on PB T cells. Furthermore, synovial T cells exhibited this property ex 
vivo, which was IL-15 dependent. Thus, polyclonal synovial T cells can induce 
macrophage activation and TNFa production, with pro-inflammatory consequences. 
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It is attractive to hypothesise that IL-15 may also be produced by similarly activated 
macrophages, providing a positive feedback loop leading to further T cell 
recruitment and activation (Figure 7.1). This hypothesis therefore predicts firstly, 
that IL-15 activated T cells will induce production of IL-15 by synovial 
macrophages or fibroblasts. Secondly, interruption of IL-15 mediated T cell 
activation using neutralising antibodies against IL-15, or soluble IL-15Ra. chain, 
will down regulate TNFa. production, either in animal models or in synovial 
membrane culture systems. Thirdly. effective anti-T cell therapies will exhibit 
efficacy in proportion to the extent of synovial T cell binding or inhibition of T cell 
adhesion (Kavanaugh. et al, 1995; Choi, et aI, 1996). Finally, T cells need have no 
absolute requirement for T cell cytokine production, nor for the recognition of local 
antigen. Further investigations are now required to test at least the first two 
predictions. 
IL-15 may contribute to RA synovitis by several means other than T cell activation 
and cell-contact. Effects of IL-15 on adhesion molecule redistribution on T cells 
have been reported (Nieto. et aI, 1996). Furthermore. IL-15 is also a potent 
chemotactic factor for T lymphocytes. Evidence in vitro (Wilkinson & Liew, 1995; 
Al-Mughales, et al, 1996) and in vivo in the current study indicates that IL-15 can 
induce significant T cell recruitment. The combination of effects on adhesion and 
locomotion imply an important role for IL-15 in regulating T cell extravasation and 
simultaneous endothelial contact events, which mediate lymphocyte migration to the 
synovial compartment. In addition, the ability to activate B cells and to induce 
isotype switching indicates a possible role in rheumatoid factor production in the 
synovial membrane. Significant numbers of plasma cells synthesising rheumatoid 
factor are present in synovial membrane, often surrounding T cell aggregates (Ottcn, 
et aI, 1993; Brown, et aI, 1995), but their pathological role is unclear. Immune 
complexes formed from local auto-antibody production can contribute to synovial 
inflammation, through complement fixation, and up regulation of cytokine 
Figure 7.1 IL-I5 mediated T cell activation leads to up regulation ofThTFa production 
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production (Chantry, et al, 1989; Plater-Zyberk, et aI, 1992). Whether IL-15 is 
involved in these processes remains unclear. Finally, IL-15Ra chain expression has 
been detected in activated macro phages (Girl, et aI, 1995; Anderson, et aI, 1995b), 
and it remains possible that IL-15 can exert direct effects on macrophages in an 
autocrine fashion. Taken together, these data indicate a crucial role for IL-15 in RA 
patho genesis. 
The present study represents the first demonstration of IL-15 expression in a 
pathological setting. Preliminary experiments have now identified the presence of 
IL-15 by immunohistochemistry in alveolar macrophages from asthmatic patients 
(Leung, B.P. & McInnes, I.B. unpublished observations). Moreover, IL-15 
increases IL-5 production by human Th2 cell clones (Mori, et aI, 1996), and mast 
cells proliferate and mature through IL-15 mediated binding to its own IL-15X 
receptor (Tagaya, et aI, 1996b), indicating a possible role in type I bronchial 
hypersensitivity. IL-15 has also now been identified in alveolar macrophages from 
patients with pulmonary sarcoidosis (Agostini, et aI, 1996). It is intriguing that 
sarcoid, like RA, is associated with macrophage activation, and has possible 
aetiological associations with mycobacterial species. Furthermore, M. tuberculosis 
and B.C.G. are inducers of IL-15 expression, at least in murine macrophages 
(Doherty, et al, 1996). IL-15 likely constitutes an important component of early 
host defence to infection. However, tight control of IL-15 mRNA translation has 
been reported (Bamford, et aI, 1996a; Bamford, et aI, 1996b) and rapid down 
regulation of IL-15Ra chain follows T cell activation, in comparison to IL-2Ra 
(Kumaki, et aI, 1996), indicating that its functional role is short lived in the normal 
event. Such close control of protein synthesis implies that excess production 
comprises a danger to the host. It is therefore attractive to hypothesise that RA 
could result from failure to properly regulate IL-15 expression following an 
infective insult, leading to T cell recruitment and activation and subsequent 
chronicity. Further investigation of the factors which up regulate IL-15 production 
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by human synovial macrophages and synoviocytes is required to clarify the 
significance of such observations. 
The recent recognition that NO was a potent immunoregulatory molecule prompted 
investigation of its presence and functional contribution in RA synovial membrane. 
The present study has characterised the expression of iNOS ex vivo in human 
synovial membrane. NO production in the articular environment has now been 
detected in cartilage, bone and synovial membrane (Stadlcr, et aI, 1992; Charles, et 
aI, 1993; Rediske, et aI, 1994; Ralston, et aI, 1995) in both inflammatory and 
degenerative arthropathies. Prior to the present study, the net effect of such NO 
generation in vivo in arthritis models has been detrimental (Ialenti, et aI, 1993; 
Stefanovic-Racic, et aI, 1994a; MacCartney-Francis, et aI, 1994). Whereas the 
staphylococcal infectious arthritis model is not directly comparable to other auto-
immune inflammatory diseases in rodents, it does provide an opportunity to study 
the mechanisms whereby T cell mediated articular destruction can occur. In this 
context, failure to generate high output NO synthesis was clearly detrimental to the 
host, manifest as increased incidence and severity of septicaemia and of arthritis. 
Poor clinical outcome was associated with enhanced Thl responses in iNOS-I- mice. 
Although specific cytokine neutralisation experiments are required to confirm that 
this relationship is causal, the evidence from SEB-induced T cell mediated shock 
suggests that this is likely to be the case (Florquin, et al, 1994). It can be inferred 
from these observations that NO functions normally to regulate Th 1 responses in 
vivo providing sufficient host defence at minimum cost. Aberrant regulation of NO 
synthesis might therefore prejudice immune responses to host destruction in certain 
circumstances. 
NO exhibits pleiotropic effects which might influence at least three areas of articular 
physiology - homeostasis, immunoregulation and synovial defence. 
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(i) Homeostasis - It is clear from studies in bovine, rodent and recently human 
bone and cartilage, that NO production is implicated in cytokine mediated 
effects on matrix biosynthesis and degradation (Hauselmann, et aI, 1994; 
Jarvinen, et al, 1995; Fukuda, et al, 1995). Remodelling is essential for normal 
tissue integrity, indicating that alterations in local NO synthesis can have 
significant consequences. At high concentrations NO down regulates 
osteoclast activity and can mediate cytokine-induced osteoblast activation. In 
contrast, at lower concentrations, NO potentiates bone resorption (Evans, & 
Ralston, 1996). These data implicate NO in erosion formation, and perhaps 
also in the local and systemic osteoporosis characteristic of RA patients. 
Similarly, NO exerts precise effects on chondrocyte function which may 
depend on the time course of inflammation, e.g. IL-l~ induced catabolism of 
bovine cartilage is inhibited by NO in the acute phase. but is enhanced in the 
chronic phase in vitro (Stefanovic-Racic, et al, 1996). 
NO may exert a vascular regulatory role in synovial membrane. High levels of 
endothelial iNOS expression were detected in the current study. NO has been 
shown to promote neovascularisation and was originally recognised as a 
vasodilator (Furchgott & Zawadski, 1980; Ignarro, et al, 1987; Lcibovich, et aI, 
1994; Tamura, et aI, 1996). It may therefore oppose the activities of 
vasoconstrictor substances, such as endothelin-l, which can also be detected in 
inflammatory synovium (Miyasaka, et aI, 1992). Synovial hypoxia has been 
implicated as pro-inflammatory factor (Blake, et aI, 1989). Thus, NO appears 
integral to several homeostatic processes, reducing its ultimate value as a 
specific therapeutic target. 
(ii) Immunoregulation - Data in the present study and elsewhere (Ialenti, et aI, 
1993; Oyanagui, 1994) indicate that immunoregulatory activities of NO can 
significantly alter the outcome of articular inflammation. NO derived from 
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endothelial cells and synovial fibroblasts might therefore influence the 
behaviour of neighbouring macrophages and T lymphocytes within the 
synovial compartment. These effects need not all be pro-inflammatory. Thus, 
in the present study, NO-donors increased TNFa. production in vitro from 
synovial macro phages I fibroblasts, and macrophage cell lines, and enhanced 
MMP and prostaglandin production by NO have also been reported (Salvemini, 
et al, 1993; Murrell, et al, 1995; Manfield, et al, 1996). However, synovial NO 
levels were sufficient to suppress T cell responsiveness in vitro (Merryman, et 
al, 1993). Moreover, observations in the T cell-driven staphylococcal model 
indicate that NO mediated effects on T cells may indeed have physiological 
relevance in articular pathology. Further investigations are now required to 
determine whether NO regulates IL-15 production in a similar manner to 
TNFa.. The possibility that a reciprocal relationship exists whereby NO 
production by synovial fibroblasts is, in turn, induced by IL-15 activated T 
cells through cell-contact is intriguing. 
(iii) Microbicidal - NO is implicated in host defence to numerous protozoans, fungi, 
viruses and bacteria and in many systems, the role of NO is crucial to 
successful outcome. A similar role in synovial defence is strongly indicated by 
the increased virulence of staphylococcal infection in iNOS-I- mice. 
Therapeutic intervention with iNOS inhibitors awaits the development of isoform 
specific agents. The above however indicates that no clear protective effect can be 
predicted. The production and regulation of NO in human and rodents is not 
synonymous, with high output of NO apparently delegated to different cell-types in 
each species. It is not known whether this has clinically significant and biological 
consequences, although it highlights that cautious interpretation of data from short 
term animal models is required. 
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It is not clear whether currently available anti-rheumatic drugs inhibit either iNOS 
activity or the effects of NO in tissue. Methotrexate, D-penicillamine, 5-amino-
salicylate, and indomethacin have been reported to inhibit NO synthesis in vitro or 
to protect against peroxynitrite production (Amin, et al, 1995; Murrell, et aI, 1996; 
Whiteman, et aI, 1996). However, many commonly used drugs show little such 
activity (Whiteman, et al, 1996), yet are of apparently similar efficacy in vivo and 
further investigation is required. Interestingly, tetracycline based antibiotics exhibit 
potent protection against nitrosylation of tyrosine residues in vitro, and have been 
implicated in treatment of RA, perhaps indicating a possible disease modifying 
mechanism (Kloppenberg, et al, 1994; Tilley, et ai, 1995). Recently, NO has been 
conjugated to NSAIDs to produce agents with anti-inflammatory activity in acute 
murine inflammation models, but which are associated with significantly reduced 
gastrointestinal toxicity, apparently through local release of NO (Del Soldato, et aI, 
1996). Whether the latter also has protective activity at the site of inflammation is 
unclear. 
Conclusions 
The present study was concerned with immunoregulation in RA synovial membrane 
(section 1.6). 
1. It set out to address mechanisms of synovial T cell activation in RA and 
thereafter to implicate polyclonal T cells in pro-inflammatory pathways in the 
synovial membrane. The identification of IL-15 in synovial membrane and the 
demonstration that IL-15 can activate synovial T cells, induce T cell migration in 
vivo and, through T cell-contact with macrophages, up regulate TNFa 
production, provides a novel pro-inflammatory pathway with potential for 
therapeutic intervention. 
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2. Definitive evidence for NO production by human synovial membrane has been 
obtained and the distribution of iNOS in inflammatory and degenerative 
synovium has been characterised. NO was shown to increase TNFa. production 
by synovial macrophage I fibroblast cultures, providing a further mechanism for 
TNFa. up regulation. This provides a precedent for modulation of synovial 
cytokine production by NO. The in vivo activity of NO in a model of septic 
arthritis suggested a protective role, at least in part through regulation of T cell 
activity. This again provided evidence for immunoregulatory modification of 
articular pathology by NO. These observations have implications for therapeutic 
manipulation of NO synthesis in human arthritis. 
Future Studies 
Reference has been made in the text to further investigations at specific points of 
interest. Key areas include the following: 
• IL-15 receptor expression - its distribution and regulation of expression in 
synovial membrane. 
• IL-15 in arthritis models - Development of appropriate murine reagents to 
allow investigation of the role of IL-15 in animal models of articular 
inflammation. 
• Regulation of IL-15 production - identification of the factors which 
up regulate IL-15 production in synovial membrane. 
• Regulation of NO production - investigation of the role of cytokincs and of T 
cell contact in activation of fibroblast iNOS in the synovial membrane. 
• NO in cytokine regulation - what is the role of NO in regulation of other pro-
inflammatory cytokines in synovial membrane, including IL-151 
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Appendix I 
Buffers 
1. PES (x 10 stock) 
80g NaCl 
11.6g NaH2P04 
2g KCl 
2g KH2P04 
2. PBS I Tween 
0.5 ml Tween 20 
1000 ml PBS (xl) 
3. Coatin~ buffer (ELlS A) 
O.IM NaHC03. pH 8.2 
4. Vector Kit buffer 
O.IM Tris-HCI, pH 8.2 
5. TBS (Ice Wash buffer) 
900 ml 0.9% NaCl 
100 ml50mM Tris-HCl, pH 3.6 
50 mM Tris-HCI 
6. ParaformaIdebyde 
IgPFA 
lOOm! PBS 
- Add cone HCI to 25 ml 0.2M tris-HCI to pH 7.36 
Make up to 100 ml with dH20 
100 J.11 2M NaOH 
Heat to 6(}<>C then gently mix until solution clears. 
7. Fast red solution 
A 100 mg naphthol-AS-MX phosphate 
5 ml N.N.-dimethylformamide 
lOO ml TBS, pH8.2 
B O.lM levamisole in dH20 
8. NSE stain phosphate buffers 
B 11.9 g/l Na2HP04, 2H20 (0.067M) 
Add 98.5 ml of A to 1.5 ml of B. 
9. Griess Reaction 
A 0.1 % a-naphthyl-amine in dH20 
B 1% sulfanilamide in 5% phosphoric acid 
Mix equal volumes for Griess reagent 
Store away from light 
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Appendixll 
A wards arising 
1. Young Investigator Award 
XVI European Workshop for Rheumatology Research 
McInnes, I.B., Al-Mughales, 1., Leung, B.P., Sturrock. R.D., Huang. F-P., 
Wilkinson, P.C., Field, M., Liew, F.Y. (1996) Interleukin-15 may potentiatc 
inflammation in rheumatoid arthritis synovitis. 
2. Scottish Society for Experimental Medicine 
Research Prize 1996 
Mclnnes, lB., Leung, B.P., Al-Mughales, J., Wilkinson, P.C., Field, M., 
Sturrock, R.D., Liew, F.Y. (1996) Role for interleukin 15 in pathogenesis of 
rheumatoid arthritis. 
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Appendix DJ 
Publications 
Original Papers 
1. McInnes, LB., Leung, B.P., Field, M., Sturrock, RD., Liew, F.Y. (1996) 
Interleukin 15 mediates T cell dependent regulation of TNFa production in 
rheumatoid arthritis. Nature (Medicine) (in press) 
2. McInnes, I.B., Leung, B.P., Field, M., Wei, X.Q., Huang, F-P., Sturrock, 
R.D., Kinninmonth, A., Mumford, RA & Liew, F.Y. (1996) Production of 
nitric oxide in the synovial membrane of rheumatoid and osteoarthritis 
patients. J. Exp. Med. 184, 1519-1525. 
3. McInnes, LB., Al-Mughales, J., Field, M., Leung, B.P., Huang, F-P., Dixon, 
R., Wilkinson, P.C., Sturrock, R.D. & Liew, F.Y. (1996) The role of 
Interleukin 15 in T cell migration and activation in rheumatoid arthritis. 
Nature (Medicine) 2, 151-159. 
Clinical and related papers published in parallel studies 
4. Porter, D.P., Capell, H.A, McInnes, I.B., Hunter, J,. Madhok, R., Munro, R., 
Thomson,. E.A.. (1996) Is RA becoming a milder disease? Or are we 
starting second line treatment earlier? Brit. J. Rheumatol. (in press) 
5. McInnes, I.B., Porter, D., Thomson, E.A, Pullar, T., Hunter, J., Madhok, R., 
CapeU, H.A. (1996) Sulphasalazine desensitisation does not reduce the 
incidence of adverse effects in rheumatoid arthritis. Ann. Rheum. Dis. SS, 
328-330. 
6. Crilly, A., McInnes, LB., MacDonald, A, CapeU, H.A., Madhok, R (1995) 
Interleukin 6 and soluble interleukin 2 receptor levels during methotrexate 
therapy in rheumatoid arthritis. J. Rheumatol. 22, 224-226. 
7. Neilly, B., McInnes, I.B., Kelly, I., Field, M., Gray, H. (1995) Scintigraphic 
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Production of Nitric Oxide in the Synovial Membrane of 
Rheumatoid and Osteoarthritis Patients 
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Summary 
We have demonstrated spontaneous nitric oxide (NO) production by primary synovial cultures 
from rheumatoid (RA) and osteoarthritis patients. Increased NO production followed addition 
of staphylococcal enterotoxin B. Immunochemical double staining with specific anti-human 
inducible NQ synthase (iNOS) and nonspecific esterase (NSE), or anti-CD68 (markers for tis-
sue macrophages) showed that although many lining layer cells in RA synovium expressed 
iNOS, most (rv90%) were NSE- and CD68-, with only a minor population (rvl0%) which 
were iNOS+, CD68+/NSE+. These data demonstrate the capacity for high output of NO by 
human synovial tissue and show that, although human macrophages can express high levels of 
iNOS, the majority of cells expressing iNOS are fibroblasts. We also report that synoviocytes, 
and macrophage cell lines, cultured with the NO donor, S-nitroso-acetyl penicillamine, pro-
duced high concentrations of tUlllor necrosis factor (TNF)-a. These results suggest that NO 
may mediate pathology in RA through the induction ofTNF-a production. 
R heumatoid art?ritis (~A) is characteriz.ed by ~hronic inflammatory mfiltratJon of the synovlUm, WIth de-
struction of cartilage and underlying bone, mediated by cy-
tokines, metalloproteinases and superoxide radicals (1). Ni-
tric Oxide is produced constitutively by endothelial (eNOS) 
Or neuronal NO synthases, or in higher concentrations by 
inducible NO synthase (iNOS) after stimulation by bacte-
rial products and cytokines, including IFN-'Y, TNF-a, and 
IL-1 (2, 3). As such, it has emerged as an important regula-
tory and effector mediator in several models of inflamma-
tion (3), including streptococcal cell wall and adjuvant ar-
thritis in the rat (4, 5) and renal and articular pathology in 
MRL-/pr//pr mice (6, 7). iNOS activity has been demon-
strated in rodent synoviocytes and macrophages, and in ro-
dent and human ncutrophils, chondrocytes and mast cells 
(2, 8-10). Evidence for NO production in human syn-
ovium is provided by elevation of nitrite levels in synovial 
fluid relative to serum in RA patients (11) and by demon-
Stration of elcvated urinary nitrate/creatinine ratios in RA 
(12). FurthemlOre, a recent report has suggested the pres-
ence of iNOS in human synovium and implied that mac-
rophages are the major source of synovial NO (13). 
We now provide direct evidence for spontancous NO 
production by human synovial tissue from RA and osteoar-
thritis (OA) patients, which may be further upregulated by 
bacterial superantigen. We have shown that the predomi-
nant cellular source of NO is the synovial fibroblast. Fur-
thermore, NO activated synovial cells produced TNF-a, a 
critical proinflammatory cytokine in RA synovitis (1). 
Materials and Methods 
Patiellts/Cell Culture. Synovial tissue was obtained at arthro-
plasty from 25 paticnts satisfying American College of Rheuma-
tolob'Y criteria for RA (14), and 7 with clinical and radiological 
features of OA (mean age 62, range 28-83 yr). Single-cell suspen-
sions were prepared from 13 RA and 7 OA tissues as previously 
described (15). Cell subsets assessed by FACS® analysis fell within 
ranges previously reported (15), 106 cells/ml were cultured in 
triplicate in complete Dulbecco's MEM, 10% FCS (GIUCO llRL, 
Paisley, UK) for 72 h unless indicated. LPS, stephylococcal entero-
toxin II (SEll) (Sigma Chemical Co., Poole, UK), NG-11l0n011le-
thyl-L-arginine (L-NMMA) (provided by Dr. H. Hodson, WelI-
come, Beckenham, UK). L-NMMA did not reduce cell viability or 
proliferation by synovial cultures to SED (data not shown). 
NO MC<lSlIrelll!'llt. NO production was measured as its oxida-
tive product, nitrite, using the Griess reaction as described (7). 
Sensitivity was 2 I1M. 
IIl1tnlJlw/iis/(lcilemis/ry. Acetone fixed frozen sections (3-6 11ll1) 
from 10 RA synovia, blocked with goatlhuman serum, were in-
cubated with rabbit antiserum against a human' iN OS peptide 
(N053), (16) then with biotin goat anti-rabbit 19 (DAKO, High 
Wycombe, UK), streptavidin-alkaline phosphatase (DAKO), fast 
red (Vector, Peterborough, UK) and hemotoxylin for light mi-
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Table 1. Prodl/crioll of NO by Prilllary RA alld OA SYllollial 
Cllltl/res 
Drug 
Patients Durati on Therapy Unstimulated SE13* 
R.A yr N i(rite /-LM 
RAl 14 H 9.3 (3 .0) 33 (7) * 
RA2 20 M 13 (1.7) 34 (0. 5) 
RA3 5 M+H+P 51 (2.7) 131 (6) 
RA4 13 G < 2 6 (2 .2) 
RA5 9 M 10.5 (1.3) 16 .2 (0.5) 
RM 19 A + P < 2 11.7 (3.2)+ 
RA7 22 S+P 10.1 (0.3) 32 (5 .9) 
RAS 20 < 2 <2 
R.A9 15 D l OA (2) S.S (1.0)+ 
I~Al 0 20 5.2 ( 1.2) 6 .7 (2.S)+ 
RAIl 10 3 .2 (0.5) 44 (8) 
R.A1 2 10 M 4.3 (0.5) 41 (3 .9) 
I~A13 15 <2 19 (2 .5) 
OA 
OAI 10 15 (0.5) 32 (3 .6) 
OA2 7 <2 3.3 (1.0)+ 
OA3 5 < 2 3 .2 (1.0)+ 
OA-l 10 22 (2.5) 57 (8) 
OA5 3 128 (26) ')8 (8) 
OM 5 10 (3.3) 24 (3) 
OA7 8 76 (9) 11 2 (8) 
SEU-stimulated RA synovial tissues produce en hanced nitrite! It-vc:ls 
(111ean ::':: SI), P <D.n l). 
*Optimal respome to SE13 (range 1- 10 1-1-£/ 1111) at 72 h for each patient. 
* I I-I-g/ ml LPS present. " IM gold; S, sulpha\a lazi m:; M, methotrexate; 
H, hydro),.')'chloroquine; D, penicillamine; A, aza thioprine; and 1' , 
prednisolone. 
croscopy. For double immunofluorescence, murine anti-CD3 or 
anti-C0 68 was fo llowed by FITC Fab2 goat anti- mouse Ig 
(DAKO), and anti- iNOS antiserum by biotin goa t anti- rabb it Ig 
and PE-streptavidin (OAKO). Positive staining was acquired by 
confocal microscopy (Nikon Optiphot-2; Bio-Rad, Hertford-
shire, UK). Normal rabbit serum (NRS) or murin e IgG I 
(DAKO) of irreleva nt specificity served as contro ls and were neg-
ative even after coincubati on with ant i- 0 68 o r NRS, respec-
tively (data not shown) . For neutraliza tion experiments, the im-
munizing iNO peptide Y I~SLEMSAL, rat iNOS peptide 
YE EPKATR..L (COOH tenllinus rat iNOS), or recombinant hu-
man eN S (gift of Dr. I. harles, The rucifo n11 Proj ect, Uni-
vers ity o llege London, UK) at 50 I-I-g/ ml were incubated over-
night at 4°C with anti - iNOS before staining. N onspecific esterase 
(NSE) was detected as described (17) on sec ti ons sta ined with 
anti - iNO developed with fast blue (Vector) to contrast with 
N E. Staining \vas assessed by two histologists cOllnting >500 
cells in 111 0 re th an three high power fields per sec ti on (X400). 
The percentage of iNO positive ce lls is expressed as (positive 
cells) / (total number ce lls in fie ld) X 100. 
RT-PCR. R T-PC R. was perfonm:d as previously desetibed (8). 
Primers for hUlllan iNOS were a gift from Dr. I. C harles: -5'-
GCCTCGCTCTGGAAAG-3' and 5'-TCCATGCAGCAA-
CCTT -3'. Human chondrocyte iNOS cD NA and [3-actin primers 
5'-CCACACTGTGCCCATCTACGAGGGGT-3' and 5'-AGG-
GCAGTGATCTCCTT TGCATCCT -3' (Genosys, Ca mbridge, 
UK) served as internal co ntrols. The PC lt produ ct was se-
quenced (Am ershall1 Life Science, 13uckin ghal1lshire, UK) and 
was identical to that pred icted fi'om human chondrocyte iN OS (8). 
/"dll((io" <?JTNF-a SYllliIcsis by 1\ '0. Synoviocyte/ mK rophage 
cultures were prepa red using adh ere llt ce lls afte r 16 h culwn: of 
primary synovial ti ssue digests , o r synov ial fluid mononucl ea r ce lls 
obtain ed using lyll1ph oprep (Nyco med Pharma, O slo, N orway) · 
U,)37 ce lls were matured for 24 h with I () nM PMA (SignIa). 
Cells at 2 X 10"/ml were stimulated with S- nitroso-acetyl pel]l-
cillamin e (SN AP) o r i\'-acetyl penicillamine (N AP , gifts fi 'o m \Jr. 
I. C harles) for 48 h and TNF-a concentrati ons determined bb 
ELl SA using paired antibod ies (MAb I , MAbll , sensiti vity <: I 
pg/ml; PharMin gen, Sa n Diego, C A). Cell viabi li ty was >90'!/c, by 
trypan blue exclusion. U,)37 ce lls cultured with '1 mM SNA P fOI 
48 h, then pulsed with 1 J.lC i IOH Ith ymidin e fo r 6 h , show simIlar 
uptake to co ntrols (data not shown). 
Statistical Allal),sis. Comparison between groups was by Mann-
Whitn ey test. Paired sa mpl es were compared usin g a ( test or 
Wilcoxon matched pairs signed rank sum test. 
Results and Discussion 
Nitrite prod u ction by primary syn ovia l cultures fi'oill 91 
13 RA patients and 5/7 OA pat ients was detected in th e 
abse n ce of exogenous stimulation (Table I). Toge ther \vld~ 
th e demonstration of iNOS I11RNA expressio n in synoVJJ 
ti ssu e (F ig . I), th ese o bse rvat io ns show that NO ge n era tI On 
has been initi ated in vivo in both RA and OA syn o viuJ1l · 
No differen ce w as observed b e twee n nitrite produced by 
syn ovial cultures frolll RA and OA ti ssu es, nor waS serunl 
ac ute phase responsc co rre lated with nitrite leve ls (data n ot 
sh own) . The supe ranti ge n SE13 induces T cell pro li fc ratlOn, 
cytokin e secretion, and upregulatcs m onon u clea r cell cY; 
tokine expressio n a ftc r MH class 11 binding ( 18, 19· 
Additi o n of SE13 to synovial cultures from RA and OA pa-
ticnts clearly induced in c reased NO synthesis in a dose-
iNOS 
~-actin 
M1234567 
'11-
Figure 1. R T- I'C R. for human iNOS II1RNA in ~ n 'lp-froZCI1. bA 
oviu ll1 . LJnes /- -/, rcpresclltJtivt: RA patiellt~; lane 5, rcpresentanvc 
patient; bne 6, human iNOS cDNA; "mc 7, negative cOl1tro l. 
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Fig ure 2. (a) SE ll- induced nitrite prod ucti o n by , ynovial culture, rro nl 
rcpn·<t·ntat ive pati ents RA I :! (tll'm) and O AO(, (r/osClQ. D . SE ll 1 fig / ml ; 
0 , SEU ( 1 fi g/ m I) + LI'S ( I fig/ ml). (h) Nitrite produ ctio n by ItA syn-
ovial ti<sue over time (represeming ro ur simii.Jr e"periments) . Superna-
and time-dependent m anner (Fig . 2, Table 1). When LPS 
(0 .1 - 10 IJ.-g/ ml) was added w ith SEB, no signi ficant in -
crease in n itrite concentration was observed . Producti o n of 
nitri te was in hibited by additi on of L-NMMA (1 mM) , a 
competitive iNOS inhibitor (Fig. 2 b). T hus, in ad diti o n to 
cartilage (20), human synovial membrane itself has the po-
tential for signifi cant NO ge neration . 
Prev ious efforts to loca li ze iNOS in human synovi um 
used cross-reac tin g an tibo di es to ro dent iN OS (13) . We 
used rabbit antiserum rai sed specifi ca lly aga inst a peptide 
ft'o m hu man iNOS (17), w hich recogn ized neither human 
eNOS no r rodent iNOS. Intracytoplasmic sta ining (Fig. 3 (1) 
was observed in 10 RA synovia in the fo Llowing disnibution 
(Ill ean ± SO [range]): lining b yer 19 ± 13. 1 [2- 561, inter-
stitium 5 ± 5.6 [0-20], aggregates 7 ± 7.8 10-37J (P < 0.001 
LL vs Is o r Agg). Variable iN OS staining be tween patients 
reflected th e heterogeneity of spo ntaneous ni trite produ c-
ti o n in primary culture. iNOS+ sm ooth muscle and endo-
th eli al cells were identifi ed aro un d blood vesse ls in 81 I 0 
RA tissues. Stai ning was abo li shed by prein cubation w ith 
human iN OS pep tide (Fig . 3 b), but not w ith e ith er rodent 
iNOS peptide o r recombinant huma n eNOS (Fig. 3 c), 
demonstr:lting spcc ift city fo r hUl11 an iNOS. 
The RA synovial lining layer consists primari ly of acti -
vated Ill acrophages and fibrob lasts (1) . Double staining w ith 
NSE and ant i- iN OS (Fig. 3 d) revea led that the majority of 
iN OS + cells (89 ± 5%) in the lining layer, or interstitiul11, 
were NSE- and therefore unlikely to be l1l acro phages (Ta-
t :1 nt~ \ve re harvested at tilll es indi cJted :l nd ke pt for ~ i ll\l1l t:l ll l'O ll ~ :l ~c; :l yo 
0 , SEU (1 fi g/ IlII); 0 , SE U ( I I-lg / llIl) + LI'S ( I I-lg/ IlII): stJphyloco ccal 
ex tero to" in , SE ll ( I I-lg/ llIl) + L- MMA ( I IlIM): f:; . LI'S ( 1 I-lg/ IlI I). 
Figure 3. ItA synovial lin ing la ye r stailll'd with (,1) anti- hulllan iNOS amiSctulll (f.1S t red), preincubated with (b) hUllI an i 0 peptide , or (r) ,lmi-
rodent iN OS pt'f>ti de. Preincubation with human e N OS was silllilar to (r). ((~ D ouble stain w ith anti - hul1lan iNOS (fJ st blu e) and NSE (red- brown): ar-
row shows a do uble-Iabek d cell (X 30()). 
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Figure 4. Confocal images of RA synovia l sections double-stained with anti- human iNOS (red) and (a) ami-CD68 (green), showing that most iNOS-
positive cells are CD68- (X250); (b) anti-CD68 at higher magnification, showing that CD68+ / iNOS + cells are prescm (double stain appears yellOW 
[X500]); or (c) ami-CD3 (green), showing that T cells arc iNOS - (X 400). 
ble 2). Confocal microscopy also demonstrated that most 
iNOS+ cells were CD68- (Fig. 4 a), although iNOS+ / 
CD68+ ce IJs were occasionally observed (Fig. 4 b). Thus, 
alth ough synovial macrophages po ess the capability of 
NO generation, fibrobl astl ike synoviocytes are the pre-
dominant source of NO in vivo. Moreover, a majority of 
NSE+ and CD68 + cells in the lining layer were iNOS- , 
indicating that most macro phages are not directly involved 
in NO production (Table 2). CD3+ syno vial T cells were 
all iNOS- (Fig. 4 c). The shared species and isotype of anti -
CD3 with anti-CD68 antibody provided an additiona l 
spec ifi city control for the double sta ining observed with 
anti-iNOS and anti-CD68. 
There is currentl y controversy as to th e capacity of hu-
man macrop hages to produce NO (21, 22) . Optimal con-
ditions for iNOS expression in murine macrophages are 
appare ntly distinct from those required in the human, per-
haps reflecting the tissue of origin, since blood monocytes 
are mainly used in human experiments. Where NO pro-
duction by human macrophages was detectable (22), levels 
Table 2. Colocaliz alioll cif iNOS 1I)j11t N E ill RA Sy"ovilll" 
49 :!: 24 
(0-80) 
Percelll posilive cells 
45 :!: 23 
(16- 93) 
5 :!: 3.1 
(0- 12.5) 
I~A secti ons (/I = 4) were double stained with ami- human iNOS and 
NS E. Grea ter than 250 lining layer and interstiti al area cells positive fo r 
N E and / o r iNOS were counted per section and the number of single 
or double pos itive ce lls exprc. sed as a percentage o f th e to tal nUll1ber o f 
stained ce lls counted (mean :!: SI) Irange l) . 
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Figure 5. TNF-a production (mean :!: SEM) in response to SNAP bY 
(a) adhercm cells from ItA synovial fluid (SFAC) (0, /I = 4), o r RA,sY;~ 
ovial tis ue (0, /I = 2); o r (b) I'MA- lllatured U937 cells (t:., SNAI , e 
NAP: representati ve of ducc similar experimems). NAP did not ind
'
: p 
TNF-a production from SFA C (/I = 3, data not shown). 2 mM SN .' 
contained < 0.00 15 IU LPS by limulus amebocyte lysate assay (E_toxatc. 
Sigma). 
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Were an order of magnitude lower than those from murine 
macrophages. Our study demonstrates clearly that some syn-
ovial macrophages in RA can express high levels of iNOS. 
The reason why only a limited number of macrophages is 
activated to produce NO is at present unclear. 
We next investigated a potential role for NO in the syn-
ovial membrane. U937 cells or synovial mononuclear cells 
cultured with the NO donor, SNAP, produced TNFa in a 
dose-dependent manner (Fig. 5). RA synovial macrophages 
are activated, producing proinflammatory cytokines such as 
IL-1, TNF-a (1), and IL-15 (23) and clinical trials using 
monoclonal anti-TNF-a therapy indicate that such cyto-
kine generation is critical in ongoing synovitis (24). How-
ever, factors responsible for TNF-a upregulation remain 
unclear. Our data clearly show that synovial macrophages 
may express iNOS, but are unlikely to be the principle 
producers of NO. A reciprocal pathway may exist whereby 
NO from synovial fibroblasts enhances proinflammatory 
cytokine production by macrophages, which in turn may 
upregulate iNOS expression (2, 3), thereby generating a 
posItIve feedback loop. NO also upregulates MMP pro-
duction (25) and is implicated in IL-l f3 mediated inhibition 
of proteoglycan synthesis (26), suggesting a proinflamma-
tory role for NO. However, NO levels in our synovial cul-
tures are sufficient to suppress T cell proliferation and may 
contribute to the hypo responsiveness of synovial T lym-
phocytes (27). In addition, an acute chondroprotective role 
for endogenous NO in bovine cartilage has recently been 
proposed (28). Thus, in contrast to the situation in animal 
models in which NO is usually detrimental (4, 5), the net 
effect of NO production in human arthritis remains un-
clear. 
Both RA and OA synovia produced NO. Although 
some OA synovial tissue contains an inflammatory infil-
trate, the etiology of OA is not considered to be inflamma-
tory. NO production is therefore unlikely to be a unique 
feature of primary inflammatory arthritides, but may reflect 
a nonspecific synovial response to injury or inflammation 
with potential protective or pathologic consequences. 
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